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Abstract 
Colorectal cancer is the third most common cancer and the second most common cause of 
cancer death in the UK. Outcome is directly related to stage at diagnosis with over 90% of 
patients with Stage I disease surviving their disease to 5 years compared to less than 10% 
of those with Stage IV disease. Symptoms for colorectal cancer can be non-specific, 
particularly when the disease is at its early stage, and hence screening has been introduced. 
Population screening in the UK, using faecal occult blood testing (FOBt) has been 
introduced over the past 10 years following several major randomized control trials and a 
Cochrane review that has shown improved cancer specific mortality in the region of 15% 
in those individuals invited. This has been attributed to the detection of early stage disease 
with around 50% of all tumours detected through screening being Stage I. 
 
However, it has previously been shown that there are additional tumour and host 
prognostic factors outside of stage that can determine outcome. For example, the presence 
of venous invasion and the presence of an elevated host systemic inflammatory response 
have been associated with poorer cancer specific survival. These additional factors have 
not previously been studied within the context of a population screening programme or 
indeed within early stage disease. Moreover, the FOBt screening programme itself is not 
without its pitfalls. Uptake of the test is below that of other established cancer screening 
programmes and it is recognised that repeated screening rounds are required to achieve an 
acceptable sensitivity of the test.  
 
This thesis sought to examine the first round of the Scottish Bowel Screening Programme 
within the West of Scotland and assess its effect on tumour and host determinants of 
outcome. In Chapter 1 an overview of colorectal cancer and current determinants of 
outcome is provided. In addition, colorectal cancer screening is explored in detail 
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including the evidence behind the current screening programme. Chapter 2 presents 
original data, utilising population databases, examining the changes in mode, site and stage 
of presentation across the West of Scotland that have accompanied the introduction of the 
national screening programme. It identifies that within non-metastatic disease there has 
been a shift towards a higher proportion of Stage I disease being present following 
screening introduction. Chapter 3 presents a detailed examination of the first round of 
screening in NHS Greater Glasgow & Clyde (NHS GG&C) emphasising the importance of 
the impact of deprivation throughout the screening programme. For example, deprived 
patients were less likely to take part, more likely to test positive, less likely to proceed to 
colonscopy following a positive test and less likely to have cancer detected at colonoscopy 
following a positive test.  
 
Chapters 4, 5 and 6 utilise an original dataset of over 4000 patients who underwent 
colonoscopy following a positive test in the first round of screening in NHS GG&C 
generated through work from Chapter 3. Firstly, in Chapter 4, a theoretical model 
proposing a flexible sigmoidoscopy as a first line test, rather than a colonoscopy, is 
examined. It found a missed cancer rate of 17% and that around a third would require a 
completion colonoscopy, concluding that this would not be a desirable change to the 
current screening algorithm. Chapter 5 then examines the importance of potentially 
chemopreventative medications such as statins and aspirin, on the risk of neoplasia at 
colonoscopy, determining that patients on such medications did indeed have lower rates of 
neoplasia, significant neoplasia and cancer than those not on them. Chapter 6 then looks at 
symptoms in this population, identifying that around 40% had at least one bowel symptom 
however that these correlated poorly with the risk of significant neoplasia at colonoscopy. 
Chapter 7 explores outcomes in those who were invited but did not have a screen-detected 
cancer in order to examine the incidence of interval cancers (colorectal cancer within 2 
years of a negative FOBt) and cancers in non-responders. Overall it identified a 30% 
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interval cancer rate. The chapter then explores differences in tumour and host factors 
between screen-detected and non screen-detected disease reporting that stage for stage, 
patients with non screen-detected disease had higher rates of systemic inflammation. 
Furthermore it characterises the similarity between interval and non-responder tumours 
suggesting that rather than representing biologically more aggressive tumours, interval 
cancers arise due to limitations of the test itself. Chapter 8 presents long-term outcomes in 
patients who have undergone a resection for Stage I disease prior to the introduction of 
screening. The results report an excellent 5-year cancer specific survival of 95% however 
an overall survival of 76%. It identifies the presence of an elevated pre-operative host 
inflammatory response as being associated with a worse overall outcome.  
 
Tissue work exploring the local immune-cell microenvironment of both early stage and 
pre-malignant disease is the focus for Chapters 9 and 10. This characterisation of immune 
cell infiltrate identifies similar rates of peritumoural inflammation between T1 and T2 
disease and validates a previously published automated scoring system. When exploring 
local inflammation within premalignant polyps there appears to be a change from low-
grade to high-grade dysplasia signifying a specific response to early disease progression 
suggesting host immunosurveillance. Chapter 11 summarises the main findings of the 
thesis and presents future directions. 
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1 INTRODUCTION 
1.1 Colorectal Cancer 
1.1.1 Epidemiology 
Colorectal cancer has an estimated worldwide annual incidence of 1.2 million cases and is 
the third most common cancer in men and the second most common cancer in women. The 
highest incidence rates are in North America, Australia, New Zealand, Europe and Japan, 
with lowest rates in Africa and South central Asia (American Cancer Society 2011).  
In the UK, colorectal cancer is the fourth most common cancer, and the third most 
common cancer in both males and females separately (Cancer Research UK). Annually, 
there are over 40, 000 new diagnoses accounting for 14% of all male cancer diagnoses and 
11% of all female diagnoses. The overall incidence rate is rising, however this has been 
predominantly in males. In the UK, from 1975 to 2011, the European age-standardised 
incidence rate has risen from 45 per 100,000 to 58 per 100,000 in males, and from 35 per 
100,000 to 38 per 100,000 in females (Cancer Research UK).  
  
 23 
 
 
  
Figure 1.1: The 20 most common cancers in the UK  
(reproduced Cancer Research UK)  
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1.1.2 Risk factors 
The majority of cases of colorectal cancer are sporadic, arising on a background of genetic 
and epigenetic changes. There have been a variety of both modifiable and non-modifiable 
risk factors identified as being associated with an increased risk and will be discussed 
below. 
1.1.2.1 Patient demographics 
There are clear associations noted between patient age and sex and the development of 
colorectal cancer. In the UK alone, males have a lifetime risk of 1 in 14 of contracting the 
disease and females a risk of 1 in 19. Incidence increases with age, with a marked increase 
in incidence rate above the age of 50 years. It is estimated that 95% of cases occur in 
patients aged 50 or over (Cancer Research UK). 
Socioeconomic deprivation is a global term used to describe an individual or group relative 
to the local community or wider society with regards to a variety of factors such as income, 
housing and education (Townsend 1987). There is evidence that those who are more 
deprived have higher rates of colorectal cancer, although more recently this has been 
shown to be a phenomenon that appears to only affect males (Oliphant, Brewster et al. 
2011; Cancer Research UK). A recent study examining this within the West of Scotland 
suggested that cancer incidence rates were some 20% lower in males who were least 
deprived compared to the most deprived (Oliphant, Brewster et al. 2011). It is likely that 
the link between cancer risk and deprivation represents an overall assessment of a variety 
of modifiable risk factors associated with increased cancer risk that are associated with a 
deprivation. 
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1.1.2.2 Dietary and Lifestyle factors 
There is evidence for a variety of both dietary and lifestyle factors to affect an individuals 
risk of colorectal cancer. In 2010, a large systematic literature review performed by the 
World Cancer Research Fund examined the current evidence available examining these 
factors and is summarised in Table 1.1 (World Cancer Research Fund 2010). The 
preventability of colorectal cancer through alterations of these lifestyle factors has been 
estimated at 28% in males and 15% in females in the UK alone (Parkin, Olsen et al. 2009). 
Key factors associated with risk will be discussed below. 
1.1.2.2.1 Red	and	processed	meat		
 
Red meat (all fresh, minced and frozen beef, veal, pork and lamb) and processed meat (any 
meat preserved by methods other than freezing including marinating, smoking, salting, air 
drying or heating (including ham, bacon, sausages and tinned meat)) are associated with an 
increased risk of both colorectal cancer (Chan, Lau et al. 2011) and colorectal adenomata 
(Sinha, Kulldorff et al. 2001). This is thought to arise due to a direct effect on the local gut 
mucosa of several potentially carcinogenic compounds found in red and processed meat. 
These include heterocyclic amines and polycyclic aromatic hydrocarbons formed when 
frying meat (Ohgaki, Kusama et al. 1984), high haem-iron content of the meat (Tappel 
2007), and endogenous formation of N-nitroso compounds (Cross, Pollock et al. 2003).  
With regards colorectal cancer specifically, a recent meta-analysis has shown a relative 
risk of 1.22 when comparing those eating the lowest with those eating the highest amount 
of red or processed meat. This dose-response showed risk increasing up to 140g/day of 
intake, after which risk increase is less pronounced.  Examining the risk of colorectal 
adenomas separately showed a similar summary risk 1.20 per 100g/day of red or processed 
meat ingested (Chan, Lau et al. 2011).   
 
 26 
 
1.1.2.2.2 Dietary	fibre	
Dietary fibre is found in cereals, such as whole grains and vegetables. Diets high in fibre 
have been shown to be associated with a lower risk of colorectal cancer (Aune, Chan et al. 
2011). The mechanisms explaining the link are thought to include increased stool bulk 
causing dilution of carcinogens in the colonic lumen, reduced colonic transit time and 
bacterial fermentation of fibre to short chain fatty acids which may have protective effects 
against colorectal cancer (Lipkin, Reddy et al. 1999). A recent meta-analysis found a dose 
response with increasing quantities of dietary fibre reduced colorectal cancer incidence 
(Aune, Chan et al. 2011). The summary relative risk for 10g of total daily dietary fibre was 
0.93 with relative risk reductions also found when fibre subtypes were examined 
separately.  
 
1.1.2.2.3 Physical	activity	
There is strong evidence that high levels of physical activity are associated with a reduced 
incidence of colon but not rectal cancer. The reasoning for this is likely to reflect the effect 
that regular exercise has on obesity and body fatness. In addition, physical activity reduces 
insulin resistance and insulin levels and has beneficial effects on lowering systemic 
inflammation which may further reduce risk (Harriss, Cable et al. 2007). A recent meta-
analysis has estimated an inverse relationship with a relative risk of colon cancer of 0.80 in 
men and 0.86 in women in those who had increased leisure time physical activity (Harriss, 
Atkinson et al. 2009). A dose response was also seen across both genders adding further 
supportive evidence to this link.  
 
1.1.2.2.4 Obesity	
 
There is an overwhelming link between being overweight or obese and having a higher 
likelihood of a large number of cancers, including colorectal cancer (Harriss, Atkinson et 
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al. 2009). It has been proposed that overall obesity causes approximately 20% all cancers 
and 11% of all colorectal cancers (Cancer Research UK). The mechanisms for this are 
thought to be similar to those for sedentary lifestyle. This includes high insulin levels, high 
levels of circulating pro-inflammatory cytokines and higher levels of circulating sex 
hormones, all of which are associated with carcinogenesis (Giovannucci 2007; 
Giovannucci and Michaud 2007).  
1.1.2.2.5 Alcohol	intake	
There is evidence to suggest that high levels of alcohol intake are associated with increased 
risk of colorectal cancer, particularly in males (World Cancer Research Fund 2010). In a 
meta-analysis of over 15 papers a 10% increase per 10g/day of alcohol ingested was found. 
This differed significantly between sexes with 11% in males and 7% in females. The 
precise mechanisms for the link between alcohol and colorectal cancer are unclear but may 
reflect carcinogenic metabolites of ethanol (World Cancer Research Fund 2010). In 
addition, those with higher alcohol levels are also more likely to have higher cumulative 
lifestyle risk factors as discussed above.  
 
Table 1.1: Summary of dietary and lifestyle factors and risk of colorectal cancer  
(adapted from World Cancer Research Fund 2010) 
 
 Decreased Risk Increased Risk 
 
Convincing evidence Physical activity 
Dietary fibre 
Red meat 
Processed meat 
Alcoholic drinks (men) 
Body/abdominal fatness 
Probable link Garlic 
Milk 
Calcium  
Alcoholic drinks (women) 
Suggestive evidence Non-starch vegetables 
Fruits 
Vitamin D 
Foods containing Iron 
Cheese 
Animal fats 
Added sugars 
Limited evidence – no 
conclusions 
Fish; glycaemic index; folate; vitamin C; vitamin E; selenium; 
low fat; dietary pattern 
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1.1.2.3 Pharmacological therapy 
There is evidence, predominantly from observational studies, that a variety of commonly 
used medications are associated with a reduction in risk of colorectal cancer and as such 
could be considered as chemopreventative agents. The mechanism of action of these 
medications appears multifactorial and related to both systemic and local influences 
(Garcia-Albeniz and Chan 2011). 
1.1.2.3.1 Aspirin	and	Non-steroidal	anti-inflammatory	drugs		
 
The evidence for aspirin is perhaps the strongest of the proposed chemopreventative 
medications, as it has been shown to reduce the likelihood of developing both precancerous 
adenomas (Cole, Logan et al. 2009) and colorectal cancer (Flossmann and Rothwell 2007). 
It has been estimated that the reduction in risk of adenoma development is around 30% 
(Cole, Logan et al. 2009) and of colorectal cancer development around 26% (Cooper, 
Squires et al. 2010). This has been shown both in vivo and in vitro to be related to both a 
direct local effect on tumour cells and the tumour microenvironment and also a systemic 
effect on circulating cytokines (Garcia-Albeniz and Chan 2011). No clear evidence exists 
as to the optimal dose or duration and caution should be taken regarding the universal 
prescribing at a population level due to adverse effects such as gastrointestinal bleeding. 
However, there is now robust evidence that patients with hereditary cancers such as 
Hereditary Non-Polyposis Colorectal Cancer (HNPCC) or Familial Adenomatous 
Polyposis (FAP) may derive more substantial benefit form aspirin chemoprophylaxis 
(Burn, Bishop et al. 2011; Burn, Gerdes et al. 2011).   
There is limited evidence for other non-steroidal anti-inflammatory drugs (NSAIDs) 
outwith selective COX-II inhibitors, which had been shown to reduce adenoma recurrence 
by 34% (Cooper, Squires et al. 2010). However, selective COX-II inhibitors are no longer 
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in clinical use due to the relatively high risk of adverse serious cardiovascular events such 
as stroke. 
1.1.2.3.2 Statins	
 
Hydroxylmethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, also called statins, 
are commonly used medications that lower serum-cholesterol and are used to reduce 
cardiac morbidity and mortality. A large meta-analysis encompassing over a 2.5 million 
patients has shown that there is a modest effect on both colorectal cancer incidence of 
around 9% with statin usage, however no effect of adenoma development was seen 
(Bardou, Barkun et al. 2010). It has been proposed that statins exert their antitumour effect 
through induction of apoptosis, inhibition of cell growth or angiogenesis or enhancement 
of immune response (Gauthaman, Fong et al. 2009).  
 
1.1.2.3.3 Angiotensin	II	converting	enzyme	–	inhibitors	
 
There is some evidence that Angiotensin II converting enzyme inhibitors (ACE-I) may 
have an effect on both colorectal cancer and adenoma development (Lever, Hole et al. 
1998). It has been previously shown that ACE is present within colorectal adenomas and 
that by targeting this local tumour growth and neoangiogenesis may be arrested (Rocken, 
Neumann et al. 2007). Observational studies have found a reduction in advanced adenomas 
in users of ACE-I compared to non users estimated at 41% (Kedika, Patel et al. 2011), 
however direct evidence of an effect on colorectal cancer incidence is currently lacking. 
 
1.1.2.3.4 Metformin	
 
Metformin belongs to the biguanide class of agents and is the most commonly used drug in 
the treatment of type-2 diabetes mellitus (T2DM). Several observational studies have 
identified a reduced incidence of colorectal cancer in patients with diabetes who are being 
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treated with metformin (Libby, Donnelly et al. 2009; Lee, Hsu et al. 2011). This is likely 
due to both local effects on cell growth and proliferation, and systemic inhibitions of 
growth factors including insulin-like growth factor (IGF-1)(Belda-Iniesta, Pernia et al. 
2011). 
 
1.1.2.4 The systemic inflammatory response 
Colotta et al (Colotta, Allavena et al. 2009) proposes that cancer-related inflammation is 
the seventh hallmark of cancer (Hanahan and Weinberg 2000) and that it is essential in 
causing activation of oncogenes and inactivation of oncosuppressors. It is recognised that 
an inflammatory component is present in the microenvironment of most neoplastic tissues, 
however, more recently, the systemic inflammatory response (SIR) has been identified as 
being a regulator of cancer progression and development (Box, Rogers et al. 2010).   
C-reactive protein (CRP) is the prototypical marker of the SIR (Gabay and Kushner 1999). 
It is an acute phase protein that is elevated in response to several pathological conditions 
and diseases i.e. bacterial infections, sepsis, surgery, trauma, myocardial infarction 
inflammatory diseases and cancer. It is produced by hepatocytes under the control of 
cytokines (primarily interleukin-6) originating at the site of pathology. While bacterial and 
viral infections usually undergo a self-limiting acute phase response, some inflammatory 
agents will elicit a prolonged low-grade immune response that leads to a continuous, 
unresolved low-grade inflammation. It is this chronic state of low-grade inflammation that 
may predispose to malignant disease (Box, Rogers et al. 2010). In these cases CRP levels 
will be elevated and can be used as a measure of the magnitude of the SIR. 
There is now good evidence that circulating levels of CRP are elevated in patients with 
cancer (Proctor, Talwar et al. 2010). Several epidemiology studies have examined the 
relevance of raised CRP in apparently healthy individuals and found it is associated with 
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an increased risk of cancer (Allin and Nordestgaard 2011). For example, Allin et al 
observed over 10 000 individuals in the Danish population and followed them up for 16 
years after a baseline CRP level was measured. The risk of any cancer in individuals with a 
baseline CRP in the highest quintile was 1.3 times that of those with a baseline CRP 
protein in the lowest quintile (Allin, Bojesen et al. 2009). When colorectal cancer was 
examined independently from other cancers the association remained and this has been 
supported by other more recent work (Prizment, Anderson et al. 2011). 
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1.1.3 Aetiology 
1.1.3.1 Sporadic colorectal cancer 
The vast majority of colorectal cancers arise sporadically through the adenoma-carcinoma 
sequence. This model put forward by Vogelstein states that through a combination of 
genetic mutations adenomatous polyps develop and progress from low-grade to high-grade 
dysplasia changes to invasive malignancy (Vogelstein, Fearon et al. 1988). It is estimated 
that around a quarter of polyps greater than 10mm will develop into cancer over 20 years 
(Stryker, Wolff et al. 1987). Features in keeping with increased risk of malignant 
transformation in adenomas include size, sessile morphology and villous architecture 
(Hardy, Meltzer et al. 2000). Patients with colorectal adenomata are therefore 
recommended to undergo surveillance colonoscopy with current guidelines on frequency 
of examinations summarised in Figure 1.2 (Cairns, Scholefield et al. 2010). The genetic 
alterations driving sporadic colorectal cancer development are outlined in more detail in 
Section 1.1.3.3. 
  
 33 
 
 
 
 
 
Figure 1.2: Surveillance guidelines after removal of adenomas 
(Reproduced from Cairns et al 2010) 
  
 34 
 
1.1.3.2 Non-sporadic colorectal cancer 
Approximately 15% of colorectal cancers arise through non-sporadic routes either via 
inherited conditions or systemic diseases that pre-dispose individuals to the development 
of colorectal malignancy.  
1.1.3.2.1 Hereditary	Non-Polyposis	Colon	Cancer	
 
Hereditary Non-Polyposis Colon Cancer (HNPCC), also known as Lynch syndrome, is an 
autosomal dominant genetic condition that is the most common of the inherited colorectal 
cancer conditions. Its incidence is approximately 1 in 3000 in the general population, 
accounts for approximately 1-2% of all colorectal cancer diagnoses and has an average age 
of onset of 45 years (Dunlop et al. 2002). It is characterised through mutation in DNA 
mismatch repair (MMR) genes leading to tumours with microsatellite instability (MSI). 
These tumours are predominantly right sided, patients have an increase risk of synchronous 
and metachronous tumours, and overall the disease has a better prognosis than colorectal 
cancers not arising through this pathway. Lynch syndrome is also associated with other 
cancers such as endometrial, gastric and urinary tract tumours (Vasen, Watson et al. 1999).  
Not all MMR mutated tumours are due to HNPCC and therefore diagnosis can be difficult 
with genetic testing alone. The Amsterdam criteria, now modified to the Amsterdam II 
criteria, and the Bethesda criteria have therefore been developed to aid in diagnosis. The 
Amsterdam II criteria is based on family history and requires each of the following criteria 
required to be met: >3 relatives with colorectal or associated cancer; >2 successive 
generations affected; >1 relatives diagnosed before the age of 50 years; Familial 
Adenomatous Polyposis (FAP) syndrome excluded; and tumours verified by pathological 
examination (Vasen, Watson et al. 1999). The Bethesda guidelines identify patients who 
should undergo MMR genetic testing following a diagnosis of colorectal cancer and do not 
fit into the Amsterdam II criteria. They include any of the following: colorectal cancer in a 
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patient under 50 years; presence of synchronous or metachronous colorectal cancers; 
patient under the age of 60 years with microsatellite instability on histology; patient with 
colorectal cancer in >1 first degree relative with >1 under 50 years; or patient with 
colorectal cancer in >2 first or second degree relatives regardless of age (Umar, Boland et 
al. 2004). In patients meeting the Amsterdam II criteria the lifetime risk of colorectal 
cancer is approximately 80% (Vasen, Taal et al. 1995). In view of this, endoscopic 
surveillance with biennial colonoscopy is recommended from the age of 25 years or 5 
years less than the first cancer case in the family and should continue until 75 years old 
(Dunlop et al. 2002). Following a diagnosis of colorectal cancer, there is a relatively high 
risk of a second cancer following partial colectomy. Therefore a full discussion of pros and 
cons of a subtotal colectomy should be discussed, this is particularly important with 
younger patients (Vasen, Watson et al. 1999).  
1.1.3.2.2 	Familial	adenomatous	polyposis	syndrome		
 
Familial adenomatous polyposis syndrome (FAP) is an autosomal dominant condition 
characterised by the development of multiple adenomas across the colon and rectum 
(Bulow 1989). The incidence in the general population is about 1 in 14 000 individuals and 
accounts for less than 1% of all colorectal cancers seen (Bulow, Bulow et al. 1995). It 
arises due to a germline mutation in the tumour suppressor gene adenomatous polyposis 
coli (APC), which is located on band 5q21. Loss of APC function leads to chromosomal 
instability and this affects proliferation, differentiation, migration and apoptosis of cells 
(van der Luijt, Khan et al. 1997). This ultimately allows hundreds to thousands of 
adenomatous polyps to develop across the colon and rectum all of which have malignant 
potential. The majority of patients are diagnosed in the second decade of their life and if 
not treated early then will develop colorectal cancer by their fourth decade. Diagnostic 
criteria is the presence of >100 polyps in the colon or rectum. The mainstay of treatment is 
endoscopic surveillance beginning in suspected individuals at age 13 and then prophylactic 
 36 
 
colectomy in early adulthood. The treatment of choice is panproctocolectomy and ileoanal 
pouch, or permanent ileostomy, as rectal cancers can develop in those with rectum left in-
situ. In those who do undergo colectomy and ileorectal anastomosis then endoscopic rectal 
surveillance is required at regular intervals (Dunlop, British Society for et al. 2002). In 
addition to the colonic manifestations, FAP is associated with extra-colonic malignancies 
such as desmoid tumours and upper gastrointestinal malignancies (Gurbuz, Giardiello et al. 
1994). 
An attenuated form of FAP (AFAP) is also now recognised. This is a milder phenotype 
characterised by the presence of 100 or less colorectal adenomas, a delay in onset of 
adenomatosis up to 20-25 years old, a delay in onset of colorectal cancer to 10-20 years old 
and ultimately a reduced risk of colorectal cancer (Knudsen, Bulow et al. 2010). Treatment 
and surveillance of these patients can be modified accordingly.    
1.1.3.2.3 Inflammatory	bowel	disease	
 
It is widely accepted that patients with inflammatory bowel disease (IBD), namely 
Ulcerative Colitis (UC) and colonic Crohn’s disease have an increased risk of developing 
colorectal cancer (Devroede, Taylor et al. 1971; Ekbom, Helmick et al. 1990). The risk is 
associated with severity and duration of symptoms with figures derived from meta-
analyses estimating risk in Crohn’s disease at 3% at 10 years (Canavan, Abrams et al. 
2006), and in UC at 2%, 8% and 18% after 10, 20 and 30 years respectively (Eaden, 
Abrams et al. 2001). It is hypothesised that chronic inflammation results in genetic 
alterations leading to the development of colonic dysplasia, which in turn can develop into 
invasive malignancy. As such, surveillance guidelines have been developed as summarised 
in Figure 1.3. All patients should have a screening colonoscopy at 10 years from duration 
of symptoms with subsequent scopes dependent on findings (Cairns, Scholefield et al. 
2010).  
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Figure 1.3: Surveillance guidelines for follow-up of colitis 
(Reproduced from Cairns et al 2010) 
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1.1.3.3 Colorectal Carcinogenesis at a molecular level 
Whether arising sporadically or non-sporadically there are several molecular pathways that 
have been implicated in the development and progression of colorectal cancer.  
1.1.3.3.1 Chromosomal	instability	
 
The Vogelstein model of colorectal carcinogenesis proposed that a variety of genetic 
alterations at a local level led to the transformation of colonic mucosa to dysplastic 
adenoma and then into invasive malignancy (Vogelstein, Fearon et al. 1988). These genetic 
changes include alterations in chromosomal number (termed aneuploidy) and deletion of 
the APC gene. The original model of molecular changes in the adenoma-carcinoma 
sequence proposed that changes in oncogenes such as K-ras and ultimately mutation of p53 
occurred in a stepwise manner, leading to invasive cancer (Figure 1.4). p53 is a DNA 
binding protein transcriptional activator and arrests the cell cycle in response to damage, 
however, mutations at the p53 gene locus cause the protein to become hyperstable and lead 
to its accumulation in the nucleus. This stepwise change in response to chromosomal 
instability is now thought to be an over simplistic representation of more complex process 
and that multiple oncogenes and tumour suppressor genes are responsible simultaneously 
(Wood, Parsons et al. 2007). 
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Figure 1.4: The adenoma-carcinoma sequence and accompanying molecular changes 
(Reproduced from Toribara et al. 1995) 
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1.1.3.3.2 Microsatellite	instability	
 
Microsatellites are repeated sequences of DNA made up of repeating units of one to six 
base pairs that occur throughout the human genome. Due to their repetitive nature they are 
prone to changes during replication. Mutations in DNA mismatch repair genes (MMR) 
result in a failure to repair errors in repetitive sequences leading to microsatellite instability 
(MSI). This results in an accumulation of base pair mismatches (Boland and Goel 2010). 
The MSI pathway accounts for approximately 15% of all sporadic colorectal cancers 
however is closely linked to HNPCC, as discussed above. This occurs through two 
different mechanisms: in sporadic colorectal cancer epigenetic changes affect the MMR 
gene function without genetic changes per se; whereas in HNPCC there is a germline 
mutation in the MMR enzyme (Soreide, Janssen et al. 2006). Colorectal cancers with MSI 
tend to be right-sided and large, however have a better prognosis than other tumours 
(Soreide, Janssen et al. 2006).    
 
1.1.3.3.3 DNA	Hypermethylation	
 
A third pathway has been described as being responsible for the development of colorectal 
cancer through epigenetic rather than genetic changes (Toyota, Ahuja et al. 1999). 
Aberrant DNA methylation, in the form of hypermethylation of CpG islands, results in 
repression of transcription of tumour suppressor genes. The presence of this within a 
tumour is termed the CpG island methylator phenotype (CIMP). CIMP positive tumours 
have certain characteristic clinicopathological features such as being right-sided, older age 
at diagnosis, female gender, poor differentiation, and have a high frequency of BRAF and 
K-ras mutations (Curtin, Slattery et al. 2011). 
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1.1.4 Diagnosis 
1.1.4.1 Mode of presentation 
Prior to the introduction of screening patients presented either electively or as an 
emergency and the majority were symptomatic. Mode of presentation is important as those 
that present as an emergency have a poorer outcome compared to those diagnosed and 
operated on electively.  
A study by McArdle, looking at over 3000 patients diagnosed with colorectal cancer, 
identified that emergency patients were more likely to be older, female, with left sided 
lesions and with tumours of a higher stage and therefore more likely to have distant spread 
(McArdle and Hole 2004). Fewer of these patients who presented as an emergency were 
able to undergo curative resections and their 30-day post operative mortality was higher 
than the elective patients. In those that had potentially curative surgery, 5 year overall 
survival and 5 year cancer specific survival rates were significantly worse (58% and 71% 
in the patients presenting electively and 39% and 53% in the emergency patients, 
respectively). When the node-negative patients were examined separately, emergency 
presentation was still identified as being a negative prognostic indicator. A further study 
identified the individual components of emergency presentation that were important. When 
compared to those presenting electively, who had a 5-year cancer specific survival of 75%, 
blood loss (61% cancer specific survival), obstruction (52% cancer specific survival) and 
perforation (47% cancer specific survival) were all shown to be significant (McArdle, 
McMillan et al. 2006). 
In the elective setting, the majority of patients present with three primary symptoms either 
in combination or isolation; rectal bleeding, change in bowel habit and abdominal pain 
(Keddie and Hargreaves 1968). Additional features that can lead to presentation in the 
elective setting include anaemia or a palpable mass. Identifying malignant from benign 
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causes of these symptoms is problematic however a previous study has examined age and 
symptom combinations to identify who is most at risk (Thompson, Perera et al. 2007). In a 
prospective study examining over 8000 patients referred for investigation, change in bowel 
habit was the most significant symptom with a positive predictive value for colorectal 
cancer of 9%, however when combined with rectal bleeding and the absence of perianal 
symptoms this increased to 20%. When combined with age, this symptom combination 
achieve a positive predictive value of cancer in the over 80s of over 30% (Figure 1.5) 
(Thompson, Perera et al. 2007). 
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Figure 1.5: The value of symptom combination and age in predicting colorectal 
cancer risk 
(Reproduced from Thompson et al. 2007) 
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1.1.4.2 Diagnostic investigations 
Colonoscopy is currently viewed as the gold standard investigation for patients at risk of 
colorectal cancer and allows tissue biopsies of identified lesions.  Other diagnostic options 
include CT colonography which has been shown to have good sensitivity for lesions 
greater than 1 cm. Double barium contrast enema has now been superseded by CT 
colonography and is rarely used in the UK.  A more detailed exploration the sensitivity, 
specificity and risks of diagnostic investigations is covered in Section 1.2 exploring the 
accuracy of these tests within a screening setting.  
1.1.4.3 Pre-operative staging investigations 
Following a tissue diagnosis of invasive cancer, pre-operative staging is required to assess 
for the presence of metastatic disease, and particularly in the case of rectal cancer, for 
primary location and local spread. Pre-operatively, computed tomography (CT) of the 
chest, abdomen and pelvis is routinely used. In the case of rectal tumours, which are 
defined as being a lesion that is within 15cm of the dentate line when examined by rigid 
sigmoidoscopy and the patient in the left lateral position, a magnetic resonance imaging 
scan (MRI) of the pelvis is included to assess for local invasion of the tumour and nodal 
involvement. Additional imaging includes ultrasound scanning (USS) and MRI to better 
delineate indeterminate liver lesions identified at CT. Endoanal USS may also have a 
complimentary role to MRI in examining local invasion and nodal involvement in rectal 
cancer (NICE 2004; SIGN 2011). 
Positron Emission Tomography (PET) can be of use in patients prior to undergoing major 
resections (i.e. hepatic or lung metastases) to ensure no occult metastatic disease is present, 
and also in characterising some indeterminate lesions identified on CT. It utilises Fluoro-
deoxy-glucose (FDG), which is a positron emission radiotracer that is a marker for uptake 
of glucose by cells. Therefore, in highly metabolically active tumour cells FDG activity is 
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usually high and by superimposing PET onto CT scans FDG activity across the body can 
be monitored. This can also be used in cases where a raised carcinoembryonic antigen 
(CEA) has been identified with no evidence of colorectal cancer on standard imaging 
modalities (NICE 2004; SIGN 2011).  
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1.1.5 Management 
1.1.5.1 Surgical intervention 
1.1.5.1.1 Surgical	resection	
 
The mainstay of management is surgical resection of the affected segment of bowel along 
with its lymphatic drainage with high ligation of vascular pedicles. If surgical excision is 
possible, this offers the best chance of good long-term prognosis. Oncological resection is 
determined by location and blood supply, as is the decision to restore gut continuity with 
an anastomosis or to exteriorise a stoma.  
In the case of rectal cancers the decision has to be made regarding preservation of the anal 
sphincter complex. This depends on the distance of the cancer from the anal verge. If it is 
deemed too low to safely preserve the complex, achieve distal margin clearance and 
provide good rectal function then abdomino-perineal resection (APR) is performed with 
complete excision of the anus and permanent end colostomy. Recently, more radical APR 
excisions have involved excision of the levator muscles, so called ‘cylindrical’ or extra-
levator APR. Whether or not the sphincter complex is excised, any rectal resection below 
the peritoneal reflection should involve total mesorectal excision (TME) by preserving the 
mesorectal fat plane intact as an envelope around the rectum which has been shown to 
reduce local recurrence rates (Heald and Lockhart-Mummery 1972; Heald and Ryall 
1986).     
The more distal the anastomosis in the large bowel the higher the risk of anastomostic 
dehiscence and hence in the case of a low anterior resection a defunctioning loop ileostomy 
is commonly performed. Stomas are designed to reduce the consequences rather than 
lessen the prevalence of anastomotic leaks. Risk factors associated with higher rates of 
anastomotic leak include neoadjuvant radiotherapy, comorbidity, male sex and prolonged 
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surgery and hence stomas should be considered in such situations (Matthiessen, Hallbook 
et al. 2004).  
1.1.5.1.2 Polyp	cancers	
 
Polyp cancers, where the invasive carcinoma is confined to a polypoidal lesion protruding 
into the lumen of the bowel of where endoscopic resection is primarily attempted, present a 
surgical dilemma. It is unclear whether such patients can be managed with local resection 
only or whether a formal oncological resection is required. Such a formal resection would 
serve to both clear the patient of residual tumour and also to accurately stage the patient 
through pathological assessment of the lymph nodes harvested. However, there is 
associated morbidity with a formal resection when compared to endoscopic management 
alone and hence if this could be avoided it would be of benefit to the patient. Also, a 
substantial proportion of patients undergoing resection have no residual disease identified 
(Christie 1984). It could be argued that such patients have undergone an unnecessary 
operation.  
Several criteria have been used to help guide who requires formal resection and have been 
summarised by SIGN (SIGN 2011). SIGN suggest formal resection should be considered 
in sessile polyps or in peduculated polyps with invasive carcinoma <1mm from the 
resected edge, those with poor differentiation and those with lymphovascular invasion 
present. Additional staging systems have been proposed, for example the Haggitt criteria. 
This grades the degree of invasion in pedunculated polyps based on the level of the stalk 
involved. With those in whom the invasion is confined to the head and neck (levels 1, 2 & 
3) having less likelihood of lymphatic involvement compared to those in whom it invades 
beyond the level of the stalk (Level 4) (Haggitt, Glotzbach et al. 1985).  
The Kikuchi criteria can be used for sessile polyps to estimate the risk of lymphatic 
involvement and splits the submucosa into 3 layers with Sm1 and Sm2 lesions (the inner 
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2/3 of the submucosa) having a below 10% risk and those with Sm3 having a near 25% 
risk of involvement of the lymph nodes (Kikuchi, Takano et al. 1995). However, the type 
of endoscopic resection undertaken limits both of these staging systems. For example, 
piecemeal excision renders the sample difficult to process and orientate, and, with the 
Kikuchi criteria, the full thickness submucosa must be present along with some muscularis 
propria. Such an excision with this depth of resection is not routinely performed 
endoscopically, however in some situations endoscopic submucosal resection (ESR) can be 
performed. 
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Figure 1.6: Anatomic landmarks of pedunculated and sessile malignant polyps   
(Reproduced from Haggitt, Glotzbach et al. 1985) 
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1.1.5.2 Pathological processing 
Following formal surgical resection, specimens should be processed either as fresh or 
formalin-fixed samples and reported as per The Royal College of Pathologist Guidelines 
(Williams 2007). This clearly details the macroscopic and microscopic details required for 
appropriate prognostic stratification. These core-dataset items are summarised in table 1.5. 
Of note, particular care with the reporting of rectal tumours should be taken and includes a 
grade of plane of surgical excision such as mesorectal or intramesorectal referring to TME 
resection. In order to promote high standards of pathological processing, audit standards of 
a median number of 12 lymph nodes and a venous invasion rate of 30% have been 
recommended. To achieve improved detection of venous invasion the use of special stains 
to identify endothelial structures such as elastic stains have been recommended (Roxburgh 
and Foulis 2011). 
Table 1.2: Core-dataset items in pathological reporting of colorectal cancer resections 
 
Macroscopic • Nature of specimen and type of operation 
 • Site of tumour 
 • Maximum tumour diameter 
 • Distance to longitudinal resection margin 
 • Tumour perforation 
 • Relationship to peritoneal reflection
a
 
 • Grade of plane of surgical excision
a
 
 • Distance of tumour from dentate line
b
 
  
Microscopic • Histological tumour type 
 • Histological differentiation 
 • Maximum extent of local spread (pT stage) 
 • Grade of tumour regression following neoadjuvant therapy 
 • Resection margin status (longitudinal and circumferential) 
 • Lymph node status; number present/examined, highest node status. (pN 
stage) 
 • Venous invasion (extramural / intramural) 
 • Histologically confirmed distant metastases (pM stage) 
 • Separate abnormalities (i.e. additional polyps) 
 
a
rectal tumour only, 
b
APR only 
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1.1.5.3 Neoadjuvant therapy 
There is a role for neoadjuvant external beam radiotherapy in some patients with rectal 
cancers in order to downstage the tumour and improve outcomes. This can have the added 
advantage of allowing for sphincter preservation. It is currently indicated in rectal tumours 
with T3/T4 disease, nodal involvement, or threatened or involved circumferential margins 
suspected on pre-operative imaging (Engstrom, Arnoletti et al. 2009).  
 Irradiation involves firing high energy electrons from a linear accelerator at a target that 
causes release of photons. These photons are then directed at the patient to a localised area. 
This causes an effect on the tumour in three ways: physical, chemical and biological. 
Physically high speed radiation leads to DNA ionisation and damage. Chemically these 
damaged atoms interact causing chemical bonds to breakdown and free radicals to form, 
and biologically these free radicals damage the tumour cell DNA which can lead to cell 
death. The use of a chemotherapy agent such as capcitabine or 5-fluorouracil (5-FU) has 
been shown to improve the efficacy of radiotherapy and is commonly used in conjunction 
(NICE 2004)  
There is ongoing debate as to the optimal method of delivering neoadjuvant treatment with 
short course (larger fractions delivered over a short time frame) and long course (smaller 
fractions over a longer timeframe) options available (Sign.  
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1.1.6 Post-operative prognostic stratification 
There are a variety of features of both the tumour and the patient, the so-called ‘host’, that 
identify patients who are at a higher risk of both local and systemic recurrence. Such 
features are key, not only to better inform patients, but also to allow risk stratification and 
hence identification of those who may benefit the most from adjuvant therapy or more 
intensive follow-up. 
1.1.6.1 Tumour factors 
1.1.6.1.1 Tumour	Stage	
 
Tumour stage remains the main determinant of outcome following both a diagnosis and a 
resection for colorectal cancer. This can be expressed through either the tumour, node, 
metastases (TNM) stage produced by the American Joint Committee on Cancer (AJCC) or 
the Turnbull modification of the Duke’s staging (Dukes and Bussey 1958; Turnbull, Kyle 
et al. 1967).  In the UK, TNM 5
th
 Edition is used for staging, as despite newer versions 
being produced recently that have altered the definition of lymph node involvement, these 
have limited evidence of clinical reliability (Compton, Fielding et al. 2000). Table 1.6 
summarises the staging of colorectal cancer. This can be expressed as clinical (cTNM) or a 
pathological (pTNM) stage dependent on whether a resection has taken place or not. The 
prefix of  ‘y’ is used in cases where neoadjuvant therapy has been given (i.e. 
ypT1ypN0ypM0). In those with residual tumour following neoadjuvant therapy, current 
figures from the UK estimate 5-year cancer specific survival at 95%, 80%, 66% and 7% 
with TNM Stage I, II, III and IV disease respectively (Cancer Research UK).  
With particular regard to lymph node status there is evidence that the ratio of positive to 
negative lymph nodes (LNR) may be superior to the actual number of nodes involved in 
predicting outcome (Rosenberg, Friederichs et al. 2008; Ceelen, Van Nieuwenhove et al. 
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2010; Rosenberg, Engel et al. 2010). This includes a systematic review including 16 
studies and over 30 000 patients (Ceelen, Van Nieuwenhove et al. 2010). 
 
Table 1.3: Staging of colorectal cancer  
 
Dukes 
Stage 
 
TNM 
Stage 
T-stage N-stage M-stage 
A I T1: Tumour invades 
submucosa 
N0 M0 
T2: Tumour invades 
muscularis propria 
B II T3: Tumour invades through 
muscularis propria into 
subserosal or into non-
peritonealised pericolic or 
perirectal tissues 
N0 M0 
T4: Tumour directly invades 
other organs or structures 
+/- perforates visceral 
peritoneum  
C1 III T1-4 N1: 1-3 lymph nodes 
involved (highest 
lymph node spared) 
M0 
N2: 4+ lymph nodes 
involved (highest 
lymph node spared) 
C2 T3-4 N1/2: highest lymph 
node involved 
D IV T1-4 N0-2 M1: distant 
metastatic disease 
present 
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1.1.6.1.2 Additional	tumour	factors	
 
There is evidence that a variety of additional features of the tumour are related to poor 
prognosis, and so should be included in the pathological reporting of resected specimens 
(Compton, Fenoglio-Preiser et al. 2000). Venous invasion, perineural invasion, resection 
margin status and degree of tumour differentiation have been used to identify high risk 
node negative tumours (Compton, Fielding et al. 2000). Tumour differentiation has been 
shown to be associated not only with T stage but also with the presence of lymph node 
involvement within that stage. For example, Derwinger et al. found that within T2 cancers, 
low grade tumours had a 17% risk of node involvement versus a 44% risk for those with a 
high grade tumour (Derwinger, Kodeda et al. 2010). 
Peterson et al. established a pathological scoring system for use in Dukes B colonic 
cancers to stratify risks of loco-regional recurrence. Scores are assigned based on the 
presence or absence of 4 variables. Peterson Prognostic Index (PI) is 1 if there is peritoneal 
involvement, plus 1 if extramural or submucosal venous spread is present, plus 1 if the 
margin is involved or inflamed and plus 2 if tumour perforation is present. A score of 1 or 
less equated with an 86% 5 year survival compared with a 50% survival in those with a 
score greater or equal to 2 (Petersen, Baxter et al. 2002).  
With regards the components of the PI, more recently the presence of venous invasion has 
been emphasised as being of particular prognostic importance (Roxburgh, McMillan et al. 
2010). The ability to detect venous invasion is improved through the use of elastic staining 
and such staining improves its role as a prognostic factor (Roxburgh and Foulis 2011). 
The presence of tumour necrosis has also been shown to be important in predicting 
outcome (Pollheimer, Kornprat et al. 2010). Tumour necrosis is thought to develop from 
tumour ischaemia due to rapid cell growth. It has been shown not only to correlate with 
more advanced tumour stage, the presence of vascular invasion and the presence of poor 
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differentiation, but also to be a predictor of poorer cancer-specific survival (Pollheimer, 
Kornprat et al. 2010; Richards, Roxburgh et al. 2012).   
1.1.6.1.3 Tumour	genetics	
Colorectal cancer can arise from a variety of different genetic alterations and in addition to 
being associated with the site of tumour these can impact on outcome. Patients whose 
tumours have high levels of MSI have consistently been shown to have better outcomes 
compared to those that do not (Soreide, Janssen et al. 2006). There are inconsistencies in 
determining the prognostic importance of CpG island methylator phenotype (CIMP) 
positive colorectal cancers particularly in view of the influence of other factors such as 
MSI (Ogino, Nosho et al. 2009). Work is ongoing to better delineate the link between 
genetic phenotype and outcome.    
 
1.1.6.2 Host factors 
1.1.6.2.1 Patient	demographics	
 
Clearly, patient characteristics will impact on outcome following a diagnosis of colorectal 
cancer. In a large population study from Scotland older patients and those who were more 
socioeconomically deprived have been shown to have both higher post-operative mortality 
rates and also poorer 5-year relative survival rates compared to those that are younger and 
less deprived (Hole and McArdle 2002). These associations appear to be significant 
independent of comorbidity, stage and emergency presentation that themselves are 
associated with a poorer outcome. There is also some evidence that males may have a 
worse outcome (McArdle, McMillan et al. 2003). 
 
1.1.6.2.2 Anaemia	
The presence of pre-operative anaemia in patients with colorectal cancer is relatively 
common and has been shown to be present in 40% of patients with early stage disease and 
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up to 80% of patients with advanced disease (Knight, Wade et al. 2004). The cause for 
anaemia is multifactorial and cannot purely be explained by enteric blood loss due to 
tumour bulk (Dunne, Gannon et al. 2002). There is evidence that it may be related to both 
nutritional status and the presence of an elevated systemic inflammatory response. In 
particular, it has a link with the up regulation of pro-inflammatory cytokines in a situation 
similar to the anaemia of chronic disease (Spivak 2005). 
The presence of anaemia has been associated with a worse outcome (Dunne, Malone et al. 
2002; Leichtle, Mouawad et al. 2011) as well as identifying those who will have a poorer 
response to chemotherapy (Tampellini, Saini et al. 2006). Furthermore, there is some 
evidence that transfusions have been linked to adverse effects on the immune system 
(Dunne, Lee et al. 2008).  
1.1.6.2.3 The	systemic	inflammatory	response	
 
There is increasing evidence that an elevated host systemic inflammatory response is an 
independent marker of poor outcome in patients with colorectal cancer. This has been 
quantified by the GPS (Glasgow Prognostic Score) subsequently modified to the mGPS 
which is a score based on elevated circulating concentrations of C-reactive protein (CRP) 
and hypoalbuminaemia (McMillan, Crozier et al. 2007; Proctor, Morrison et al. 2011). In 
brief, an mGPS score of 0 is given when CRP is <10mg/l; a score of 1 when CRP > 10mg/l 
and albumin >35g/l; and a score of 2 when CRP>10mg/l and albumin <35g/l.  
Whilst the mGPS has been shown to be related to T-stage, patients with a high mGPS have 
been shown to have poorer cancer specific survival independent of T-stage (Crozier, 
McKee et al. 2007) and to have a poorer outcome despite chemotherapy (Crozier, McKee 
et al. 2006; Ishizuka, Nagata et al. 2007; Ishizuka, Nagata et al. 2009). Moreover, 
combining the mGPS with an index examining tumour factors, such as the Petersen Index, 
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can further stratify those patients with node negative colorectal cancer (Roxburgh, Crozier 
et al. 2009).  
 
1.1.6.2.4 The	local	Inflammatory	response	
 
With regard to the local inflammatory response, there is evidence that the presence of a 
high grade of local inflammatory infiltrate at the invasive margin is indicative of a better 
prognostic outcome. There is evidence that both that the adaptive and innate anti-tumour 
response play key roles in determining cancer progression (Roxburgh and McMillan 2012). 
Klintrup et al, have simplified the assessment of the inflammatory reaction by looking at 
the intensity of inflammatory cell reaction by all leucocytes at this margin on routine 
haematoxylin and eosin staining. Scores were based on the appearances of tumour invasion 
at the deepest area. A score of 0 to 4 was given for the degree of inflammation at the 
inflammatory margin. These scores were then subsequently classified as low grade (scores 
0 and 1) or high grade (scores 2 and 3). They reported that 5-year survival in TNM Stage I-
II cancers was 88% with high grade, compared to 47% with low grade (Klintrup, Makinen 
et al. 2005). 
Clearly interactions between host and tumour characteristics exist and this has important 
implications for our understanding of the pathogenesis and natural history of early disease. 
For example, it has recently been shown that the presence of tumour necrosis is closely 
related to both a poorer local and a more pronounced systemic inflammatory response, 
themselves all independently identified as predictors of poorer outcome. It has been 
suggested that necrosis itself may act as a trigger for the systemic inflammatory response 
(Richards, Roxburgh et al. 2012). 
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1.1.7 Adjuvant therapy 
Following a potentially curative resection for colorectal cancer, adjuvant chemotherapy 
should be considered in selected patients. This is based on the rationale that occult 
metastatic disease at the time of operation is responsible for any subsequent recurrence. 
There are associated side effects with chemotherapy and therefore any adjuvant therapy 
should involve a considered discussion between patients and health professionals regarding 
the balance of risks and benefits.  
Current guidelines suggest it should be considered in all patients with Stage III disease and 
in selected patients with Stage II (SIGN 2011). Such high risk Stage II features have been 
discussed above and include T4 disease, poor differentiation, tumour perforation, 
inadequately sampled lymph nodes and the presence of extramural vascular invasion 
(Benson, Schrag et al. 2004).  
Commonly combination chemotherapy using cytotoxic drugs is given within 8 weeks of 
surgery provided the patient has suitably recovered. Cytotoxic drugs act relatively 
indiscriminately through a variety of mechanisms such as DNA damage impairing cell 
mitosis, inhibiting the cell cycle and inducing apoptosis. Such drugs include 5-fuorouracil 
(5-FU), an antimetabolite drug that primarily has its effect through irreversible inhibition 
of the enzyme thymidylate sythensase which is required for DNA replication (Longley, 
Harkin et al. 2003) which can be taken in oral form as Capecitabine. Other drugs such as 
Oxaloplatin, which is a platinum based chemotherapy agent that also acts through 
inhibition of DNA synthesis, can also be used. Common side effects with oxaloplatin 
include a severe peripheral neuropathy that can persist for years after treatment. Newer 
targeted monoclonal antibody therapies such as Cetuximab, an antibody against epidermal 
growth factor receptor, are now being used either for down staging of liver metastases or in 
advanced disease (Karapetis, Khambata-Ford et al. 2008). These treatments offer a 
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promising alternative to cytotoxic agents for some patients with improved side effect 
profiles and work is ongoing regarding their role in the adjuvant setting.     
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1.1.8 Follow-up 
There is on going debate regarding appropriate follow-up of patients following potentially 
curative surgery for colorectal cancer. Follow-up programmes are aimed at early detection 
of recurrent local or metastatic disease with the intention that earlier detection and 
treatment will result in improved survival. Furthermore, patients are followed up as they 
are at an increased risk of developing adenomas or a metachronous primary in the 
remaining large bowel (Heald and Lockhart-Mummery 1972). Additional benefits also 
include psychological support for patients and the ability of follow-up to aid with audit 
purposes. 
Options for follow-up include clinical assessment, cross-sectional imaging (routinely with 
CT scanning) and blood based tests such as carcinoembryonic antigen (CEA). Debate 
exists over the timing and use of such interventions. Current NICE guidelines recommend 
6 monthly CEA tests for 3 years after treatment, at least two CT scans of the chest, 
abdomen and pelvis within 3 years of treatment, and a surveillance colonoscopy at 1 year 
post treatment (NICE 2004). Guidelines from the Scottish equivalent, SIGN, are less 
stringent and state that while CEA and CT are useful in detecting recurrent disease, the 
exact timing is not clear. In addition, they recommend that unless there is a clear indication 
then there is no requirement for routine colonoscopy until 5 years post treatment and 
thereafter every 5 years dependent on patient co-morbidity (SIGN 2011). 
The reason for such debate is that there is limited high quality evidence that routine follow-
up has an impact on survival. Two systematic reviews have examined this and found 
difficulty with heterogeneity of studies and a lack of information on potential harms and 
costs associated with follow-up regimes. Overall, both reviews did conclude that intensive 
follow-up was associated with a moderate improvement in overall survival when compared 
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to minimal follow-up, but were not able to identify specific factors that were required 
(Renehan, Egger et al. 2002; Jeffery, Hickey et al. 2007).      
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1.2 Screening for colorectal cancer 
1.2.1 Overview of screening 
In order to improve outcome from colorectal cancer, bowel screening programmes have 
been introduced across the UK in a staged manner over the past 10 years, with the first 
complete round of the current UK bowel screening programmes being completed in 
December 2011. There are several key elements underlying population screening (Wilson 
and Jungner 1968): it must be targeted at an important health issue; the screening 
procedure should be simple, safe, precise and validated; early stage treatment should be 
more beneficial than late stage treatment; there should be evidence that screening reduces 
mortality/morbidity; the benefits should outweigh the harm; the process should be 
economically viable; the programme should be audited against set standards; and screening 
participants should be fully informed of the implications of participation. Colorectal cancer 
is considered to be a good target for screening because it incorporates most of these key 
elements (Bretthauer 2011). 
In addition to this, colorectal cancer also has the apparent advantage of developing from a 
precursor lesion with what is considered to be a relatively long average interval from the 
precursor to development of invasive disease. Around 90% of colorectal cancers are 
adenocarcinomas and are thought to develop from dysplastic polyps, with around 8% of 
polyps greater than 10mm developing into cancer at 10 years (Stryker, Wolff et al. 1987). 
It is considered that targeting these adenomas with endoscopic resection should prevent 
them developing into tumours. As the majority of polyps are symptomless, then a 
screening tool to identify them should potentially lead to a reduction in colorectal cancer 
incidence and ultimately improve outcomes. Patients with polyps can be followed up as 
they are at higher risk of further polyp development and subsequently at a higher risk of 
developing colorectal cancer (Cairns, Scholefield et al. 2010). 
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There are currently 2 other population screening programmes for cancer in the UK; breast 
and cervical.  
The Scottish Breast Screening Programme was developed in 1988 and invites all females 
aged 50 to 70 years for 3 yearly mammograms. It is designed to detect early stage breast 
cancer and hence reduce cancer specific mortality. Between 2009 and 2010, uptake across 
Scotland was noted at 75% with recall rates for abnormal mammograms between 10%, for 
those on their first round of screening, to 4% for those on subsequent screening rounds. In 
total, looking at figures from 2007 to 2010, there were 6 invasive cancers detected per 
1000 woman screened (Scottish Government 2011a).   
In Scotland, the cervical screening programme has also been running since 1988 and is 
available to all women aged 20 to 60 years with 3 yearly screening invites. The procedure 
involves a smear test assessing for dysplastic cells at the cervix. Rather than being aimed at 
detecting early disease and reducing cancer-specific mortality, it is designed to reduce the 
incidence of cervical cancer through removal of precancerous cells. Between 2007 and 
2010, uptake of the test across Scotland was 74% with 2.2% of tests having mild 
dyskaryosis and 1.2% of tests having moderate to severe dyskaryosis that required a further 
test. Since it’s inception the incidence of cervical cancer has fallen by approximately 49% 
across Scotland (Scottish Government 2011b). 
While it is interesting to consider these programmes as a means of comparison for the 
current bowel screening programmes in terms of uptake and recall rates, it is important to 
remember that the disease processes they are designed against are different. For example, 
the overall 5-year unadjusted cancer specific mortality is 15% with breast cancer and 33% 
with cervical cancer compared to 45% with colorectal cancer (Cancer Research UK). 
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1.2.2 Options for screening for colorectal cancer 
1.2.2.1 Colonoscopy 
Colonoscopy is currently viewed as the gold standard for imaging the large bowel and 
identifying colorectal cancer, with superior sensitivity and specificity to other methods. A 
flexible fibreoptic tube is passed per rectum to the caecum allowing for direct luminal 
visualisation and biopsy of any lesions identified. It is, however, an invasive test with a 
complication rate of colonic perforation of approximately 0.05% (Lorenzo-Zuniga, 
Moreno de Vega et al. 2010). There are also resource and cost issues in instigating this as 
an initial screening tool. Also, the public acceptance of undergoing endoscopic evaluation 
of the large bowel is at present thought to be limited. For example, when flexible 
sigmoidsocopy was compared to stool sampling tests in a screened population compliance 
rates with non-invasive testing were almost double that of the endoscopic group (Hol, van 
Leerdam et al. 2010).  
While it is accepted as the standard for large bowel imaging it is important to note that 
there have been no randomised trials published examining the effect of population 
colonoscopy screening and outcome. There is, however, currently a large randomised 
control trial underway, comparing colonoscopy with CT colonograpy as a primary 
population screening tool for colorectal cancer (de Wijkerslooth 2010). It will require long 
term follow to assess its efficacy in reducing cancer specific mortality. 
 
1.2.2.2 Flexible sigmoidoscopy 
As the majority of tumours occur distal to splenic flexure (Cancer Research UK), flexible 
sigmoidoscopy has been proposed as a screening tool. Several randomised controlled trails 
have been conducted examining this. The UK flexible sigmoidoscopy screening trial 
(Atkin, Edwards et al. 2010) was the largest of these and enrolled 170 000 people aged 55-
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64. Participants were assigned at random to either receive a once off screening flexible 
sigmoidoscopy or no screening at all. There was a 71% uptake of the test and over 11 years 
those that attended the test had a reduced incidence of colorectal cancer of 23% and 
reduced cancer specific mortality of 33%. The trial however only enrolled those that had 
previously expressed an interest in participating and was therefore not a population based 
trial. There remains doubt as to the compliance that can be achieved with a population 
screening flexible sigmoidoscopy programme and to whether current endoscopy resources 
would be able to provide it. However, it has now been introduced as an adjunct to the 
screening programme in England and pilot studies are underway in Scotland to do similar. 
The use of flexible sigmoidoscopy as a screening tool has other inherent issues such as the 
very definition of what a ‘complete’ flexible sigmoidoscopy is and these are discussed in 
more detail in Chapter 4.   
 
1.2.2.3 CT colonography 
CT colonography allows for non-interventional assessment of the colon and rectum. It 
requires limited bowel preparation prior to the procedure and then the individual to pass 
through a CT scanner for 3D imaging while air is insufflated per rectum to distend the 
large bowel. It has been shown to have a comparable sensitivity and specificity with 
colonoscopy for colorectal cancer and for polyps greater than 10mm (Halligan, Altman et 
al. 2005; Pickhardt, Hassan et al. 2011). No randomised trials have been published 
examining cancer specific mortality with regards to CT colonography screening, however 
uptake and individual acceptance of the test has been found to be more favourable than 
colonoscopy (de Wijkerslooth 2010). 
Clearly, the downside is a requirement for subsequent colonoscopy in order to directly 
visualise and remove any lesions identified, and this two stage process has considerable 
resource and cost implications to healthcare providers and patients. Also, there is a not-
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insignificant radiation dose associated with the procedure, averaged at 5.7 mSv equivalent 
to approximately 57 plain chest X-rays (Liedenbaum, Venema et al. 2008). In addition 
there have been reports of colonic perforations (Bassett, Liotta et al. 2008). One further 
point on CT colonography is that it detects extracolonic intra-abdominal abnormalities. 
The incidence of significant findings requiring either further investigation or operation is 
thought to be around 11% (Veerappan, Ally et al. 2010). Such incidental findings can be 
viewed as either an advantage of screening or as a drawback, depending on how 
individuals are consented prior to the procedure. For example, an abnormal liver area 
requiring further interval scanning that ultimately turns out to be benign may cause undue 
anxiety to an individual who had only consented to have screening of their colon. 
 
1.2.2.4 Faecal occult blood tests 
The screening tool currently in use in the UK is the stool based faecal occult blood test 
(FOBt). Currently in use as a first line test is a guaiac-based test that detects the peroxidase 
activity of haematin in faeces (gFOBt). In the case of a weakly positive test, a confirmatory 
Faecal Immunochemical Test (FIT) is used in Scotland, Wales and Northern Ireland. In 
England, following a weakly positive gFOBt, a second gFOBt is used as a confirmatory 
test. The FIT specifically targets human haemoglobin and, rather than the binary response 
that the gFOBt produces, FIT tests have the potential to be quantitative. This allows cut-off 
thresholds to be determined based on relative sensitivity and specificity of the test. With 
the use of an optimal threshold, FIT has been shown to have a higher sensitivity for 
advanced neoplasia and a similar specificity (Hol, Wilschut et al. 2009). The gFOBt has 
the disadvantage of being positive when certain foods are eaten such as animal food 
products high in haem content (e.g. raw meat) and raw peroxidase-rich fruits and 
vegetables (e.g. broccoli and cauliflower)(Caligiore, Macrae et al. 1982). Therefore, gFOBt 
can have a higher false positive rate than FIT, however this will be dependent on the 
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threshold of FIT used. There is an option to rehydrate a gFOBt for processing, with 
rehydration increasing the sensitivity but decreasing the specificity of the test. Tests are not 
currently rehydrated in the UK. The FOBt based screening programmes are less invasive 
and have higher compliance rates than endoscopic programmes, however they have a 
lower sensitivity and specificity (Levin, Lieberman et al. 2008; Hol, van Leerdam et al. 
2010).  
 
1.2.2.5 DNA stool tests 
There has been some progress in the use of stool tests that have molecular assays for DNA 
mutations and methylation biomarkers that are associated with colorectal cancer. Initially 
these tests were very expensive and had limited sensitivity and specificity, overall 
conferring no great advantage over faecal occult blood screening tests (Imperiale, 
Ransohoff et al. 2004; Ahlquist, Sargent et al. 2008). However, advances in the processing 
of samples and the use of more discriminate markers has led to an overall improvement in 
test characteristics. Several studies are on going assessing the efficacy of such tests and 
will be publishing results in the near future (Ahlquist 2010). 
 
1.2.2.6 Systemic markers 
As discussed previously, it is proposed that cancer-related inflammation is the seventh 
hallmark of cancer (Hanahan and Weinberg 2000; Colotta, Allavena et al. 2009) and that it 
is essential in causing activation of oncogenes and inactivation of oncosuppressors. 
Therefore, it would seem prudent to assume that patients with an elevated systemic 
inflammatory response have a higher propensity to develop cancer. Therefore, testing 
serum markers of an elevated systemic inflammatory response may be a useful screening 
tool. To date, the role of elevated C-reactive protein levels within a bowel screening 
programme has yet to be examined. 
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Table 1.4: Comparison of test characteristics of commonly used population screening 
tests for colorectal cancer  
(Adapted from Bretthauer 2011) 
 
 
 
 Cancer 
sensitivity  
 
(%) 
Advanced 
adenoma 
sensitivity  
(%) 
Cancer 
specificity  
 
(%) 
Advanced 
adenoma 
specificity  
(%) 
     
gFOBT 
 
11-64 11-41 91-98 n/a 
FIT 
 
56-89 27-56 91-97 n/a 
Flexible Sigmoidoscopy 
 
60-70 50-81 60-70 50-80 
Colonoscopy 
 
95 95 95-99 90-95 
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1.2.3 Background evidence underpinning the UK bowel screening 
programmes 
Bowel cancer screening was introduced in Scotland in a staged manner from 2007 
following the results of three major randomised control trials (Mandel, Bond et al. 1993; 
Hardcastle, Chamberlain et al. 1996; Kronborg, Fenger et al. 1996) and a Cochrane review 
(Towler, Irwig et al. 2000) that examined the use of gFOBt as a population screening tool.  
In these trials, patients testing positive on gFOBt were referred on for assessment with a 
view to undergoing a colonoscopy. 
The Minnesota trial (Mandel, Bond et al. 1993) enrolled 46,551 patients aged 50 to 80 and 
randomised them to 3 groups (annually screened, biannually screened and a control group). 
In the annual screened group, uptake was on average 75% and a reduction in cancer 
specific mortality of 33% was seen after a median of 13 years versus the controls. The 
biannual group uptake was at 78% while a reduction of mortality in 6% was seen in a 
similar follow-up. In this study the gFOBt was rehydrated and no dietary restrictions 
imposed so the overall positivity rate was relatively high at 10%. 
The Funen study (Kronborg, Fenger et al. 1996) randomised 61,933 patients between the 
ages of 45 and 75 into a control group and a group undergoing biannual screening. Uptake 
was at 67% and after a median of 10 years a reduction of cancer specific mortality of 10% 
was seen. Tests were not rehydrated and dietary restrictions were imposed giving a 1% 
positivity rate.   
The Nottingham trial (Hardcastle, Chamberlain et al. 1996) identified over 150,000 people 
aged 45 to 74 over a ten year period and randomised them to undergoing biennial gFOBt or 
not. 60% uptake was achieved and of these 38% completed all the tests during the time 
period. After a median of 8 years follow-up, a 15% reduction in cancer specific mortality 
 70 
 
in the screening group was found. Tests were not rehydrated and dietary restrictions only 
imposed in borderline cases with a positivity rate of 2%. 
The results of these trials were the subject of a Cochrane review in 2000 (Towler, Irwig et 
al. 2000). This noted that screening benefits included reduction in colorectal cancer 
mortality, possible reduction in cancer incidence through detection and removal of 
colorectal adenomas and potentially, treatment of early colorectal cancers may involve less 
invasive surgery. However, it noted the harmful effects of screening including the physical 
complications of colonoscopy, disruption to lifestyle, stress and discomfort of testing and 
investigations, and the anxiety caused by false positive screening tests. For example, if 10 
000 people are invited to screening, and two-thirds choose to take part, 8.5 deaths would be 
prevented within 10 years, however 2800 patients will have undergone colonoscopy 
through the programme. Nevertheless, it was felt that the screening benefits were likely to 
outweigh harm for populations at increased risk of colorectal cancer, however more 
information was required prior to widespread adoption of a screening policy (Towler, 
Irwig et al. 2000).  
The evidence prompted the introduction of a pilot bowel screening programme in 2000 in 2 
health authorities in England and 3 health boards in Scotland involving a total of 478 250 
people aged 50-69. Results were similar to the Funen and Nottingham studies with uptake 
at 57%. The positive predictive values of finding a cancer at colonoscopy following a 
positive gFOBt screening test in the Scottish population was 12% and of a cancer or 
adenoma of 47% (UK Colorectal Cancer Screening Pilot Group 2004). 
A further Cochrane review published in 2007 and subsequently updated in 2010 
(Hewitson, Glasziou et al. 2007) performed a meta-analysis of the risks and benefits of 
screening with regards the follow up data from the 3 initial trials (Minnesota, Nottingham, 
Funen) and included a fourth trial published from Gothenburg in 2008 (Lindholm, 
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Brevinge et al. 2008). Overall, based on biennial screening, a reduction of colorectal 
cancer mortality of 15% was seen and in those who took up testing this increased to a 25% 
reduction. Median follow up in this updated review was 18 years for Minnesota, 17 years 
for Funen, 15 years for Gothenburg and 11 years for Nottingham. There was no reduction 
in all-cause mortality as cancer-related mortality is associated with only a small proportion 
of deaths in early stage disease. 
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Table 1.5: Summary of gFOBt trials  
 
Trial N Intervention Uptak
e 
+gFOBt 
rate 
 
%+gFOBt 
undergoing 
full 
investigation 
No. of CRC 
 
N 
(%+gFOBt) 
No. of 
Adenoma 
> 10mm 
n(%+gFOBt) 
Tumour Stage
a
 
N (% total screen detected) 
Mean/ 
Median 
F/U 
 
(Years) 
Reduction 
CRC spec. 
mortality 
 
I II III IV n/a 
Funen,  
1996 
 
30,967 
screened 
 
30,966 
control 
45-75 yrs 
-Biennial FOBt 
 
Dietary restrictions, 
non rehydrated 
 
67% 
 
1% 
 
89% 
 
37 (17%) 
 
68 (32%) 
 
48 
(40%) 
 
43 
(36%) 
 
19 
(11%) 
 
8 
(7%) 
 
2 
(2%) 
 
10 
 
16% 
Nottingham, 
1996 
76, 466 
screened 
 
76,384 
control 
- 45-74 yrs 
- Biennial FOBt 
- Dietary restriction 
only in borderline 
cases, non re-
hydrated 
 
53% 
 
2% 
 
- 
 
83 (10%) 
 
273 (33%) 
 
42 
(51%) 
 
17 
(20%) 
 
20 
(24%) 
 
4 
(5%) 
 
0 
 
8 
 
15% 
Minnesota, 
1993 
15,570 
screenA 
 
15,587 
screenB 
 
15,394 
control 
50-80 yrs 
Annual (screenA)   
 
 
Biennial (screenB) 
FOBt 
 
No dietary 
restriction, re-
hydrated kits 
 
75% 
(A)
 c
 
 
 
78% 
(B)
 c
 
 
 
 
9.8% 
 
83%~ 
 
 
84%~ 
 
(1-5%)
b
 
 
 
(1-6%)
b
 
 
 
 
(6-8%)
b
 
 
 
(7-10%)
b
 
 
 
107 
(30%) 
 
98 
(27%) 
 
 
 
101 
(29%) 
 
95 
(26%) 
 
80 
(23%) 
 
100 
(27%) 
 
33 
(9%) 
 
41 
(11%) 
 
33 
(9%) 
 
34 
(9%) 
 
13 
 
6% 
 
 
33% 
Gothenburg, 
2008 
 
34, 144 
screened 
 
34, 164 
control 
60-64 yrs 
 
Either 2 or 3 rounds 
of FOBt 
 
Dietary restrictions, 
re-hydrated kits 
 
63% 
 
3.8% 
 
87% 
 
47 (6%) 
 
114 (14%) 
 
44 
(42%) 
 
29 
(28%) 
 
24 
(23%) 
 
7 
(7%) 
 
0 
 
16 
 
16% 
 
1
st
 Round results and Follow-up mortality data unless otherwise specified  
a 
Nottingham: figures represent tumours picked up with a +ve FOBt and subsequent colonoscopy 1
st
 round only. Funen & Gothenburg: figures represent total amount of tumours diagnosed in 
screened cohort following a +FOBt and subsequent colonoscopy over during trial and follow-up period. Minnesota: figures represent total amount of tumours diagnosed in screened cohort 
including those who declined screening over trial and follow-up period. 
b
Based across all screening rounds PPV for cancer/adenoma. Range shown from 1 to 6 positive slides on FOBt 
c
Average across all screening rounds  
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1.2.4 The current Scottish Bowel Screening Programme pathway 
The SBoSP was introduced in a staged manner across Scotland from 2007 onward and is 
run by each individual healthboard. This began on NHS GG&C in April 2009. All males 
and females between the age of 50 and 74 and registered with a General Practitioner (GP) 
are identified via their Community Health Index (CHI) and invited to participate. Each 
participant is initially sent a pre-notification letter advising them that they would be 
receiving an invite to participate in the screening programme. This has been shown to 
increase participation (Libby, Bray et al. 2011). Each participant is then sent a gFOBt kit 
and asked to provide 2 samples from 3 separate faecal specimens (hema-screen, 
Immunostics, Ocean, New Jersey, USA, supplied by Alpha Laboratories, Eastleigh, 
Hampshire, UK). These are deposited on 6 oval windows provided in the kit and then the 
kit returned to the Scottish Bowel Screening Centre (Kings Cross Hospital, Dundee) for 
analysis in a pre-marked foil envelope (Figure 1.7). This is a purpose built test screening 
centre where tests are processed by hand. Tests are not rehydrated on arrival at the analysis 
centre and no dietary restrictions are imposed on test subjects.  
Tests are classified as positive if 5 out of 6 windows are positive, and weakly positive if 1-
4 windows are positive. In the case of a weakly positive result or a spoiled gFOBt kit, a 
further faecal immunochemical test (FIT) kit is sent out (hema-screen SPECIFIC, 
Immunostics, Ocean, New Jersey, USA, supplied by Alpha Laboratories, Eastleigh, 
Hampshire, UK) (Fraser, Digby et al. 2012). The cut-off levels for a positive result for the 
gFOBt and FIT tests are 600µg Hb/g faeces and 10 µg µg Hb/g faeces respectively. 
Following an overall positive test result, the local healthboard is contacted and are 
responsible for arranging further investigation. Individuals are pre-assessed, either face-to-
face or following telephone consultation, by a bowel screening endoscopy nurse and then 
referred on for colonoscopy if this is deemed suitable. The majority of patients in NHS 
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GG&C are pre-assessed via telephone consultation. If colonoscopy is unsuccessful then 
further bowel imaging by barium enema or CT pneumocolonography is attempted. In the 
case of a negative test the patient is re-invited 2 years later at their next screening round. 
For patients over the age of 74 who are no longer automatically invited, an opt-in system is 
possible if they so wish. The screening algorithm is summarised in Figure 1.7.  
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Figure 1.7: Current Scottish Bowel Screening Programme algorithm  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8: Scottish Bowel Screening Centre (Kings Hospital, Dundee) 
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1.2.5 Risks of colorectal cancer screening 
1.2.5.1 Complications of endoscopic procedures 
The major advantage of stool-based tests is that they are non-invasive. However a 
proportion of patients will undergo colonoscopy following a positive test and this is a 
procedure that is not without risk. Notably, there is a risk of perforation and significant 
haemorrhage. A previous study looking at over 25 000 colonoscopies quoted a perforation 
rate of 0.05% and a risk of post polypectomy bleeding of 0.15% (Lorenzo-Zuniga, Moreno 
de Vega et al. 2010). Clearly these risks will alter depending on the pathology found with 
those undergoing polypectomy at a higher risk of adverse events. Higher rates of adverse 
outcomes are associated with low-volume endoscopists and the presence of larger polyps 
(Lorenzo-Zuniga, Moreno de Vega et al. 2010). 
1.2.5.2 Psychological impact of screening 
In addition to the physical harm that can be caused by an endoscopic procedure there are 
further psychological impacts on the individual. For example, it has been suggested that 
the stress of a false positive result can adversely affect an individual. In a recent 
questionnaire study examining 600 individuals who had responded to a gFOBt screening 
invitation, it was found that anxiety levels were higher in those who tested positive 
compared to those who were negative and this persisted to 3 months post-result although 
had returned to normal by 12 months (Brasso, Ladelund et al. 2010). Interestingly there 
was no difference in the pattern of anxiety levels between those with true positives and 
those with false positives indicating that the stress is related to the process of subsequent 
investigation rather than the disease identified (Brasso, Ladelund et al. 2010). 
The converse of this is the potential reassuring nature that a negative result can have. In a 
population-based colonoscopy screening trial (n=225), 30% of patients actually had 
improved mental health scores post procedure when questioned at 5 weeks with no 
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difference between those who had polyps and those who had normal colonoscopies found 
(Taupin, Chambers et al. 2006). There were no cancers found in this relatively small 
patient cohort. The applicability of this being limited to colonoscopy, which has a much 
higher sensitivity than FOBt, is important to note. The issue with FOBt is that of false 
negatives that may falsely reassure an individual that colorectal cancer is not present. A 
previous study has noted that a negative gFOBt was associated with a delay to presentation 
in symptomatic patients (Schnell, Aranha et al. 1994).   
 
1.2.5.3 Lead-time and Length-time bias 
One of the criticisms of screening and analysis of data from screening programmes is that 
it can introduce two clear forms of bias (Kay and Witte 1991). The first is lead-time bias, 
where an earlier diagnosis of cancer in a pre-symptomatic phase artificial elongates an 
individual’s cancer-specific survival without altering that individual’s date of death (Figure 
1.9a). Secondly there is length time-bias, where the identification of indolent slow growing 
tumours artificially improves overall cancer-specific survival by detecting those who have 
a longer pre-clinical phase (Figure1.9b). The extreme form of length-time bias is 
overdiagnosis, whereby screening detects and eliminates tumours that may not have 
become apparent within a patients lifetime (Kay and Witte 1991). There is evidence from 
breast cancer screening that such overdiagnosis occurs, with a higher incidence of cancer 
being diagnosed in those who are invited to screening when followed up over 10 years 
(Allgood, Duffy et al. 2011). There is currently no evidence to support this phenomenon in 
colorectal cancer screening.  
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(a) 
(b) 
 
 
 
Figures adapted from (http://ecp.acponline.org/marapr99/primer.pdf) 
(b) 
 
Figure 1.9: Schematic representation of lead-time (a) and length-time (b) bias  
(Adapted from American College of Physicians) 
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1.3 Summary and Aims 
1.3.1 Summary 
Colorectal cancer is the third most common cause of cancer and the second most common 
cause of cancer death in the Western World. Outcome is directly related to stage at 
presentation, with those patients diagnosed at an earlier stage having excellent outcome 
following surgery and not requiring adjuvant therapy. However, independent of TNM 
Stage there are additional prognostic factors that have been shown to be of importance in 
determining outcome. These include features of the tumour, such as poor differentiation 
and venous invasion, and host-related factors both in terms of demographic profile and an 
elevated circulating host inflammatory response that are predictive of a worse outcome.  
Symptoms related to colorectal cancer can be non-specific and may not become apparent 
until tumours are at a more advanced stage. Hence a reliance on symptoms to aid with 
diagnosis of early-stage disease is problematic. There has therefore been an emphasis 
placed on screening patients either through stool based tests or endoscopic methods. While 
endoscopic methods have been shown to have improved sensitivity and specificity over 
stool tests, they are both invasive procedures, with associated risks, and resource intensive. 
Population screening for colorectal cancer using FOBt has therefore been introduced 
following three major randomised control trials and a Cochrane review that have show a 
reduction in cancer-specific mortality through the detection of early stage disease. 
However, there are concerns with this type of screening relating to uptake and test 
characteristics, and its impact at a population level has yet to be fully examined or proven. 
This is particularly important in the West of Scotland which is an area with high levels of 
socioeconomic deprivation.  
While population FOBt screening has been shown to detect early stage disease in those 
patients who choose to participate, it has been suggested that it may be limited in terms of 
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its ability to detect certain types of tumour such as more proximal colonic disease. 
Moreover, there is some evidence from screening programmes for other cancers, such as 
breast cancer, that screen-detected tumours may be different to non screen-detected 
tumours in terms of their phenotype. This has yet to be studied in detail within a population 
undergoing FOBt colorectal cancer screening. In addition, no study to date has explored 
important additional tumour and host prognostic factors, outside of TNM Stage, as 
discussed above, in relation to screening.  
Screening leads to the detection of early stage disease where the majority of patients will 
have a good outcome. However, within this some will develop recurrent or metastatic 
disease and ultimately succumb to their disease. There is a paucity of evidence examining 
determinants of outcome in TNM Stage I disease as prior to screening this made up a low 
proportion of patients encountered in clinical practice. It is therefore imperative that 
prognostic factors previously validated in TNM Stage II disease are assessed in TNM 
Stage I disease. 
Large population databases created through the organisation of screening programmes can 
be utilised not only to assess screening efficacy, but also to help explore additional factors 
associated with outcome in colorectal cancer. For, example, utilising screening data can 
improve our understanding of the development of symptoms and their relationship to 
disease progression. In addition, current concepts in chemoprevention can be examined by 
investigating relationships between potentially chemopreventative medications and 
outcomes at colonoscopy. This is something that has yet to be undertaken in detail and 
with substantial numbers within a screening programme.   
It has previously been reported that the majority of patients undergoing colonoscopy 
following a positive FOBt do not have colorectal cancer and a large proportion have 
premalignant adenomatous polyps. Stratification and prediction of outcome in these 
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patients is difficult and guidelines are currently reliant on characteristics of the adenomas 
removed. While the host inflammatory response has previously been examined in 
malignant disease, there is little evidence examining its role in adenomatous polyps. Such 
an understanding may aid not only with stratification but also with our understanding of 
the host inflammatory response to pre-malignant disease.  
The introduction of screening for colorectal cancer has not only the potential to alter the 
stage of disease at presentation and long term survival, but also the clinical management of 
the disease through a more fundamental understanding of the natural history. It is therefore 
important to examine the impact of colorectal cancer screening on the tumour and host 
related determinants of outcome.   
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1.3.2 Aims  
The first round of the population-based FOBt colorectal cancer screening in NHS Greater 
Glasgow & Clyde was used as a backdrop to examine in detail the areas of uncertainty 
described throughout the course of the introduction. The following studies were therefore 
carried out: 
1. To investigate the changes in mode, site and stage of presentation of colorectal cancer 
that have accompanied the introduction of the national screening programme 
2. To examine the first round of screening in detail with regards to the impact of age, sex 
and socioeconomic deprivation throughout all stages of the screening process. 
3. To examine the impact of altering the current screening algorithm to include flexible 
sigmoidoscopy following a positive FOBt, rather than colonoscopy, and assess the 
impact on neoplasia detection rate 
4. To examine the relationship between Aspirin, Statins and ACE-inhibitor usage and 
outcome at colonoscopy following a positive FOBt 
5. To examine the relationship between colorectal symptoms and outcome at colonoscopy 
following a positive FOBt 
6. To examine the sensitivity and specificity of the first round of screening and compare 
and contrast screen-detected and non screen-detected colorectal cancer 
7. To examine tumour and host determinants of outcome in TNM Stage I colorectal 
cancer 
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8. To examine the interrelationships between tumour and host clinicopathological 
characteristics in screen-detected T1/2 colorectal cancer 
9. To examine the local inflammatory response in screen-detected non-malignant disease 
and assess it relationship to polyp characteristics  
 84 
 
2 COLORECTAL CANCER IN THE WEST OF 
SCOTLAND: A DECADE OF EXPERIENCE  
2.1 Introduction 
Several large randomised control trials examining guaiac-based Faecal Occult Blood test 
(gFOBt) colorectal cancer screening programmes have shown a reduction in cancer 
specific mortality through the detection of early stage disease (Mandel, Bond et al. 1993; 
Kronborg, Fenger et al. 1996; Scholefield, Moss et al. 2002). Therefore, national bowel 
screening programmes have been introduced across the UK over the past ten years. 
However, it is important to consider screening within the context of the whole population 
that is being served by the screening programme. For example the current Scottish Bowel 
Screening Programme (SBoSP) is only targeted to those aged 50 to 74 years, with a few 
over the age of 74 opting in to further testing. In addition there is limited uptake, sensitivity 
and specificity of the testing algorithms in use. Therefore, clearly, not all tumours will be 
screen-detected and it is unclear what the overall impact on the population will be. 
Indeed, a previous single centre study from Scotland has suggested that screen-detected 
tumours may account for just 17% of all tumours diagnosed within a population invited to 
screening (Roxburgh, McTaggart et al. 2013). Additionally it had been noted that despite 
screening detecting an increased number of early stage tumours, it may not lead to an 
overall stage-shift to earlier disease across the population (Roxburgh, McTaggart et al. 
2013). However, there are additional benefits that may be gained from screening. For 
example, it may reduce the rate of emergency presentation (Scholefield, Robinson et al. 
1998) which has been noted to be an independent negative prognostic feature in colorectal 
cancer (McArdle and Hole 2004).   
The aim of the present Chapter was to examine the impact that screening has had on the 
mode, site and stage of presentation of colorectal cancer in the West of Scotland over the 
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past decade. The aim was to achieve this by using population statistics from the West of 
Scotland Managed Clinical Network (MCN) to compare cohorts before, during and after 
the introduction of the SBoSP.  
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2.2 Materials and methods 
The West of Scotland Colorectal Cancer Managed Clinical Network (MCN) covers 4 
Health Boards (Ayrshire & Arran, Forth Valley, Greater Glasgow & Clyde and 
Lanarkshire) comprising 16 different hospitals and covering a population of over 2.4 
million, just under half of the population of Scotland (Figure 2.1). It was created in 2000 
with the aim of improving outcomes in colorectal cancer. All patients discussed at a local 
hospital multidisciplinary team (MDT) with a diagnosis of colorectal cancer are included, 
with clinicopathological data prospectively recorded. Details including age, sex, 
socioeconomic deprivation category, mode of presentation and tumour site and stage are 
routinely stored. For the present study, data was extracted for a period from 1
st
 January 
2003 to 31
st
 December 2012.    
The mode of presentation was defined as emergency if the patient underwent management 
involving a hospital admission that was unplanned. This included but was not limited to 
significant per rectal bleeding, colonic obstruction and perforation. Other routes were 
defined as elective including screen-detected which was introduced as a data-point from 
2007 onward.   
Tumour site was classified according to anatomical site as per International Classification 
of Disease version 10 (ICD-10). Lesions up to but not including the splenic flexure were 
classified as right sided (C18.0 – C18.4), those from splenic flexure up to but not including 
the retosigmoid junction were defined as left sided (CC18.5 – C18.7) and tumours of the 
rectosigmoid junction and rectum were classed as rectal (C19 and C20). Tumour stage was 
defined according to the standard TNM (version 5) classification (Sobin and Fleming 
1997) based on histological resection of specimens and, in those who did not under go 
resection, on pre-operative imaging modalities. Polyp cancers, which underwent 
endoscopic excision only, were classified as TNM Stage I disease. Intent of procedure was 
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collated at the time of resection as either curative or palliative by the surgical team 
responsible for each individual patient. 
Socioeconomic deprivation status was calculated from the Scottish Index of Multiple 
Deprivation (SIMD) which is an index of relative deprivation (SIMD 2009). Quintiles of 
deprivation were used to assign individuals a relative deprivation category based on their 
postcode at time of diagnosis with the first quintile representing the most deprived and the 
fifth quintile, the least deprived. The most current version of SIMD was used at the time of 
data collection (i.e. SIMD 2004 for patients in 2003 to 2005, SIMD 2006 for patients in 
2006, 2007 and 2008 etc.)  
The SBoSP is a biennial gFOBt/FIT based screening programme for all individuals aged 
50-74 years. Details on the current screening algorithm have been covered in Chapter 1. 
Briefly, all individuals aged 50-74 years are sent a pre-invitation letter and then a gFOBt 
and referred for colonoscopy if this is returned and is strongly positive (>5 of 6 windows 
positive).  In the case of a weakly positive gFOBt (1-4 of 6 windows positive) or spoiled or 
untestable kit a confirmatory Faecal Immunochemical Test (FIT) is sent.  Individuals then 
proceed to colonoscopy, following pre-assessment, by a bowel screening pre-assessment 
nurse.   Screening was introduced across the 4 Health Boards at staged intervals (Figure 
2.1), therefore, the data was separated into 5 distinct time frames. 2003-2004 early pre-
screening (EPrS), 2005-2006 late pre-screening (LPrS), 2007-2008 early introduction of 
screening (ES) where the minority of the population were invited, 2009-2010 late 
introduction of screening (LS), where the majority of the population were invited and 2011 
to 2012 post introduction of screening (PoS) where screening had been introduced across 
all 4 boards. This allowed for assessment not only of the impact of screening but also of 
the temporal changes in disease presentation and management across the area across the 
decade.  
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Permission for the study was granted by the Caldicott guardian for the data and all data 
was stored and analysed in an anonymised manner 
Statistical analyses 
Associations between categorical variables were examined using χ
2
 tests for linear trend 
unless otherwise specified. A value of p<0.05 was considered statistically significant. 
Statistical analysis was performed using SPSS software (SPSS Inc., Chicago, IL, USA) 
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a
derived from invitations between 1st November 2010 and 31st October 2012 (ISD, 2013) 
 
Figure 2.1: Population of NHS Health Boards across Scotland, area covered by the 
MCN, date of screening introduction and uptake of test 
 (Adapted from Information Services Division Scotland) 
 NHS Health Board Population 
(est. 2009) 
Screening Introduction Screening 
uptake (%)
a
 
1 Ayshire & Arran           372 380 September 2007 55 
2 Borders           113 380 November 2009 60 
3 Dumfries & 
Galloway 
          151 160 December 2008 58 
4 Western Isles             27 420 July 2008 57 
5 Tayside           404 390 June 2007 59 
6 Forth Valley           294 140 December 2007 55 
7 Grampian           559 210 June 2007 61 
8 Greater Glasgow & 
Clyde 
       1 199 830 April 2009 53 
9 Highland           318 200 December 2009 61 
10 Lanarkshire           569 800 August 2009 48 
11 Lothian           816 640 May 2008 54 
12 Orkney             20 940 October 2007 63 
13 Shetland             22 790 October 2009 64 
14 Fife           361 410 June 2007 56 
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2.3 Results 
From 1
st
 January 2003 to 31
st
 December 2012, there were 14487 incident cases of 
colorectal cancer. There were 7827 (54%) males, 9912 (69%) were over the age of 65 
years and the majority were in the two most deprived quintiles of deprivation (7727 
(53%)). Overall, 2163 (15%) patients presented to surgery as an emergency (Table 2.1).  
On examining patient demographics over the decade of analysis, there were no changes 
seen in the age and sex of patients at diagnosis, however there was a weak trend for those 
in PoS to be more deprived in later years (p=0.057). There was a significant reduction in 
the proportion of patients presenting to surgery as an emergency over the timeframe from 
20% EPrS to 13% PoS (p<0.001) (Table 2.1). 
On examining tumour characteristics, there was a reduction in the proportion of rectal 
cancers diagnosed over the timeframe from 34% EPrS to 31% PoS (p=0.001). Comparing 
procedure intent, excluding those who did not undergo a procedure, more patients 
underwent a procedure with a curative intent in later years (76% EPrS vs 84% PoS, 
p<0.001) (Table 2.1). Overall, 3379 (23%) patients had incomplete TNM staging 
information and 708 (5%) patients had evidence of distant metastatic disease. These were 
subsequently excluded from analysis and Stage I to III disease was examined 
independently. Over the timeframe, there was a shift amongst those without distant 
metastases towards a higher proportion of Stage I cancers in later years (17% EPrS vs 28% 
PoS, p<0.001) (Table 2.2). 
Patients with colorectal cancer diagnosed in the PoS timeframe were further examined to 
compare screen-detected and non screen-detected disease (Table 2.3). Patients with screen-
detected disease were more likely to be younger (p<0.001), male (p<0.001), less deprived 
(p=0.002) and present electively (p<0.001). In addition screen-detected tumours were more 
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likely to be distal (p<0.001), of an earlier stage (p<0.001) and managed with a curative 
intent (p<0.001). 
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2.4 Discussion 
This Chapter provides an overview of the changes in mode, site and stage of colorectal 
cancer presentation in a single geographical area over the past decade, accompanying the 
introduction of a national screening programme. The present study has shown a reduction 
in emergency presentation, a reduction in the proportion of rectal cancers and a shift 
amongst those without distant metastases to earlier stage at diagnosis. Furthermore, an 
overall increase in the proportion of patients managed with a curative intent has been 
identified. 
Examining the impact of screening on overall TNM Stage at presentation using population-
based datasets can be problematic. This is due to high numbers of patients with incomplete 
staging information and limited information on those with metastatic disease. For example, 
in a recent population study examining tumours diagnosed within and without the English 
Bowel Cancer Screening Programme, 25% of cases were unstaged (Morris, Whitehouse et 
al. 2012), similar to the present study. In addition, patients who do not have complete 
staging information are more likely to die closer to their time of diagnosis, implying the 
presence of more advanced disease (Downing, Aravani et al. 2013).  
The MCN has been introduced to improve outcome in colorectal cancer through delivery 
of high quality care with a focus on surgical outcomes. Data is collated following local 
MDT discussion, therefore information on patients with metastatic disease who are 
managed palliatively is poorly captured. It is recognised that this limitation of the dataset is 
particularly true in the early cohorts. For example, only 1% of patients in the EPrS 
timeframe did not undergo a procedure compared to 20% of patients in PoS timeframe. 
Furthermore, examining Stage IV disease across the timeframe actually showed an 
increase from 3% (EPrS) to 9% (PoS) with a concurrent rise in unstaged disease from 13% 
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(EPrS) to 25% (PoS) (data not presented). However, this clearly identifies a failure in 
capture of metastatic or incompletely staged patients of the MCN dataset. 
Therefore, in order to maintain data quality when examining stage, the present study chose 
to focus only on those without distant metastases. When this was considered separately, a 
clear trend towards larger proportions of node-negative and Stage I disease following 
screening introduction was seen. It has been reported that tumours detected through the 
screening pathway are of an earlier stage compared to non-screen detected and the present 
study supports this finding (Morris, Whitehouse et al. 2012; Roxburgh, McTaggart et al. 
2013). In addition, despite only accounting for 18% of all tumours diagnosed, an overall 
impact on the population has been noted. Such a change may well be associated not only 
with the test itself, but with an overall improvement in the knowledge and attitudes of the 
population with the widespread publication of screening information. However, there 
should be a degree of caution used in interpreting this stage-shift amongst those without 
distant metastases, as it has been shown that the proportion of Stage I disease may well 
reduce with successive screening rounds (Steele, McClements et al. 2009). Hence, further 
work examining the impact on stage at a population level as subsequent rounds of 
screening occur is required for clarification.  
Emergency presentation has long been associated with both poorer short-term (Anderson, 
Hole et al. 1992; McArdle and Hole 2004) and long-term outcomes (McMillan, McArdle 
et al. 2010; Gunnarsson, Holm et al. 2011). This disparity has been shown to exist even 
when node-negative disease is examined independently (Oliphant, Mansouri et al. 2014). 
The reason for this poorer outcome appears multifactorial incorporating elements such as 
tumour characteristics (Wong, Jalaludin et al. 2008), pre-operative patient morbidity 
(Skala, Gervaz et al. 2009), use of a specialist surgeon (Biondo, Kreisler et al. 2010) and 
the presence of an elevated host pre-operative systemic inflammatory response (Crozier, 
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Leitch et al. 2009). There is evidence from the Nottingham gFOBt screening trial that 
emergency presentation is reduced in a population undergoing screening (Scholefield, 
Robinson et al. 1998). In addition, the Coventry arm of the population pilot study reported 
similar findings, with emergency admissions from colorectal cancer reducing from 29% in 
1999 to 16% in 2004, with a concomitant improvement in 30-day mortality, following 
screening introduction (Goodyear, Leung et al. 2008). Interestingly, the present study 
showed a reduction in the proportion of emergency presentation prior to the introduction of 
screening, however little change during its rollout and widespread adoption. It therefore 
questions the impact that screening itself has had on overall emergency presentation in our 
geographical area. This is in keeping with a recently published cohort study that has shown 
that emergency admissions are reduced when comparing participants and non-participants 
in screening, however remain similar comparing cohorts invited and not invited to 
screening (Libby, Brewster et al. 2014). Therefore, it appears that it is participation and not 
invitation that is the key determinant in reducing emergency admissions.  
In the present study, only 18% of all patients in the PoS cohort presented through the 
screening programme. This is on the background of an overall uptake of screening in our 
geographical region of 52% with lower uptake in the most deprived cohorts. Higher rates 
of emergency presentation are associated with socioeconomic deprivation and elderly age 
(Gunnarsson, Ekholm et al. 2013). However, such deprived patients are less likely to 
choose to participate in screening (Steele, Kostourou et al. 2010; von Wagner, Baio et al. 
2011) and patients over the age of 74 years are currently not routinely invited to screening. 
Moreover, it has previously been shown that those patients who are socioeconomically 
deprived have a worse outcome following a diagnosis of colorectal cancer (Kelsall, 
Baglietto et al. 2009; Oliphant, Nicholson et al. 2013). Hence, the current screening 
programme may underserve the very people who do worse. Efforts to improve uptake of 
the programme should therefore be made to target such subgroups. One of the concerns 
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raised regarding screening is that it may widen the gap in outcomes that has been created 
by socioeconomic deprivation and this may be associated with its effect on the rate of 
emergency presentation.  
The strengths of the present study are its size and the prospectively collected core dataset 
including data on emergency presentation. It is recognised that there are issues with 
utilising population-based databases such as missing data. Nevertheless, such prospective 
datasets provide an opportunity to examine overall trends. Furthermore there are additional 
tumour and host variables that determine outcome independent of TNM stage that would 
be of interest to explore, however, these were not collected prospectively over the time 
period. This is particularly relevant for Stage II disease where outcome can be varied 
(Roxburgh, McMillan et al. 2014; Park, Watt et al. 2015). Further work with mature 
follow-up and detailed tumour and host information is required to assess the impact on 
outcome particularly in Stage II disease.  
A further limitation is utilising data over a decade, where staging modalities may have 
altered. For example, changes in the sensitivity of CT in detecting metastatic disease or 
changes in the approach to the pathological processing of specimens may have led to a 
comparative understaging of those in the earlier cohorts (i.e. a more attentive approach to 
lymph node examination in later years). However, such bias is difficult to avoid when 
examining historical data. Finally, our definition of emergency presentation includes those 
admitted with acute bleeding. Recently it has been reported that those patients with 
colorectal cancer who present with GI bleeding have a better outcome than others and as 
such grouping these along with colonic perforation and obstruction is suboptimal 
(Alexiusdottir, Snaebjornsson et al. 2013). Nevertheless, this was the definition of an 
emergency as coded prospectively in the dataset therefore precluded more detailed 
analysis. 
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In conclusion, examining population data from the West of Scotland over the past decade 
has identified that the SBoSP now accounts for 18% of all tumours encountered in clinical 
practice. Over the past decade, accompanying the introduction of screening, there has been 
a reduction in the rate of emergency presentation, a rise in the proportion of operative 
procedures performed with a curative intent and, in patients with no evidence of distant 
metastases, a shift towards an increased number of earlier stage tumours. These changes 
are likely to improve outcomes overall in the West of Scotland for patients presenting with 
colorectal cancer, however, there is a need for high quality follow-up to establish this. 
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Table 2.1: Temporal trends in colorectal cancer presentation with the introduction of screening 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Pre-screening Screening Introduction Post-screening  
 All pts  
 
n (%) 
 Early 
2003-2004 
n (%) 
Late 
2005-2006 
n (%) 
Early 
2007-2008 
n (%) 
Late 
2009-2010 
n (%) 
 
2011-2012 
n (%) 
 
p-value 
  
14 487 
  
2380 
 
2384 
 
3098 
 
3282 
 
3343 
 
Age         
    <50 yrs 751 (5)  129 (5) 129 (5) 172 (6) 139 (4) 182 (5)  
    50 - 74 yrs 8142 (56)  1250 (53) 1368 (57) 1702 (55) 1897 (58) 1925 (58)  
    >75 yrs 5299 (37)  851 (35) 793 (33) 1202 (39) 1224 (37) 1229 (37) 0.584 
   Unknown 295 (2)  150 (6) 94 (4) 22 (1) 23 (1) 6 (0)  
Sex         
     Female 6364 (44)  1017 (42) 1054(44) 1384 (45) 1416 (43) 1493 (45)  
     Male 7827 (54)  1213 (51) 1236 (52) 1692 (55) 1843 (56) 1843 (55) 0.169 
     Unknown 296 (2)  150 (6) 94 (4) 22 (1) 23 (1) 7 (0)  
Deprivation category         
     1 (most deprived) 4329 (30)  667 (28) 706 (30) 935 (30) 978 (30) 1043 (31)  
     2 3398 (23)  545 (23) 555 (23) 732 (24) 776 (24) 790 (24)  
     3 2370 (16)  364 (15) 380 (16) 529 (17) 557 (17) 540 (16)  
     4 1921 (13)  307 (13) 300 (13) 406 (13) 433 (13) 475 (14)  
     5 (least deprived) 2072 (14)  247 (16) 349 (15) 474 (15) 514 (16) 488 (15) 0.057 
     Unknown 297 (2)  150 (6) 94 (4) 22 (1) 24 (1) 7 (0)  
Presentation to surgery         
     Emergency 2163 (15)  480 (20) 431 (18) 414 (13) 420 (13) 418 (13)  
     Elective - symptomatic 8948 (62)  1849 (78) 1868 (78) 1910 (62) 1729 (53) 1592 (47)  
                    - screen-detected
a
 1200 (8)  - - 107 (3) 486 (15) 607 (18) <0.001
b 
     Did not undergo procedure 2056 (14)  30 (1) 56 (2) 624 (20) 642 (20) 704 (21)  
     Unknown 115 (1)  21 (5) 29 (3) 43 (1) 5 (0) 22 (1)  
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Table 2.1: Temporal trends in colorectal cancer presentation with the introduction of screening (continued)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
Recorded from 2007 onwards 
b
 Emergency vs all Elective (including screen-detected)
  
c 
Curative vs palliative resection 
 
 
  
   Pre-screening Screening Introduction Post-screening  
 
All pts  
 
n (%) 
 Early 
2003-2004 
n (%) 
Late 
2005-2006 
n (%) 
Early 
2007-2008 
n (%) 
Late 
2009-2010 
n (%) 
 
2011-2012 
n (%) 
p-value 
 
 
14 487 
  
2380 
 
2384 
 
3098 
 
3282 
 
14 487 
 
Site of tumour         
     Right Colon  4857 (34)  753 (32) 811 (34) 1048 (34) 1099 (34) 1146 (34)  
     Left Colon 4827 (33)  790 (33) 736 (31) 997 (32) 1165 (35) 1139 (34)  
     Rectum  4647 (32)  825 (34) 818 (34) 996 (32) 983 (30) 1025 (31) 0.001 
     Multiple/unknown 156 (1)  12 (1) 19 (1) 57 (2) 35 (1) 33 (1)  
Management Intent         
     Curative intent 9980 (68)  1797 (76) 1744 (73) 1972 (64) 2238 (68) 2229 (67)  
     Palliative procedure 1877 (13)  440 (18) 389 (16) 337 (11) 334 (10) 377 (11) <0.001
c
 
     Did not undergo procedure 2056 (14)  30 (1) 56 (2) 624 (20) 642 (20) 704 (21)  
     Unknown/other 574 (4)  113 (5) 195 (8) 165 (5) 68 (2) 33 (1)  
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Table 2.2: Temporal trends in TNM stage of colorectal cancer at presentation with the introduction of screening (non-metastatic disease only) 
 
 
 
 
 
 
 
 
 
 
   Pre-screening Screening Introduction Post-screening  
 All pts  
 
 
n (%) 
 Early 
2003-2004 
 
n (%) 
Late 
2005-2006 
 
n (%) 
Early 
2007-2008 
 
n (%) 
Late 
2009-2010 
 
n (%) 
 
2011-2012 
 
n (%) 
 
p-value 
  
10400 
  
1999 
 
1992 
 
2072 
 
2118 
 
2219 
 
TNM Stage         
      I 2134 (17)  348 (17) 329 (17) 367 (18) 461 (22) 629 (28)  
      II 4124 (40)  791 (40) 803 (40) 884 (42) 834 (40) 812 (37)  
      III 4142 (43)  860 (43) 860 (43) 821 (40) 823 (39) 778 (35) <0.001 
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Table 2.3: Comparison of screen-detected and non screen-detected colorectal cancer 
in the West of Scotland (2011-2012) 
 
 
All 
patients 
 
 
Screen 
detected 
 
Non-screen 
detected 
 
 
 n(%)  n(%) n(%) p-value 
      
 3343  672 2671  
Age      
    <50 yrs 182 (5)  1 (0) 182 (7)  
    50 - 74 yrs 1925 (58)  607 (90) 1318 (49)  
    >75 yrs 1229 (37)  64 (10) 1165 (44) <0.001 
   Unknown 6 (0)  0 (0) 6 (0)  
Sex      
     Female 1493 (45)  246 (37) 1247 (47)  
     Male 1843 (55)  425 (63) 1418 (53) <0.001 
     Unknown 7 (0)  1 (0) 6 (0)  
Deprivation category      
     1 (most deprived) 1043 (31)  192 (29) 851 (32)  
     2 790 (24)  150 (22) 640 (24)  
     3 540 (16)  97 (14) 443 (17)  
     4 475 (14)  115 (17) 360 (14)  
     5 (least deprived) 488 (15)  117 (17) 371 (14) 0.002 
     Unknown 7 (0)  1 (0) 6 (0)  
Site of tumour      
     Right Colon  1146 (34)  171 (25) 975 (37)  
     Left Colon 1139 (34)  284 (42) 855 (32)  
     Rectum  1025 (31)  214 (32) 811 (30) <0.001 
     Multiple/unknown 33 (1)  3 (0) 30 (1)  
Management Intent      
     Curative intent 2229 (67)  600 (89) 1629 (61)  
     Palliative procedure 377 (11)  27 (4) 350 (13) <0.001
a
 
     Did not undergo procedure 704 (21)  40 (6) 664 (25)  
     Unknown/other 33 (1)  5 (1) 28 (1)  
Presentation to surgery      
     Emergency 418 (13)  12 (2) 406 (15)  
     Elective 2199 (65)  607 (90) 1592 (60) <0.001
b
 
     Did not undergo procedure 704 (21)  40 (6) 664 (25)  
     Unknown 22 (1)  13 (2) 9 (0)  
TNM Stage      
     I 629 (19)  256 (38) 373 (14)  
     II 812 (24)  164 (24) 648 (24)  
     III 778 (23)  155 (23) 623 (23)  
     IV 295 (9)  24 (4) 271 (10) <0.001 
     Unknown/other 829 (25)  73 (11) 756 (28)  
 
a 
Curative vs palliative resection
  
b 
Emergency vs elective presentation 
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3 THE IMPACT OF AGE, SEX AND 
SOCIOECONOMIC DEPRIVATION ON 
OUTCOMES IN A COLORECTAL CANCER 
SCREENING PROGRAMME 
3.1 Introduction 
There is evidence that an individuals risk of colorectal cancer is associated with 
socioeconomic deprivation, in particular in males, with those in the least deprived 
categories having a 20% lower incidence compared with those in the most deprived 
(Oliphant, Brewster et al. 2011). There is also evidence that following a diagnosis of 
colorectal cancer, those who are more socioeconomically deprived have both a poorer 
cancer specific and overall survival (Hole and McArdle 2002). 
As discussed in the previous chapter, bowel screening programmes utilising both gFOBt 
and FIT have been introduced across the UK and have seen overall participation rates of 
over 50% (Steele, McClements et al. 2009; von Wagner, Baio et al. 2011). Within this, 
however, participation rates may vary widely across demographic groups, with those who 
are male, younger, more deprived and more ethnically diverse reported less likely to 
engage in the process (Steele, Kostourou et al. 2010; von Wagner, Baio et al. 2011). This 
has added further weight to the suggestion that such individuals may gain a 
disproportionately low share of the survival benefits from screening (Whynes, Frew et al. 
2003).  
The Scottish Bowel Screening Programme (SBoSP) was introduced in a staged manner 
across Scotland beginning in 2007 and was introduced in NHS Greater Glasgow and Clyde 
in April 2009. In particular, this geographical area is recognised to be one in which there is 
a high incidence of multiple deprivation. For example, NHS Greater Glasgow and Clyde 
encompasses an area that includes 49% of the most deprived areas in Scotland. This is the 
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highest proportion of any health board in Scotland and can be compared to the second 
highest proportion which is 7% in Edinburgh (SIMD 2009).  
The aim of the present study was to examine, in an area of multiple deprivation, the impact 
of age, sex and socioeconomic deprivation not only on uptake, but throughout all stages of 
the screening process. 
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3.2 Materials and methods 
Beginning in April 2009 all males and females between the age of 50 and 74 and registered 
with a General Practitioner (GP) in NHS Greater Glasgow & Clyde were identified via 
their Community Health Index (CHI) and invited to participate in the SBoSP. Each 
participant was initially sent a pre-notification letter advising them that they would be 
receiving an invite to participate in the screening programme. Each participant was then 
sent a gFOBt kit and asked to provide 2 samples from 3 separate faecal specimens. The 
screening algorithm of the SBoSP has been covered in Chapter 1. Following a positive test 
result, individuals were pre-assessed, either face-to-face or following telephone 
consultation, by a bowel screening endoscopy nurse and then referred on for colonoscopy 
if this was deemed suitable. If colonoscopy was unsuccessful then further bowel imaging 
by barium enema or CT pneumocolonography was attempted. As screening is biennial, two 
years worth of test invitations were taken to comprise one complete screening round. 
Participant details were obtained from a prospectively maintained database held by the 
Public Health Screening Unit in NHS Greater Glasgow and Clyde. In order to establish a 
robust dataset, data on endoscopic findings and pathological diagnosis was obtained 
retrospectively from clinical information systems on a case-by-case basis. These results 
formed the basis of the analysis. The presence of uncomplicated diverticulosis and 
hyperplastic polyps was noted as normal findings. The presence of colitis/proctitis, 
angiodysplasia, or haemorrhoids were classified as non-neoplastic pathology as a cause of 
the positive test.  
Deprivation category was calculated using the Scottish Index of Multiple Deprivation 2009 
(SIMD) which is an index of relative deprivation combining multiple detailed indicators 
across 7 domains (SIMD 2009). The overall index is a weighted rank for each of these 
domains; income (28%), employment (28%), health (14%), education, skills and training 
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(14%), geographic access (9%), crime (5%) and housing (2%). Based on this weighted 
rank, the 6505 postcodes in Scotland are ranked in order of deprivation. Each postcode 
represents a small geographical area containing around 750 people. Quintiles of 
deprivation were used to assign individuals a relative deprivation category based on their 
postcode at time of colonoscopy with the first quintile representing the most deprived and 
the fifth quintile, the least deprived. Therefore, those in the first quintile, the most 
deprived, were likely to have higher levels of poverty, unemployment and poorer health 
than those in the fifth quintile, who were least deprived.     
In those individuals in whom a pathological diagnosis of dysplastic polyps was reached, 
they were classified as being of a low risk, intermediate risk or high risk of subsequent 
development of colorectal cancer as per British Society of Gastroenterology (BSG) 
guidelines (Atkin and Saunders 2002). (low risk; 1 to 2 polyps <1cm: intermediate risk; 3-
4 polyps <1cm or > 1 polyp > 1cm: high risk; >5 polyps or > 3 polyps of which > 1 is > 
1cm). Low risk polyps were termed non-significant and intermediate or high risk polyps 
termed significant. 
In those individuals in whom a diagnosis of colorectal cancer was reached, initial staging 
for comparison was following endoscopic and imaging modalities. Subsequent, 
pathological classification in those who underwent operations was by the standard TNM 
(version 5) classification (Sobin and Fleming 1997) based on histological resection of 
specimens. Individuals in whom a polyp cancer was considered to be completely excised 
endoscopically and hence did not undergo further colonic resection, were presumed to be 
node negative and classified as Stage I. 
The positive predictive value (PPV) for detecting cancer was defined as the number of 
individuals in whom a cancer was detected divided by the number of individuals 
undergoing colonoscopy. The PPV for neoplasia was defined as the number of individuals 
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in whom a cancer or dysplastic polyp was identified divided by the number of individuals 
undergoing colonoscopy and the PPV for significant neoplasia was the number of 
individuals with either a cancer or significant polyps divided by the number of individuals 
undergoing colonoscopy. The cancer detection rate was defined as the number of 
individuals detected with cancer divided by the number who responded to screening test 
invitation. 
 
Statistical analysis 
Associations between categorical variables were examined using χ
2
 tests for linear trend 
unless otherwise specified. Multivariate analysis was carried out using binary logistical 
regression. A value of p<0.05 was considered statistically significant. Statistical analysis 
was performed using SPSS software (SPSS Inc., Chicago, IL, USA) 
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3.3 Results 
From April 2009 to March 2011 inclusive, 395 096 individuals were invited to participate 
in screening in whom full details on age, sex and deprivation were available for 394 117 
(99.8%) which were included for analysis. 192 294 (48.8%) were in the two most deprived 
quintiles of deprivation and 192 312 (48.9%) were male. The demographic details are 
shown in Table 1 and a flow diagram of the cohort is outlined in Figure 3.1. 
 
Outcome of screening invitation 
Of the 394 117 people invited, 204 139 (51.8%) chose to take up the test (Table 3.1). 
Uptake was higher in older individuals (45.8% vs 54.6% vs 55.3%, p<0.001), females 
(55.4% vs 48.1%, p<0.001), and those who were less socioeconomically deprived (62.7% 
least deprived vs 42.0% most deprived, p<0.001). Due to significant interrelationships 
between age, sex and deprivation in the cohort invited to screening, multivariate analysis 
was undertaken. The relationships between age, sex and deprivation identified on 
univariate analysis remained significant (p<0.001). 
 
Outcome of screening test 
Of the 204 139 who took up the test, 6 079 (3.0%) tested positive (Table 3.2).  Positivity 
rates were higher with advancing age (2.0% vs 2.7% vs 4.1%, p<0.001), in males (3.8% vs 
2.3%, p<0.001), and in those who were more deprived (4.2% most deprived vs 1.9% least 
deprived, p<0.001). Due to a significant interrelationship between age and sex in the 
cohort responding to the screening invitation, multivariate analysis was undertaken. The 
relationships with both increasing age and increasing deprivation, and higher positivity 
rates, remained significant (p<0.001). 
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Figure 3.1: Outcomes of the first round of screening in NHS GG&C 
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Attendance for colonoscopy 
Of the 6 079 positive cases, following pre-assessment, 4 625 (76.1%) individuals attended 
for colonoscopy (Table 3.3). Failure to attend for colonoscopy was not associated with age 
or sex. However, it was associated with deprivation (80.0% least deprived vs 73.3% most 
deprived, p<0.001). 
 
Outcome of colonoscopy 
Cancer 
 Of the 4 625 individuals who underwent colonoscopy, full endoscopic and pathological 
results were available for 4 218 (91.2%) which were included for analysis. Cancer was 
detected in 396 individuals (9.4%) (Table 3.4). Increasing age (5.3% vs 8.1% vs 11.9%, 
p<0.001) and male sex (10.5% vs 7.7%, p=0.002) were associated with higher PPVs of 
cancer at colonoscopy. Despite the highest test positivity rates in the most deprived 
individuals, being less deprived was actually associated with a higher PPV for cancer 
(10.5% least deprived vs 7.8% most deprived, p=0.003). Due to significant 
interrelationships between age, sex and deprivation within those who underwent 
colonoscopy, multivariate analysis was undertaken. Older age and male sex remained 
significant (both p<0.05), however the relationship between reduced deprivation and a 
higher likelihood of cancer remained significant in those in the 3 least deprived quintiles of 
deprivation only.  
Of the 396 individuals with cancer, completing staging information was present in 379 
(95.7%). Of these, 181 (48.1%) tumours were Stage I, 80 (21.1%) were Stage II, 93 
(24.5%) were Stage III and 25 (6.6%) were Stage IV. There was no effect of age, sex and 
deprivation on the stage of cancer detected through screening.  
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Dysplastic polyps 
Of the 4 218 with colonoscopy results, 1 984 (47.0%) had dysplastic polyps detected 
(Table 3.5). Of the 1 984 individuals with dysplastic polyps, 662 (33.4%) individuals had 
non-significant polyps, and 1322 (66.6%) individuals had significant polyps (937 (70.8%) 
were intermediate risk and 385 (29.1%) were high risk). This gave a PPV for neoplasia 
(cancer or polyp) of 56.4% and a PPV for significant neoplasia (significant polyp or 
cancer) of 40.7% at colonoscopy. Increasing age (43.6% vs 56.3% vs 62.0%, p<0.001: 
30.2% vs 40.2% vs 45.6%, p<0.001) and male sex (66.0% vs 42.5%, p<0.001: 48.4% vs 
29.5%, p<0.001) were associated with higher PPVs of both of these measures. Again, 
despite the highest test positivity rate in the most deprived individuals, being less deprived 
was actually associated with a higher PPV for both neoplasia and significant neoplasia 
(58.7% least deprived vs 53.3% most deprived, p=0.016: 45.0% least deprived vs 36.9% 
most deprived, p<0.001). There was no apparent association between age and deprivation 
noted, therefore the data was further stratified by sex only. The relationship with increasing 
age and a higher PPV for neoplasia and significant neoplasia age remained (p<0.001). The 
relationship between deprivation and lower PPV for both neoplasia and significant 
neoplasia remained only in males (p<0.005). 
Within the 1 984 individuals with dysplastic polyps, the presence of significant polyps was 
associated with being male (68.3% vs 62.7%, p=0.015) and being less deprived (71.5% 
least deprived vs 63.9% most deprived, p=0.006) (Table 6). There was no association with 
age noted (p=0.452).. Within those with significant polyps, there were no significant 
interrelationships noted between age, sex and socioeconomic deprivation therefore 
multivariate analysis was not undertaken.  
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Non-neoplastic pathology 
Of the 4 218 with colonoscopy results, 488 (11.6%) had non-neoplastic colorectal 
pathology identified as being a cause for the positive test result (Table 3.5). Younger age 
(14.9% vs 11.6% vs 10.1%, p<0.001), and being female (14.2% vs 9.8%, p<0.001) was 
associated with an increased likelihood of non-neoplastic colorectal pathology being 
identified. No association with deprivation was found (p=0.935). The data was further 
stratified by sex and the relationship with younger age and higher likelihood of having 
non-neoplastic colorectal pathology identified remained significant (p<0.05). 
 
Normal colonoscopy 
Of the 4 219 with colonoscopy results, 1 350 (32.0%) had a normal colonoscopy (Table 
3.5). Decreasing age (41.5% vs 32.0% vs 27.9%, p<0.001), female sex (43.3% vs 24.3%, 
p<0.001) and increasing deprivation (34.9% least deprived vs 29.6% most deprived, 
p=0.012) were all associated with a higher likelihood of a normal colonoscopy. There was 
no apparent association between age and deprivation noted, therefore the data was further 
stratified by sex only. The relationship between younger age and a higher likelihood of a 
normal colonoscopy remained (p<0.001). No relationship with deprivation was seen in 
females, and a non-significant trend in males was seen (23.8% least deprived vs 27.4% 
most deprived, p=0.099). 
 
Cancer Detection rate 
The cancer detection rates was 0.19% overall. This was significantly higher in males 
(0.29% vs 0.12%, p<0.001), older individuals (0.08% vs 0.15% vs 0.33%, p<0.001) and 
more deprived individuals (0.22% most deprived vs 0.15% least deprived, p=0.006). There 
was an apparent association between age and deprivation noted, therefore the data was 
further stratified by both sex and age groups. The relationship between both increasing age 
and increasing deprivation, and higher cancer detection rates remained significant (all 
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p<0.05). Converting the cancer detection rate to a number needed to test to identify 1 
patient with colorectal cancer yielded an overall value of 515 individuals. This was lower 
with advancing age (1289 individuals vs 655 individuals vs 301 individuals) and male sex 
(351 males vs 844 females). The number needed to test was lower with more deprived 
individuals (446 most deprived vs 669 least deprived).  
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3.4 Discussion 
The results of the present study show that age, sex and socioeconomic deprivation have a 
significant impact throughout the colorectal cancer screening pathway. Males were less 
likely to respond to screening, more likely to test positive and more likely to have cancer 
diagnosed following a positive test. This was also the case with older individuals. 
Furthermore, those who were more deprived were less likely to respond to screening, more 
likely to test positive, however, were more likely to fail to proceed to colonoscopy and less 
likely to have cancer or polyps diagnosed at colonoscopy. Therefore, this study suggests 
that strategies aimed at improving participation of deprived individuals in colorectal cancer 
screening should be directed at all stages of the screening process and not just uptake of the 
test. 
Overall, our uptake of the screening test (52%) was slightly below both figures from the 
first round of the Scottish pilot study and first round of the English screening programme 
(Steele, McClements et al. 2009; Logan, Patnick et al. 2012). This is despite individuals in 
our area being sent a pre-notification letter that has previously been shown to improve 
participation rates, something that was not done in the other studies (Libby, Bray et al. 
2011). The lower overall uptake may be due to the high level of deprivation in our 
population when compared to both the Scottish pilot study and the English figures (32% of 
our population invited to screening were in the most deprived quintile of deprivation 
compared to 10% in the most deprived quintile in the Scottish pilot study and 20% in the 
most deprived quintile in the English programme). Within this, a poorer response to 
invitations in younger individuals, males, and those who were more deprived was also 
seen. This effect appeared cumulative, for example younger, males who were most 
deprived had a 34% response rate compared to older, females, who were least deprived 
who had a response rate of 69%. The gradient of disparity in response to screening invite 
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was largest in the socioeconomically deprived highlighting the important role that 
deprivation has determining the uptake of a colorectal cancer programme.  
In a recent randomised control trial, a multifaceted intervention was instigated in a 
deprived population utilising, amongst other means, an automated telephone and text 
reminder system in order to try and improve FOBt uptake (Baker, Brown et al. 2014). In 
the intervention group, uptake was increased from 37% to above 80%. The authors 
suggested that targeted intervention of at risk low uptake groups using technologies such as 
this could be feasible. Due to cost constraints such technologies are not routinely employed 
within the SBoSP however, it may be worth considering such tools in our most deprived 
areas if uptake is to be increased.  
It was also of note that deprivation was the only variable associated with failing to proceed 
to colonoscopy following a positive result. The reasons for failing to proceed to 
colonoscopy may either be participant factors (choosing not to participate) or medical 
factors (participant not being fit enough to proceed). Indeed, overall health is a facet of 
deprivation and hence more deprived individuals may be less likely to be as fit to undergo 
a colonoscopy as less deprived individuals. It has already been noted that one of the 
disadvantages of screening is the anxiety and stress of a positive result in an otherwise 
asymptomatic individual and in an individual that has a positive screening test and is not fit 
enough to proceed to colonoscopy, this effect may be magnified (Hewitson, Glasziou et al. 
2008). Our study reinforces both recent results from the English screening programme and 
results from the Scottish pilot study that have shown increased rates of non-attendance in 
those who are more socioeconomically deprived (Steele, Kostourou et al. 2010; Morris, 
Baio et al. 2012). As these previous studies did not include those deemed unsuitable for 
colonoscopy, uptake rates were higher, however it is worth noting that the gradient in 
disparity associated with deprivation was smaller than the results of the present study. One 
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explanation may be the differing spectrum of deprivation in different geographical areas. It 
is important that further work focuses on the specific barriers to proceeding to 
colonoscopy. 
The positivity rate (3%), and PPV for cancer at colonoscopy (9%) were similar to 
previously reported figures from both Scotland and England (Steele, McClements et al. 
2009; Logan, Patnick et al. 2012). However, within this, wide variations throughout the 
demographics were noted. The higher cancer detection rate found in older, males, who 
were more deprived by this study was expected, as this is indicative of the overall 
incidence of the disease. (Cancer Research UK) However, it was surprising that there was 
an inverse relationship between the PPV for cancer at colonoscopy and deprivation. The 
results of the present study found a higher PPV for cancer at colonoscopy in those who 
were less deprived. The reasons for this remain unclear. It is thought that not all screen 
detected cancers are asymptomatic, and that individuals who choose to take up screening 
are more likely to have lower gastrointestinal symptoms (Harmston, Akwei et al. 2010). It 
has been suggested that rather than only identifying occult disease, screening represents 
another pathway for symptomatic individuals to choose to present.  
Therefore, one plausible explanation is that the lower PPV for cancer at colonoscopy 
exhibited by those who were more deprived was related to the fact that they had a higher 
incidence of other non-neoplastic colorectal pathology. While not directly related to cancer 
detection, had a higher rate of non-neoplastic pathology, such as colitis, be detected in this 
subpopulation then it may be an added benefit of screening. However, the results of this 
study do not support this theory. The lower PPV for cancer appeared to be due to a higher 
number of normal colonoscopies in the more deprived group, which can be viewed as a 
‘true’ false positive rate of the test.  
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False positives with gFOBt can be due to upper gastrointestinal (GI) causes or dietary 
factors, although a link with either of these and socio-economic deprivation has not 
previously been demonstrated (Bretthauer 2011). In a study by Rockey et al. healthy 
volunteers were given small volumes of their own blood to ingest. gFOBt’s and FIT’s were 
subsequently examined, with the gFOBt’s found be positive and the FIT’s negative. The 
positivity rates of gFOBt’s increased with increasing amounts of ingested blood suggesting 
that a relationship between blood in the upper GI tract and positivity exists (Rockey, 
Auslander et al. 1999). Indeed, there is ongoing debate as to role of upper GI endoscopy in 
patients who are gFOBt positive and colonoscopy negative (Allard, Cosby et al. 2010). 
However, the applicability of this to the present study is not clear. A substantial number of 
patients in the present study will only have been weakly gFOBt positive and will have 
proceeded to colonoscopy following a subsequent positive FIT. Further work is therefore 
required to explore the disparity between a higher test positivity rate and a lower PPV of 
cancer at colonoscopy associated with deprivation within the context of a reflex 
gFOBt/FIT screening programme.  
The PPV for detecting cancer is not the only significant feature of the screening test, as the 
elimination of pre-cancerous dysplastic polyps is also important to monitor. In fact, a high 
adenoma pick up rate has been shown to reduce the incidence of colorectal cancer within a 
screened population, and the removal of dysplastic polyps at colonoscopy has recently 
been shown to reduce cancer-specific mortality in the long term (Mandel, Church et al. 
2000; Zauber, Winawer et al. 2012). The fact that our findings were consistently observed 
across the PPV for detecting cancer, and both the PPV for neoplasia and significant 
neoplasia is further validation of the impact of age, sex and deprivation and to date has not 
been previously reported. Moreover, the present study is able to examine in detail different 
types of dysplastic polyps. It would be overly simplistic to group all dysplastic polyps as 
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being of equal relevance within a screening programme and the present study has 
sufficiently large numbers to allow such a subanalysis to take place. 
This is a retrospective study using a prospectively maintained database and has a number 
of limitations. First of all, the proportion of patients in the study who had previously 
undergone colonoscopy or other lower GI investigation is unknown. This may have 
affected both an individuals’ attitude towards engaging in the screening process and the 
likelihood of finding significant pathology at colonoscopy. Indeed, the multicentre UK 
Flexible Sigmoidoscopy Trial recruited patients aged 55 to 64 years in NHS GG&C up to 
March 1999 and there may be some crossover between individuals included in the present 
study and this previous trial (Atkin, Cook et al. 2002). However, the proportion of such 
individuals is likely to be less than 10%. Furthermore the present study is not able to assess 
reasons for non-participation or outcomes in those who chose not to participate. Assessing 
outcomes, such as a subsequent colonoscopy or cancer diagnosis, in non-responders or 
those who tested negative requires complex data linkage with population based datasets 
and such information was not available in the present study. In addition, a positive test in 
the present study actually represents the outcome from three separate screening pathways; 
strongly positive gFOBt, positive FIT following a weak gFOBt or a positive FIT following 
a spoiled/untestable gFOBt. There was limited data on the type of positive test for each 
individual (either gFOBt or FIT) or compliance with FIT in those who tested weakly 
positive on gFOBt, and therefore this was not able to be included in analysis.  
In summary, this data demonstrates that there are wide variations in uptake and outcomes 
with colorectal cancer screening in its current reflex gFOBt/FIT format associated with 
age, sex and socioeconomic deprivation.  However, deprivation should be highlighted as 
the only variable that has a consistent impact throughout all stages of the process. 
Strategies aimed at improving participation of deprived individuals in colorectal cancer 
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screening should be directed at all stages of the screening process and not just uptake of the 
screening test.
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Table 3.1: Outcome of screening invitation within the SBoSP in NHS GG&C 
 
 All individuals 
invited to 
screening 
n (%) 
 
 Responders 
 
 
n (%) 
Non-
responders 
 
n (%) 
% 
Responders 
 
p-value 
 Multivariate analysis 
 
 
O.R. (95% CI) 
 
 
p-value 
 394 117   204 139  189 978  52%     
Age          
         <55y 135 145 (34%)  61 858 (30%) 73 287 (39%) 45%   1.00  
         56y-64y 126 032 (32%)  68 797 (34%) 57 235 (30%) 55%   1.41 (1.39 – 1.44) <0.001 
         > 65y 132 940 (34%)  73 484 (36%) 59 456 (31%) 55% <0.001  1.47 (1.45 – 1.49) <0.001 
Sex          
        Male 192 912 (49%)  92 723 (45%) 100 189 (53%) 48%   1.00  
        Female 201 205 (51%)  111 416 (55%) 89 789 (47%) 55% <0.001  1.34 (1.32 – 1.35) <0.001 
Deprivation quintile          
         1 (most deprived) 125 263 (32%)  52 604 (26%) 72 659 (38%) 42%   1.00  
         2 67 031 (17%)  32 838 (16%) 34 193 (18%) 49%   1.32 (1.30 – 1.35) <0.001 
         3 64 237 (16%)  34 984 (17%) 29 253 (15%) 54%   1.65 (1.62 – 1.68) <0.001 
         4 58 687 (15%)   34 230 (17%) 24 457 (13%) 58%   1.95 (1.91 – 1.99) <0.001 
         5 (least deprived) 78 899 (20%)  49 483 (24%) 29 416 (16%) 63% <0.001  2.34 (2.29 – 2.38) <0.001 
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Table 3.2: Outcome of screening test within the SBoSP in NHS GG&C 
 
 All individuals 
responding to 
screening invite 
 
n (%) 
 
 Positive 
screening test 
 
 
n (%) 
Negative 
screening test 
 
 
n (%) 
% 
Positive 
 
p-value 
 Multivariate 
analysis 
 
 
O.R. (95% CI) 
 
 
p-value 
  
204 139  
  
6 079  
 
198 060  
 
3% 
    
Age          
         <55y 61 858 (30%)  1 256 (21%) 60 602 (31%) 2%   1.00  
         56y-64y 68 797 (34%)  1 842 (30%) 66 955 (34%) 3%   1.35 (1.26 – 1.45) <0.001 
         > 65y 73 484 (36%)  2 981 (49%) 70 503 (36%) 4% <0.001  2.07 (1.93 – 2.21) <0.001 
Sex          
        Male 92 723 (45%)  3 560 (59%) 89 163 (45%) 4%   1.00  
        Female 111 416 (55%)  2 519 (41%) 108 897 (55%) 2% <0.001  0.57 (0.54 – 0.60) <0.001 
Deprivation quintile          
         1 (most deprived) 52 604 (26%)  2 237 (37%) 50 367 (25%) 4%   1.00  
         2 32 838 (16%)  1 137 (19%) 31 701 (16%) 3%   0.80 (0.75 – 0.86) <0.001 
         3 34 984 (17%)     989 (16%) 33 995 (17%)  3%   0.65 (0.60 – 0.70) <0.001 
         4 34 230 (17%)     766 (13%) 33 464 (17%) 2%   0.51 (0.47 – 0.56) <0.001 
         5 (least deprived) 49 483 (24%)      950 (16%) 48 533 (25%) 2% <0.001  0.44 (0.40 – 0.47) <0.001 
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Table 3.3: Attendance for colonoscopy within the SBoSP in NHS GG&C  
 All individuals with a 
positive screening test 
 
n (%) 
Attended for 
colonoscopy 
 
n (%) 
Did not attend for 
colonoscopy 
 
n (%) 
% 
Attenders 
 
p-value 
  
6 079  
 
4625  
 
1454  
 
76% 
 
Age      
         <55y 1 256 (21%) 961 (21%) 295 (20%) 77%  
         56y-64y 1 842 (30%) 1 416 (31%) 426 (29%) 77%  
         > 65y 2 981 (49%) 2 248 (49%) 733 (50%) 75% 0.331 
Sex      
        Male 3 560 (59%) 2 732 (59%) 828 (57%) 77%  
        Female 2 519 (41%) 1 893 (41%) 626 (43%) 75% 0.152 
Deprivation quintile      
         1 (most deprived) 2 237 (37%) 1 639 (35%) 598 (41%) 73%  
         2 1 137 (19%) 868 (19%) 269 (19%) 76%  
         3    989 (16%) 764 (17%) 225 (16%) 77%  
         4    766 (13%) 594 (13%) 172 (12% 78%  
         5 (least deprived)     950 (16%) 760 16%) 190 (13%) 80% <0.001 
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Table 3.4: Detection of cancer at colonoscopy within the SBoSP in NHS GG&C 
 
 All individuals 
with a 
colonoscopy 
result 
n (%) 
 Cancer 
 
 
 
n (%) 
Not cancer 
 
 
 
n (%) 
% 
Cancer 
 
p-value 
 Multivariate 
analysis 
 
 
O.R. (95% CI) 
 
 
p-value 
 4 218  396  3 822 9%     
Age          
         <55y 880 (21%)  47 (12%) 833 (22%) 5%   1.00  
         56y-64y 1 289 (31%)  105 (27%) 1 184 (31%) 8%   1.53 (1.08 – 2.19) 0.018 
         > 65y 2 049 (49%)  244 (62%) 1 805 (47%) 12% <0.001  2.38 (1.72 – 3.29) 0.001 
Sex          
        Male 2 506 (59%)  264 (67%) 2 242 (59%) 11%   1.00  
        Female 1 712 (41%)  132 (33%) 1 580 (41%) 8% 0.002  0.73 (0.58 – 0.90) 0.004 
Deprivation quintile          
         1 (most deprived) 1516 (36%)  118 (30%) 1 398 (37%) 8%   1.00  
         2 791 (19%)  67 (17%) 724 (19%) 8%   1.06 (0.78 – 1.45) 0.710 
         3 676 (16%)  74 (19%) 602 (16%) 11%   1.42 (1.05 – 1.94) 0.025 
         4 530 (13%)  63 (16%) 467 (12%) 12%   1.60 (1.15 – 2.21) 0.005 
         5 (least deprived) 705 (17%)  74 (19%) 631 (17%) 10% 0.003  1.36 (1.00 – 1.85) 0.050 
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Table 3.5: Complete outcomes of colonoscopy within the SBoSP in NHS GG&C 
 
 All individuals at 
colonoscopy  
 
n (%) 
Colorectal 
Cancer 
 
n (%) 
Dysplastic polyps 
 
 
n (%) 
Non-neoplastic 
colorectal 
pathology
a
 
n (%) 
 
Normal 
colonoscopy 
 
n (%) 
 
p-value 
 4 218 396 (9%) 1 984 (47%)  488 (12%) 1 350(32%)  
Age       
         <55y 880 (21%) 47 (12%) 337 (17%) 131 (27%) 365 (27%)  
         56y-64y 1 289 (31%) 105 (27%) 621 (31%) 150 (31%) 413 (31%)  
         > 65y 2 049 (49%) 244 (62%) 1 026 (52%) 207 (42%) 572 (42%) <0.001 
Sex       
        Male 2 506 (59%) 264 (67%) 1 389 (70%) 245 (50%) 608 (45%)  
        Female 1 712 (41%) 132 (33%) 595 (30%) 243 (50%) 742 (55%) <0.001 
Deprivation quintile       
        1 (most deprived) 1 516 (36%) 118 (30%) 690 (35%) 179 (37%) 529 (39%)  
        2 791 (19%) 67 (17%) 395 (20%) 82 (17%) 247 (18%)  
        3 676 (16%) 74 (19%) 319 (16%) 89 (18%) 194 (14%)  
        4 530 (13%) 63 (16%) 240 (12%) 56 (12%) 171 (13%)  
        5 (least deprived) 705 (17%) 74 (19%) 340 (17%) 82 (17%) 209 (16%) 0.001 
a
Includes patients with colitis/proctitis, angiodysplasia and haemorrhoids  
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Table 3.6: The effect of age, sex and deprivation on the likelihood of significant polyps at colonoscopy the SBoSP in NHS GG&C   
 
 All individuals with dysplastic 
polyps 
 
n (%) 
 
Significant polyps 
(intermediate/high-risk) 
 
n (%) 
Non-significant polyps 
(low-risk) 
 
n (%) 
 
p-value 
 1 984 (47%)  1 322 (67%) 662 (33%)  
Age     
         <55y 337 (17%) 219 (17%) 118 (18%)  
         56y-64y 621 (31%) 413 (31%) 208 (31%)  
         > 65y 1 026 (52%) 690 (52%) 336 (51%) 0.452 
Sex     
        Male 1 389 (70%) 949 (72%) 440 (67%)  
        Female 595 (30%) 373 (28%) 222 (34%) 0.015 
Deprivation quintile     
         1 (most deprived) 690 (35%) 441 (33%) 249 (38%)  
         2 395 (20%) 259 (20%) 136 (21%)  
         3 319 (16%) 208 (16%) 111 (17%)  
         4 240 (12%) 171 (13%) 69 (10%)  
         5 (least deprived) 340 (17%) 243 (18%) 97 (15%) 0.006 
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4 THE USE OF FLEXIBLE SIGMOIDOSCOPY 
FOLLOWING A POSITIVE FAECAL OCCULT 
BLOOD TEST WITHIN A BOWEL SCREENING 
PROGRAMME: THEORETICAL EFFECT ON 
NEOPLASIA DETECTION 
4.1 Introduction 
The current method of screening in the Scotland utilises the gFOBt to identify individuals 
who are subsequently referred on for colonoscopy. In addition, faecal immunochemical 
tests (FIT) are used in individuals with weakly positive results or in those with a spoiled 
test. Both the sensitivity and specificity of these, as screening tests, are low. In addition, 
response rates to invitation for screening nationwide are just over 50% (von Wagner, Baio 
et al. 2011). Furthermore, not all those that test positive are willing, or medically fit 
enough to undergo a full colonoscopy. It has also been noted that cancers detected through 
a gFOBt bowel screening programme may be disproportionately found in the left side of 
the colon (Logan, Patnick et al. 2012; Steele, McClements et al. 2012). Therefore, it was 
hypothesised that initial endoscopic examination of the left side of the colon only in gFOBt 
or FIT positive patients may be preferable and may not compromise screening efficacy.   
There has been considerable interest in utilising flexible sigmoidoscopy as a primary 
screening tool for colorectal cancer and there is evidence that it can reduce both the 
incidence of colorectal cancer and cancer-specific mortality (Atkin, Edwards et al. 2010). 
This is based on the premise that approximately 60% of all neoplastic colonic pathology 
lies distal to the splenic flexure. In trials assessing the use of flexible sigmoidoscopy, those 
with significant polyps or cancer in the left side of the colon would progress for full 
colonoscopy (Atkin, Kralj-Hans et al. 2010). Flexible sigmoidoscopy is thought to be a 
more cost effective and acceptable screening test allowing higher throughput compared 
with colonoscopy and has recently been introduced as an adjunct to gFOBt as part of the 
 125 
 
English bowel screening programme with a pilot study underway in Scotland assessing a 
similar plan.  
The present study includes participants who tested positive on gFOBt or FIT and who 
underwent colonoscopy in the first round of the Scottish Bowel Screening Programme 
(SBoSP) in NHS Greater Glasgow & Clyde (NHS GG&C). The study aims to compare the 
detection rate of colonic adenomas/adenocarcinomas if a theoretical flexible 
sigmoidoscopy-first protocol was to be used as the diagnostic tool compared with full 
colonoscopy.  
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4.2 Materials and methods 
Beginning April 2009 all males and females between the ages of 50 and 74 and registered 
with a GP in NHS GG&C were identified via their Community Health Index (CHI) and 
invited to participate in the SBoSP. Each participant was sent a gFOBt kit and asked to 
provide two samples from three separate faecal specimens. The gFOBt/FIT testing process 
of the SBoSP has been described fully in Chapter 1. Following a positive result screening 
result, patients were pre-assessed, either face-to-face or following telephone consultation, 
by a bowel screening endoscopy nurse and then referred on for colonoscopy if this was 
deemed suitable. If colonoscopy was unsuccessful then further bowel imaging by barium 
enema or CT pneumocolonography was attempted. As screening is biennial, two years 
worth of screening invitations was taken to comprise one complete screening round. 
Participant details were obtained from a prospectively maintained database held by the 
Public Health Screening Unit in NHS Greater Glasgow and Clyde. Data on endoscopic 
findings and pathological diagnosis was obtained retrospectively from clinical information 
systems. These results formed the basis of our analysis.  
Patients with a pathological diagnosis of adenomatous polyp were classified as being of 
low, intermediate or high risk of subsequent development of colorectal cancer in 
accordance with the British Society of Gastroenterology (BSG) guidelines (Cairns, 
Scholefield et al. 2010) (low risk; 1 to 2 polyps <1cm: intermediate risk; 3-4 polyps <1cm 
or > 1 polyp > 1cm: high risk; >5 polyps or > 3 polyps of which > 1 is > 1cm).  
In order to allow comparison between the results of a full colonoscopy screening 
programme with definitive colonic visualisation, and the potential results of a ‘flexible 
sigmoidoscopy-first’ protocol, a theoretical flexible sigmoidoscopy was calculated. All 
pathology up to and including the splenic flexure was deemed detectable by flexible 
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sigmoidoscopy.  In those patients with pathology up to and including the splenic flexure, 
the results of potential adherence to the UK Flexible Sigmoidoscopy Trial protocol were 
considered.  The indications for subsequent full colonoscopy, as per the UK Flexible 
Sigmoidoscopy trial (Atkin, Edwards et al. 2010), were > 3 polyps; 1 polyp > 1cm; 
presence of high grade dysplasia; villous or tubulovillous polyp histology.  
The study was approved by the Public Health Directorate, NHS Greater Glasgow & Clyde 
as a review of current practice. No formal ethical approval was required. 
Statistical analysis 
Associations between categorical variables were examined using χ
2
 tests for linear trend 
unless otherwise specified. A value of p<0.05 was considered statistically significant. 
Statistical analysis was performed using SPSS software (SPSS Inc., Chicago, IL, USA). 
The positive predictive value (PPV) of detecting cancer was defined as the number of 
patients in whom a cancer was detected divided by the number of patients undergoing 
endoscopy. The PPV of neoplasia was defined as the number of patients in whom a cancer 
or adenomatous polyp was identified divided by the number of patients undergoing 
endoscopy and the PPV of significant neoplasia was the number of patients with either a 
cancer or, intermediate or high risk polyps divided by the number of patients undergoing 
endoscopy.  
  
 128 
 
4.3 Results 
From April 2009 to March 2011 inclusive, of 395 097 individuals invited to participate in 
screening, 204 461 (52%) responded of whom 6 085 (3%) tested positive. Of the 6085 
positive tests, 1200 (20%) were strongly gFOBt positive, 4083 (67%) were FIT positive 
following a weakly positive gFOBt and 802 (13%) were FIT positive following an expired, 
incomplete or spoiled gFOBt kit. Of the 6 085 positive results, 4 631 (76%) attended for 
colonoscopy. Full results were available for 4 223 (91%) patients which formed the basis 
of our analysis. 
 
Outcomes of colonoscopy  
Of the 4 223 in whom complete results were available, cancer was detected in 398 (9%) 
and adenomatous polyps in 1 985 (47%) (Figure 4.1a). Of those with adenomatous polyps, 
1 323 (67%) were classified as intermediate or high risk polyps as per BSG guidelines, and 
therefore would have required further surveillance at 1 yearly or 3 yearly intervals. Overall 
there was a PPV for cancer of 9%, a PPV for significant neoplasia of 40%, and a PPV for 
all neoplasia of 56%.  
 
Outcome from flexible sigmoidoscopy 
Of the 4 223 in whom complete results were available, if a flexible sigmoidoscopy alone 
had been performed instead of a colonoscopy then cancer would have been detected in 307 
(7%) and adenomatous polyps in 1 662 (39%) including high or intermediate risk in 1 152 
(69%)  (Figure 4.1b). Overall a PPV for cancer of 7%, a PPV for significant neoplasia of 
35% and a PPV for all neoplasia of 47% would have been seen.  
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(a) 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Outcome of colonoscopy (a) and theoretical outcomes of flexible 
sigmoidoscopy-first model (b)  
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Outcome using flexible sigmoidoscopy-first protocol 
If the ‘flexible sigmoidoscopy-first’ protocol had been utilised then 1 546 (37%) of the 4 
223 undergoing flexible sigmoidoscopy would have proceeded to a full colonoscopy 
(Figure 4.1b). Following this two stage process it can be calculated that a further 22 
cancers would have been detected, resulting in 329 cancers that would have been 
diagnosed overall. Therefore, it can be calculated that 69 (17%) cases of cancer would 
have been missed with the ‘flexible sigmoidoscopy-first’ compared with the colonoscopy 
protocol. No further patients would have had a new diagnosis of adenomatous polyps, but 
of the 510 patients with low risk polyps seen on flexible sigmoidoscopy, 86 would have 
undergone a subsequent colonoscopy and nine would have an increased risk of polyps 
warranting further surveillance colonoscopy in due course. Overall, using the ‘flexible 
sigmoidoscopy-first’ model a PPV for cancer of 8%, a PPV for significant neoplasia of 
35% and a PPV for all neoplasia of 47% would have been seen (Table 4.1).  
Comparing the cancers detected through colonoscopy with the ‘flexible sigmoidoscopy-
first model’ (Table 4.2) there were no differences in the age, sex or overall Dukes stage. 
The flexible sigmoidoscopy-first model detected fewer right sided cancers (7% vs 23%, 
p<0.001) and tumours were of an earlier T-stage (p=0.049).  
 
Adjustment for type of positive test 
The data were further stratified into three groups to adjust for the type of positive test that 
prompted referral for colonoscopy (strong gFOBt positive (gFOBt), FIT positive following 
a weak gFOBt (gFOBt/FIT) and FIT following an expired, incomplete or spoiled gFOBt 
kit (FIT)) (Table 4.3). The PPV for cancer, significant neoplasia and neoplasia at 
colonoscopy were highest in the gFOBt group (18%, 48% ,60% respectively) and lowest in 
the FIT group (4%, 27%, 45%  respectively). Comparing the colonoscopy and ‘flexible 
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sigmoidoscopy-first’ model, the difference in the PPV for significant neoplasia and 
neoplasia remained significant across all three types of positive test. However, the 
difference in the PPV for cancer remained significant in the gFOBt group only (Table 4.3). 
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4.4 Discussion 
The results of the present study confirm that a flexible sigmoidoscopy-first protocol would 
reduce detection of neoplasia within the context of a gFOBt/FIT bowel screening 
programme.  Of the 398 cancers identified at colonoscopy, 329 (83%) would have been 
identified using the flexible sigmoidoscopy-first model compared with the current practice 
of colonoscopy. There was a relatively small reduction in the positive predictive value for 
detecting cancer, but there was a much larger reduction in the significant neoplasia and 
overall neoplasia rates. It was of particular interest that 1 546 (37%) patients would require 
a further procedure and only 31 (2%) of these would have had subsequent cancer or 
significant neoplasia detected as a result of the second procedure.  
In the present study the overall results from the first screening round were similar to that 
from other regions with regards uptake, positivity and outcome following colonoscopy 
(Steele, McClements et al. 2009; Logan, Patnick et al. 2012). In particular, the fact that 
46% of tumours detected through the screening programme were TNM Stage I tumours is 
in keeping with other studies confirming that large numbers of early stage tumours can be 
detected through the use of gFOBt (Steele, McClements et al. 2009). However, as with 
other studies, there was increased detection of left sided lesions, with 77% of tumours 
detected at colonoscopy in our series being distal to the splenic flexure (Morris, 
Whitehouse et al. 2012; Roxburgh, McTaggart et al. 2013; Steele, McClements et al. 
2012). This disparity may be due to gut transit. The gFOBt tests for the peroxidase activity 
of haematin in faeces and so when haemoglobin is released by right sided tumours it can be 
degraded as it passes through the remainder of the large bowel, thereby leading to a false 
negative result (Morris, Whitehouse et al. 2012).  The majority of patients who tested 
positive in the present study did so following a weak positive gFOBt and subsequent 
positive FIT, however, this will not have altered the false negative rate caused by the initial 
gFOBt. The higher proportion of left sided lesions detected by gFOBt is likely positively to 
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bias the results for the diagnostic yield of flexible sigmoidoscopy versus colonoscopy. As a 
result, it is possible that an even greater number of cancers would not be detected if other 
less discriminatory baseline screening tools had been employed such as the FIT.  
The sub analysis performed in the present study to explore the difference between gFOBt, 
gFOBt/FIT and FIT was of interest as the SBoSP differs from the current gFOBt screening 
programme used in England, in that a ‘positive test’ actually represents the outcome from 
three separate possible screening mechanisms each with their own test characteristics of 
sensitivity and specificity (Fraser, Digby et al. 2012). The present study found the 
difference in the PPV of cancer between colonoscopy and a flexible sigmoidoscopy-first 
model was significant only in the gFOBt group and not in the gFOBt/FIT or FIT group. 
This is likely to be due to the lower overall PPV for cancer in both the latter groups, a 
finding that has been reported previously (Fraser, Digby et al. 2012).  
Although there were no differences seen in the patient demographics of those having 
cancer detected via colonoscopy or theoretically via the flexible sigmoidoscopy-first 
model, tumours were of a more advanced T-stage in the colonoscopy group. This is likely 
due to the fact that right sided tumours detected through screening are larger than left sided 
tumours. Use of a flexible sigmoidoscopy-first protocol may increase the number of early 
stage left sided lesions while allowing right sided lesions to grow undetected. Small right 
sided tumours may not bleed to the extent that larger tumours do and as a result there may 
be a higher threshold for tumour size before gFOBt assessment reliably detects these 
cancers. 
Therefore, it may be that the recent decision to combine the current biennial gFOBt with an 
additional once off flexible sigmoidoscopy in England may also result in a disproportionate 
increase in the number of left-sided lesions detected. A potential solution to this problem 
of detection may lie with the use of FIT as a primary screening tool as a recent study has 
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shown that FIT may be equally as sensitive at detecting proximal and distal colonic lesions 
(de Wijkerslooth, Stoop et al. 2012). FIT specifically targets human haemoglobin and, 
rather than the binary response that the gFOBt produces, it can be quantitative. This can 
allow thresholds to be determined based on relative sensitivity and specificity of the test 
for a given population. Moreover, there is evidence that the FIT may also increase 
participation (Hol, van Leerdam et al. 2010). The present study had lower PPVs for cancer, 
neoplasia and significant neoplasia in the FIT group than the gFOBt group.  This may be 
related to the current low analytical detection limit that the FIT test uses compared with 
gFOBt (10µg Hb/g faeces for the FIT compared with 600µg Hb/g faeces for the gFOBt). 
Were FIT to be used as a primary screening tool this detection limit can be adjusted 
accordingly. 
One further aspect that should be considered in this analysis is the cost of a two stage 
diagnostic test following a positive gFOBt/FIT to the NHS. Although the present study 
was not designed to perform a full economic analysis of the current screening pathway and 
the proposed flexible sigmoidoscopy-first model, figures from a recent study (Whyte, 
Chilcott et al. 2012) estimate the average cost of a flexible sigmoidoscopy (+/- 
polypectomy) to be £191 and the average cost of a colonoscopy (+/- polypectomy) to be 
£221. A simple costing based on these figures and the results from the present study would 
estimate the overall cost of performing diagnostic tests to be around £933 200 for the 
colonoscopy group and that the overall cost of performing diagnostic tests if a flexible 
sigmoidoscopy-first model had been used, to be around £1 146 100. This represents a 20% 
increase in cost over the use of single diagnostic colonoscopy. Moreover, given the 
additional costs of a two stage diagnostic test this estimate is likely to be conservative. In 
order to carry out a more detailed cost analysis further details of the flexible 
sigmoidoscopy-first model would need to be estimated. These would include the number 
of procedures performed on a given day, the duration of the procedure, use of sedation and 
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choice of bowel preparation. Additionally, there would also be substantial additional cost 
implications for the patients themselves, if a two stage diagnostic test were to be employed. 
This information was not available in the present analysis.  
An additional factor when discussing the use of flexible sigmoidoscopy within a screening 
setting is that of quality control. The SBoSP currently records caecal intubation rate (QIS 
2007) as its mainstay of endoscopic quality control as a clear end point for colonoscopy 
with rates above 90% as a minimum standard. The bowel screening programme in England 
(BCSP 2011) has additional auditable control measures such as cancer detection rate, 
adenoma detection rate and colonoscope withdrawal time for negative colonoscopies. 
There are currently no such national standards for flexible sigmoidoscopy. For example, 
there is no clear end-point to the examination. In the UK flexible sigmoidoscopy trial 
(Atkin, Cook et al. 2002) the endoscope was inserted as far as could be achieved without 
causing undue pain or distress which was usually the junction of the sigmoid and 
descending colon. The Italian flexible sigmoidoscopy trial (Segnan, Armaroli et al. 2011) 
aimed beyond this point, and one of the key factors for an adequate flexible sigmoidoscopy 
in the PLCO trial (Weissfeld, Schoen et al. 2005) was passing the endoscope beyond 
50cm. Clearly, these definitions differ and the use of the splenic flexure as the cut-off point 
in the present study is theoretical. Hence, the differences in neoplasia rates between the 
colonoscopy and flexible sigmoidoscopy-first model may be underestimated in the present 
study.  
The present study has not considered adverse events. In a recent analysis of the Bowel 
Cancer Screening Programme in England, of the 18 135 colonoscopies performed 17 
(0.09%) colonic perforations and 42 (0.2%) episodes of post procedure per rectum 
bleeding were noted (Logan, Patnick et al. 2012). This rate is higher than the findings of 
the UK Flexible Sigmoidoscopy Trial where, following 40 332 flexible sigmoidoscopies 
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only 1 (0.002%) perforation occurred and 77 (0.2%) episodes of post procedure rectal 
bleeding were noted (Atkin, Cook et al. 2002). A rudimentary calculation based on these 
figures would estimate that 4 (4223 x 0.09%) perforations and 8 (4223 x 0.2%) episodes of 
bleeding would be expected in our population following colonoscopy and that 1 (4223 x 
0.002% + 1546 x 0.09%) perforation and 11 (4223 x 0.2% + 1546 x 0.2%) episodes of 
bleeding would be expected if a flexible sigmoidoscopy-first protocol had been used. It is 
of interest, therefore, that complication rates may be similar in these two approaches, 
although it is important to note that there may be confounding factors not included in this 
simple analysis. 
This study has limitations in that it is based on a theoretical model and does not entirely 
represent what would be seen in the real world. For example, the uptake of colonoscopy 
following a positive test in this study was 76%, either due to the patient declining the test 
or not being medically fit to take part. It might be that the uptake would have been higher 
had flexible sigmoidoscopy been offered instead. However, performing a randomised 
controlled trial to obviate such bias is no longer feasible.  
In summary the results of the present chapter indicate that, despite evidence that a high 
proportion of test positive patients have left sided colonic pathology, the use of flexible 
sigmoidoscopy as a primary diagnostic tool would not detect a substantial proportion of 
both cancers and adenomatous polyps. Furthermore, it would also subject a significant 
proportion of patients to two procedures with considerable implications for patient and 
cost.  
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Table 4.1: Comparison of neoplasia detection rates at endoscopy 
 
 
 
 Colonoscopy 
 
 
n (%) 
 
Flexible 
sigmoidoscopy-first 
 
n (%) 
 
 
p-value 
All patients 4223 (100) 4223 (100)  
    
Cancer 
 
398 (9) 329 (8) 0.007 
Significant neoplasia 
 
1721 (40) 1469 (35) <0.001 
Neoplasia 
 
2383 (56) 1969 (47) <0.001 
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Table 4.2: All patients diagnosed with cancer: colonoscopy vs flexible sigmoidoscopy-
first model 
 
 Colonoscopy 
 
 
n (%) 
Flexible 
sigmoidoscopy-first 
 model 
n (%) 
 
 
 
p-value 
 398 (100%) 329 (100%)  
Age (years)    
         <55 47 (12%) 42 (13%)  
         56-64 106 (27%) 94 (29%)  
         > 65 245 (62%) 193 (59%) 0.463 
Sex    
        Male 265 (67%) 227 (69%)  
        Female 133 (34%) 102 (31%) 0.489 
Site    
         Rectal 113 (28%) 113 (34%)  
         Left sided 193 (49%) 193 (58%)  
         Right sided 92 (23%) 23 (7%) <0.001 
TNM Stage
a
    
         I 182 (46%) 170 (47%)  
         II 81 (20%) 55 (17%)  
         III 95 (23%) 70 (21%)  
         IV 26 (7%) 23 (7%) 0.348 
T-stage
b
    
         1 144 (39%) 138 (45%)  
         2 58 (16%) 51 (17%)  
         3 141 (38%) 101 (33%)  
         4 27 (7%) 16 (5%) 0.049 
N-stage
b
    
         0 269 (73%) 231 (76%)  
         1 67 (18%) 54 (18%)  
         2 34 (9%) 21 (7%) 0.288 
 
a
Patients with full staging details (n=384 colonoscopy, n=318 flexible sigmoidoscopy-first) 
b
Patients who underwent resection (n=370 colonoscopy, n=306 flexible sigmoidoscopy-first)  
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Table 4.3: Comparison of neoplasia detection rates at endoscopy adjusted for type of 
positive test 
 
 Colonoscopy 
 
 
n (%) 
 
Flexible 
sigmoidoscopy-first 
model 
n (%) 
 
 
p-value 
 
gFOBt 
 
747 (100) 
 
 
747 (100) 
 
    
    Cancer 
 
132 (18) 102 (14) 0.033 
    Significant neoplasia 
 
359 (48) 311 (42) 0.013 
    Neoplasia 
 
450 (60) 372 (50) <0.001 
    
gFOBt/FIT 2995 (100) 
 
2995 (100)  
    
     Cancer 
 
245 (8) 212 (7) 0.108 
     Significant neoplasia 
 
1234 (41) 1056 (35) <0.001 
     Neoplasia 
 
1719 (57) 1433 (48) <0.001 
    
FIT 481 (100) 
 
481 (100)  
    
      Cancer 
 
21 (4) 15 (3) 0.308 
      Significant neoplasia 
 
128 (27) 102 (21) 0.049 
      Neoplasia 
 
214 (45) 164 (34) 0.001 
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5 THE IMPACT OF ASPIRIN, STATIN AND ACE-
INHIBITOR USE ON THE LIKELIHOOD OF 
SIGNIFICANT NEOPLASIA IN PATIENTS 
UNDERGOING COLONOSCOPY FOLLOWING A 
POSITIVE SCREENING TEST 
5.1 Introduction 
While screening may improve outcomes through the detection of early stage disease, not 
all tumours are detected through the programme in its current format. Therefore there is 
substantial ongoing interest in the field of chemoprevention, with the use of certain drugs 
to reduce an individual’s risk of cancer. For example, there is considerable evidence that 
aspirin may reduce an individual’s likelihood of developing both pre-cancerous adenomata 
(Baron, Cole et al. 2003; Benamouzig, Deyra et al. 2003; Sandler, Halabi et al. 2003; Cole, 
Logan et al. 2009) and colorectal cancer (Thun, Namboodiri et al. 1991; Flossmann and 
Rothwell 2007). Moreover, it may have an impact on reducing cancer deaths in those with 
colorectal tumours (Rothwell, Wilson et al. 2010; Rothwell, Fowkes et al. 2011).  The 
precise mechanism for aspirin’s effect is not entirely clear but appears to be due to both its 
role in modulating the inflammatory response and also through more complex direct 
effects on tumour cells themselves (Chan, Arber et al. 2012). 
In addition, statins have also been suggested to reduce an individual’s risk of developing 
both colorectal cancer and advanced adenomas. The evidence for this has been variable in 
individual trials (Poynter, Gruber et al. 2005; Jacobs, Kodach et al. 2011; Simon, 
Rosenberg et al. 2012), however a recent meta-analysis involving 11 randomised control 
trials, 13 case-control studies and 8 cohort studies concluded that chronic statin usage did 
indeed have a small protective impact on colorectal cancer occurrence (Bardou, Barkun et 
al. 2010). The mechanism for its effect is thought to arise through a combination of 
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increased induction of tumour cell apoptosis, inhibition of cell growth or angiogenesis, or 
through enhancement of the immune response (Gauthaman, Fong et al. 2009).  
Furthermore, some evidence has emerged that angiotensin converting enzyme inhibitors 
(ACE-i) may also have a chemopreventative effect (Lever, Hole et al. 1998), and in 
particular for colonic cancer their use may reduce the development of pre-cancerous 
adenomata (Kedika, Patel et al. 2011). This may be due to a role of angiotensin converting 
enzyme in influencing local tumour growth and neoangiogenesis (Rocken, Neumann et al. 
2007).  
However, each of these drugs each has their own side-effect profile. This may be 
magnified when used in high doses, and so far no single agent has been recommended for 
chemopreventive use in the general population. Use of these drugs for chemoprevention in 
combination has previously been suggested (Zhou, Cheng et al. 2012) but not studied in a 
population setting, however, the concept of a ‘polypill’ to reduce cardiovascular risk has 
previously been proposed (Wald and Law 2003; Rodgers, Patel et al. 2011).  
The aim of the present study was to assess the affect of aspirin, statins and ACE-inhibitors 
both in isolation and in combination, on an individual’s risk of neoplasia in patients who 
tested positive in a colorectal cancer screening programme and subsequently underwent 
colonoscopy.  
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5.2 Materials and methods 
Beginning in April 2009 all males and females between the age of 50 and 74 and registered 
with a GP in NHS Greater Glasgow & Clyde (NHS GG&C) were identified via their 
Community Health Index (CHI) and invited to participate in the Scottish Bowel Screening 
Programme (SBoSP). Participants were sent a gFOBt kit and asked to provide 2 samples 
from 3 separate faecal specimens. In the case of weakly positive or spoiled kits participants 
were sent a FIT kit. Analysis and processing of the gFOBt/FIT kits in the SBoSP has been 
described previously in Chapter 1. Following a positive result, patients were pre-assessed, 
either face-to-face or following telephone consultation, by a bowel screening endoscopy 
nurse and then referred on for colonoscopy if this was deemed suitable. Details on patient 
medications were automatically uploaded to the Bowel Screening IT system from the 
Scottish Care Information (SCI) Gateway system which provides an interface between 
primary and secondary care records. This allows for details of patients regular medication, 
as held by their General Practitioner to be obtained. As part of the pre-assessment 
interview patient medications were checked with this electronic record. A user of 
medication was defined as an individual who had either aspirin, statin or ACE-i usage at 
time of pre-assessment documented as per this method. Patient details were obtained from 
the prospectively maintained Bowel Screening IT system managed by the Public Health 
Screening Unit at NHS GG&C.  
Data on endoscopic findings and pathological diagnosis was obtained retrospectively from 
clinical information systems. The presence of any colorectal pathology that could account 
for a positive stool test was noted. This included, but was not limited to colorectal cancer, 
dysplastic polyps, and non-neoplastic colorectal pathology such as colitis or haemorrhoids. 
The presence of uncomplicated diverticulosis and hyperplastic polyps were noted as 
normal findings.  
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In those patients in whom a pathological diagnosis of dysplastic polyps was reached, they 
were classified as being of a low risk, intermediate risk or high risk of subsequent 
development of colorectal cancer as per British Society of Gastroenterology (BSG) 
guidelines (Atkin and Saunders 2002) (low risk; 1 to 2 polyps <1cm: intermediate risk; 3-4 
polyps <1cm or > 1 polyp > 1cm: high risk; >5 polyps or > 3 polyps of which > 1 is > 
1cm). Advanced neoplasia was defined as patients with either colorectal cancer or 
dysplastic polyps classified as intermediate or high risk as per BSG guidelines.   
Deprivation category was calculated using the Scottish Index of Multiple Deprivation 
(SIMD) which is an index of relative deprivation combining 38 indicators across 7 
domains, namely: income, employment, health, education, skills and training, housing, 
geographic access and crime. The overall index is a weighted rank for each domain 
allowing postcodes to be ranked in order of deprivation across Scotland. Quintiles of 
deprivation were used to assign patients a relative deprivation category based on their 
postcode at time of colonoscopy with the first quintile representing the most deprived and 
the fifth quintile, the least deprived (SIMD 2009). 
Permission for the study was granted by the Caldicott Guardian of the data, and data was 
stored and analysed in an anonymised manner. 
 
Statistical analysis 
Associations between categorical variables were examined using χ
2
 tests for linear trend 
unless otherwise specified. Both univariate and multivariate logistical regression was used 
to calculate odds ratios.  A value of p<0.05 was considered statistically significant. 
Statistical analysis was performed using SPSS software (SPSS Inc., Chicago, IL, USA) 
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5.3 Results 
From April 2009 to March 2011 representing the first complete round of screening in NHS 
GG&C, 395 096 individuals were invited to participate, 204 461 (52%) responded and 6 
085 (3.0%) tested positive. Of those who tested positive, 4 631 (76%) patients proceeded 
to undergo colonoscopy. Complete results on both outcomes following colonoscopy and 
medications noted at pre-assessment were available for 4 188 (90%) patients which formed 
the basis of our analysis. The majority of positive results were due to a positive FIT (3449 
(82%) patients). 
 
Presence of colorectal pathology 
Of the 4 188 patients in whom complete results were available, colorectal pathology was 
identified in 3 043 (73%) patients (Figure 5.1). Patients with colorectal pathology were 
more likely to be older (p<0.001), male (p<0.001), less deprived (p<0.05) and have tested 
positive through the gFOBt route (p<0.05) than those without any (Table 5.1). In contrast, 
those that were on aspirin were less likely to have colorectal pathology identified at 
colonoscopy (p<0.05). There were no associations between statin or ACE-i usage and the 
presence of colorectal pathology. On multivariate analysis, older age and male sex was 
remained associated with increased risk of colorectal pathology (both p<0.001) and aspirin 
usage remained associated with a reduced risk of colorectal pathology (p<0.001). 
 
Presence of advanced neoplasia 
Of the 3 043 patients with colorectal pathology, advanced neoplasia was identified in 1 704 
(56%) patients (Figure 5.1). Patients with advanced neoplasia were more likely to be older, 
male, less deprived and have tested positive through gFOBt route (all p<0.001) than those 
without (Table 5.2).  In contrast, those on aspirin (p<0.001), statins (p<0.001) or ACE-i 
(p<0.05) were all less likely to have advanced neoplasia at colonoscopy. As the majority of 
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patients on at least one of these medications were in fact on multiple medications for the 
purposes of multivariate analysis the variable >1 medication was entered into the model. 
The associations identified on univariate analysis persisted in the multivariate model. The 
risk of advanced neoplasia was also then examined in medication combinations (Table 
5.3). Similar odds ratios were seen between combinations of these three medications (OR 
0.64; 95% CI 0.50-0.83 to 0.71; 95% CI 0.57-0.89) where the risk of non-significant 
pathology was taken as the reference. Odds ratios for those on >1 medication (OR 0.67; 
95% CI 0.56-0.78) or >2 medications (OR 0.67; 95% CI 0.55 – 0.81) were also similar. 
 
Presence of cancer 
Of the 1 704 patients with advanced neoplasia, colorectal cancer was identified in 392 
(23%) patients (Figure 5.1). Patients with cancer were more likely to be older (p=0.001), 
male (p<0.05) and have tested positive through the gFOBt route (p<0.001) than those with 
advanced adenomas only (Table 5.4). These associations remained significant on 
multivariate analysis. There was a non-significant trend to those with cancer identified 
being less likely to be on a statin (p=0.071). 
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Figure 5.1: Outcomes from colonoscopy following a positive screening test 
  
4 188 patients 
Colonoscopy 
3 043 (73%) patients 
Any colorectal pathology 
1 145 (27%) patients 
Normal Colonoscopy 
1 704 (56%) patients 
Advanced neoplasia 
1 339 (44%) patients 
Non-significant pathology 
392 (23%) patients 
Cancer 
1 312 (77%) patients 
Advanced adenomas 
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5.4 Discussion 
The results of the present study report for the first time, a reduced incidence of advanced 
neoplasia in patients who are on a statin or an ACE-i that undergo colonoscopy following a 
positive stool test within a population based colorectal cancer screening programme. In 
addition, it confirms previous work that has shown a reduced incidence of advanced 
neoplasia in those on aspirin. Overall, the results suggest that there may be role for 
population based usage of these medications in reducing the incidence of colorectal 
neoplasia.  
The reduction in incidence of advanced neoplasia of 33% in those on at least one 
medication is similar to the 28% reduction seen in a recent meta-analysis of the effect of 
aspirin in preventing advanced lesions in a non-screened population (Cole, Logan et al. 
2009). Studies have also previously shown a lower yield of neoplasia in those on aspirin 
who undergo a colonoscopy following a positive gFOBt (Clarke, Jack et al. 2006; 
Sawhney, McDougall et al. 2010; Lee, Hull et al. 2012).  However, previous work has 
been unable to adjust for the false positive effect of aspirin that can occur with gFOBt 
tests, and therefore were unable to definitively attribute this to a chemopreventative effect. 
For example, there is evidence that aspirin can increase gFOBt false positives due to its 
antiplatelet activity causing occult bleeding in an otherwise normal gastrointestinal tract. In 
the present study, by removing all those in whom no cause for the positive stool test was 
found, the impact of this confounding factor was minimised. Furthermore, the majority of 
our patients tested weakly positive on gFOBt and actually proceeded to colonoscopy only 
following a confirmatory positive FIT. Indeed, previous authors have reported a limited 
effect of aspirin usage on FIT specificity (Levi, Rozen et al. 2009; Brenner, Tao et al. 
2010).  
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In addition, the reduced incidence of advanced neoplasia that was seen in the present study 
was seen not only in aspirin but in statins and ACE-i that have not previously been 
reported to cause false positive stool tests. The present study supports this assumption as 
aspirin but neither statins nor ACE-i usage was associated with a higher likelihood of 
having a normal colonoscopy.    
The stage at which these medications might impact on the adenoma-carcinoma sequence 
has been previously speculated (Rocken, Neumann et al. 2007; Gauthaman, Fong et al. 
2009; Chan, Arber et al. 2012). Of interest, in the present study there was no significant 
impact of medications on the presence of cancer within those with advanced neoplasia. 
Therefore, it may indicate that rather than affecting cancer progression and growth, these 
medications exert their influence earlier in the adenoma-carcinoma pathway by preventing 
adenoma development. 
From previous in vivo and in vitro studies there is not only debate as to which stage of the 
adenoma-carcinoma sequence is affected by both aspirin, statins, and ACE-i but also the 
precise mechanism of action. For example, with aspirin, there is evidence for both a direct 
local effect on tumour cells and the tumour micro-environment, and a systemic effect of 
the drug on circulating inflammatory cytokines (Chan, Arber et al. 2012). The clinical 
limitations with many in-vitro studies are that large concentrations of aspirin are required 
to create a local effect. Whilst not specifically noted, it is likely that the vast majority of 
patients in the present study were taking low doses designed for cardiac prevention and 
therefore the local effects on colonic mucosa were likely to be limited. This favours the 
premise that the reduction in neoplasia seen in the present study is mediated through a 
systemic effect. If this was proven to be the case then the reduction in neoplasia risk 
detected by the present study is likely to be an underestimation due to the non-
discriminatory use of these medications. There is evidence that an elevated host systemic 
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inflammatory response is associated with the presence of cancer (Proctor, Talwar et al. 
2010) and hence it may be that more targeted therapy to those at risk of neoplasia (e.g. 
with an elevated systemic inflammatory response) may yield a greater benefit. It would be 
of interest to examine medication usage, neoplasia risk and markers of the systemic 
inflammatory response within population studies and further work is warranted. 
It is important to note that conclusions drawn from the present study may not necessarily 
be representative of the population as a whole who were invited to screening. Only 52% of 
patients responded to the screening invite and just over three quarters of those who tested 
positive actually underwent colonoscopy. In Chapter 3, it has been reported that those who 
fail to respond to screening are more likely to be male, younger and more socio-
economically deprived and that those who fail to progress to colonoscopy following a 
positive test are more likely to be deprived. Further work exploring medication usage and 
subsequent development of neoplasia in those who choose not to participate in screening is 
required. 
A limitation of the present study is that data on dosage, duration or compliance with use of 
these medications was not collected. Therefore, we were not able to draw conclusions on 
favoured dosing for chemoprevention, nor were we able to separate those who had taken 
these medications for a period of weeks from those that had been on them for several 
years. Furthermore, a potential concern of the present cross-sectional study design is that 
the medication recorded does not reflect ongoing exposure. Nevertheless, given that the 
recorded medications are used to treat existing co-morbid disease it is likely that such 
medication would be taken on an ongoing basis. In addition, the majority of patients who 
were on at least one of these medications were in fact on several of them. Therefore, 
performing multivariate analysis to assess which was of most importance with this large 
degree of multicollinearity was not meaningful and the effect of an individual medication 
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could not be reliably estimated. However, this represents a real-life population setting 
where the majority of patients are likely to be on a combination of medications. Analysis 
of the risk of neoplasia and the association with medication usage, stratified for location 
within the colon was also not performed. Previous studies have found the greatest risk 
reduction with aspirin usage and with lesions of the proximal colon (Rothwell, Fowkes et 
al. 2011) and hence examining this in our population may have been of interest. However, 
there is an inherent problem with using data derived from occult blood stool based 
colorectal cancer screening programmes for this, as such screening tests are less sensitive 
for right sided lesions (Logan, Patnick et al. 2012). This altered sensitivity creates a 
skewed study population undergoing colonoscopy where lesions are mainly on the left side 
of the colon. For example only 17% of those with significant neoplasia in our study 
population had isolated right sided lesions (data not presented). Such sample bias would 
negate any meaningful conclusions being drawn from subanalysis based on the location of 
neoplastic lesions and so such an analysis was not undertaken. Also, while consideration 
was made to adjust for age, sex and socioeconomic deprivation, there are other potential 
confounding factors such as a significant family history or previous history of colonic 
neoplasia that have not been included in the present analysis. In particular, there is now 
robust evidence that patients with hereditary non-polyposis colorectal cancer (HNPCC) or 
familial adenomatous polyposis (FAP) may derive substantial benefit from aspirin 
chemoprophylaxis (Burn, Bishop et al. 2011; Burn, Gerdes et al. 2011). However, the 
overall incidence of these hereditary cancers in our study population is likely to be small 
(<10%).  
In conclusion, the present chapter reports that there is a reduced incidence of advanced 
colorectal neoplasia in patients who are on aspirin, statins or ACE-i undergoing 
colonoscopy following a positive stool test within a population based screening 
programme. This effect persists when adjustment is made for the possible false positivity 
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effect of aspirin on gFOBt testing, suggesting that this reduction may be due to a 
chemopreventative mechanism. Overall, this supports the theory that population based 
usage of these medications in this age group may reduce the incidence of colorectal 
neoplasia. Further work is required to explore not only this concept but the perceived 
association with the host systemic inflammatory response, within the context of a national 
bowel screening programme. 
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Table 5.1: Study population and likelihood of detecting any colorectal pathology at colonoscopy following a positive stool test 
 
 All pts  
n (%) 
 Colorectal pathology 
n (%) 
Normal colonoscopy 
n (%) 
 
p-value 
 Risk of colorectal pathology 
(multivariate analysis) 
O.R. (95% C.I.) 
 
p-value 
 4188   3043  1145     
Age         
     <55 877 (21)  565 (19) 312 (27)   1  
     56-64 1280 (31)  925 (30) 355 (31)   1.41 (1.17 – 1.71) <0.001 
     > 65 2031 (49)  1553 (51) 478 (42) <0.001  1.89 (1.58 – 2.27) <0.001 
Sex         
     Female 1699 (41)  1053 (35) 646 (56)   1  
     Male 2489 (59)  1990 (65) 499 (44) <0.001  2.49 (2.16 – 2.86) <0.001 
Deprivation category         
     1 (most deprived) 1506 (36)  1060 (35) 446 (39)   1  
     2 785 (19)  568 (19) 217 (19)   1.08 (0.88 – 1.31) 0.461 
     3 666 (16)  507 (17) 159 (14)   1.30 (1.05 – 1.61) 0.017 
     4 527 (13)  380 (13) 147 (13)   1.02 (0.81 – 1.28) 0.879 
     5 (least deprived) 699 (17)  525 (17) 174 (15) 0.017  1.21 (0.98 – 1.49) 0.080 
Type of positive stool test         
     FIT 3449 (82)  2482 (82) 967 (84)   1  
     gFOBt 739 (18)  561 (18) 178 (16) 0.029  1.20 (0.99 – 1.45) 0.062 
Aspirin         
     No 3531 (84)  2592 (85) 939 (82)   1  
     Yes 657 (16)  451 (15) 206 (18) 0.012  0.67 (0.55 – 0.81) <0.001 
Statin       -  
     No 3308 (79)  2422 (80) 886 (77)     
     Yes 880 (21)  621 (20) 259 (23) 0.117    
ACE-i       -  
     No 3682 (88)  2672 (88) 1010 (88)     
    Yes 506(12)  371 (12) 135 (12) 0.722    
>1 medications       -  
     No 3088 (74)  2271 (75) 817 (71)     
    Yes 1100 (26)  772 (25) 328 (29) 0.032    
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Table 5.2: Risk of advanced-neoplasia in those with colorectal pathology at colonoscopy 
 
 All pts  
n (%) 
 Advanced-neoplasia 
n (%) 
Non-significant pathology 
n (%) 
 
p-value 
 Risk of advanced-neoplasia 
(multivariate analysis) 
O.R. (95% C.I.) 
 
p-value 
 3043   1704 1339     
Age         
     <55 565 (19)  263 (15) 302 (23)   1  
     56-64 925 (30)  513 (30) 412 (31)   1.48 (1.19 – 1.83) <0.001 
     > 65 1553 (51)  928 (55) 625 (47) <0.001  1.89 (1.55 – 2.31) <0.001 
Sex         
     Female 1053 (35)  503 (30) 550 (41)   1  
     Male 1990 (65)  1201 (70) 780 (59) <0.001  1.70 (1.46 – 1.99) <0.001 
Deprivation category         
     1 (most deprived) 1060 (35)  554 (33) 506 (38)   1  
     2 568 (19)  324 (19) 244 (18)   1.16 (0.94 – 1.43) 0.160 
     3 507 (17)  278 (16) 228 (17)   1.05 (0.85 – 1.31) 0.653 
     4 380 (13)  232 (14) 148 (11)   1.33 (1.04 – 1.70) 0.021 
     5 (least deprived) 525 (17)  313 (18) 212 (16) <0.001  1.29 (1.04 – 1.60) 0.021 
Type of positive stool test         
     FIT 2482 (82)  1351 (79) 1131 (84)   1  
     gFOBt 561 (18)  353 (21) 208 (16) <0.001  1.39 (1.14 – 1.68) 0.001 
Aspirin       -  
     No 2592 (85)  1488 (87) 1104 (82)     
     Yes 451 (15)  216 (13) 235 (18) <0.001    
Statin       -  
     No 2422 (80)  1409 (83) 1013 (76)     
     Yes 621 (20)  295 (17) 326 (24) <0.001    
ACE-i       -  
     No 2672 (88)  1524 (89) 1148 (86)     
    Yes 371 (12)  180 (11) 191 (14) 0.002    
>1 medications         
     No 2271 (75)  1330 (78) 941 (70)   1  
    Yes 772 (25)  374 (22) 398 (30) <0.001  0.59 (0.50 – 0.70) <0.001 
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Table 5.3: Combinations of medications and risk of advanced-neoplasia in those with colorectal pathology at colonoscopy  
 
 
 Aspirin 
 
Statin 
 
ACE-i 
 
 Aspirin & Statin 
 
All pts       n 451  621  371   371 
     O.R. (95% C.I.) 0.68 
(0.56-0.83) 
p<0.001 0.65 
(0.55-0.78) 
p<0.001 0.71 
(0.57-0.89) 
p=0.002    
          
Aspirin     n (%) 
     No 
     Yes 
  
250 (40) 
371 (60) 
 
170 (46) 
201 (54) 
  
     O.R. (95% C.I.)   0.69 
(0.56-0.86) 
p=0.001 0.67 
(0.51-0.90) 
p=0.006    
Statin       n (%) 
     No 
     Yes  
   
93 (25) 
278 (75) 
  
     O.R. (95% C.I.)     0.64 
(0.50-0.83) 
p<0.001    
ACE-i        n (%) 
     No 
     Yes 
     
192 (52) 
179 (48) 
     O.R. (95% C.I.)        0.66 
(0.49-0.90) 
p=0.007 
 
Reference category = non-significant pathology 
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Table 5.4: Risk of cancer in those with advanced-neoplasia at colonoscopy 
 
 All pts 
n (%) 
 Cancer 
n (%) 
Advanced adenoma 
n (%) 
 
p-value 
 Risk of cancer 
(multivariate analysis) 
O.R. (95% C.I.) 
 
p-value 
 1704  392 1312     
Age         
     <55 263 (15)  46 (12) 217 (17)   1  
     56-64 513 (30)  104 (27) 409 (31)   1.22 (0.82 – 1.80) 0.323 
     > 65 928 (55)  242 (62) 686 (52) 0.001  1.72 (1.20 – 2.45) 0.003 
Sex         
     Female 503 (30)  132 (34) 371 (28)   1  
     Male 1201 (70)  260 (66) 941 (72) 0.040  0.75 (0.59 – 0.96) 0.023 
Deprivation category       -  
     1 (most deprived) 554 (33)  118 (30) 436 (33)     
     2 324 (19)  66 (17) 258 (20)     
     3 278 (16)  72 (19) 206 (16)     
     4 232 (14)  63 (16) 169 (13)     
     5 (least deprived) 313 (18)  71 (18) 242 (19) 0.184    
Type of positive stool test         
     FIT 1351 (79)  264 (67) 1087 (83)   1  
     gFOBt 353 (21)  128 (33) 225 (17) <0.001  2.41 (1.87 – 3.12) <0.001 
Aspirin       -  
     No 1488 (87)  349 (89) 1139 (87)     
     Yes 216 (13)  43 (11) 173 (13) 0.247    
Statin       -  
     No 1409 (83)  336 (86) 1073 (82)     
     Yes 295 (17)  56 (14) 239 (18) 0.071    
ACE-i       -  
     No 1524 (89)  353 (90) 1171 (89)     
    Yes 180 (11)  39 (10) 141 (11) 0.652    
>1 medications       -  
     No 1330 (78)  318 (81) 1012 (77)     
    Yes 374 (22)  74 (19) 300 (23) 0.094    
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6 AN EXAMINATION OF THE RELATIONSHIP 
BETWEEN COLORECTAL SYMPTOMS AND 
OUTCOME AT COLONOSCOPY FOLLOWING A 
POSITIVE FAECAL OCCULT BLOOD TEST 
6.1 Introduction 
Currently, within the UK and indeed within the West of Scotland as discussed in Chapter 
2, the majority of patients are diagnosed following symptomatic presentation. However, it 
is widely accepted that symptoms for bowel cancer can be multiple and non-specific.  For 
example it has been previously reported that only 6% of patients referred to a surgical 
clinic with lower gastrointestinal (GI) symptoms will have colorectal cancer detected 
(Thompson, Perera et al. 2007).  In addition, when individual symptoms are studied both in 
isolation and in combination they can only achieve positive predictive values for colorectal 
cancer of approximately 20% (Thompson, Perera et al. 2007) 
Examination of data from the UK pilot studies of the bowel screening programmes have 
found that there is a high rate of lower GI symptoms in those who test positive and 
undergo colonoscopy, and has suggested that rather than pick up asymptomatic cancers, 
screening represents an additional way of symptomatic individuals to present (Ahmed, 
Leslie et al. 2005; Harmston, Akwei et al. 2010).  Previous work however, has been limited 
by relatively small numbers and has failed to control for the confounding effect of non-
neoplastic colorectal pathology detected at screening and potentially responsible for patient 
symptoms.      
The aim of this study was to assess the prevalence of lower GI symptoms in patients who 
tested positive via the Scottish Bowel Screening Programme (SBoSP) in our geographical 
area and then subsequently underwent colonoscopy, and to correlate these with clinical 
outcomes.  
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6.2 Materials and methods 
The Scottish Bowel Screening Programme (SBoSP) is a biennial occult blood screening 
programme and was introduced in NHS Greater Glasgow & Clyde in April 2009.   
Methodology data on the screening algorithm and processing of samples and has been 
described in Chapter 2. Prior to colonoscopy, individuals were pre-assessed, either face-to-
face or following telephone consultation, by a bowel screening pre-assessment nurse.  As 
part of the pre-assessment interview individuals were asked whether they had any bowel 
symptoms.  Further details on the type and duration of symptoms were recorded as free 
text during this process.  This prospectively collected data was then analysed 
retrospectively to assess for the presence of either rectal bleeding, a change in bowel habit, 
abdominal pain or tenesmus. Individuals with significant symptoms were defined as 
individuals with either one or more of these four specific symptoms. 
Data on endoscopic findings and pathological diagnosis was obtained retrospectively from 
clinical information systems.  The presence of uncomplicated diverticulosis and 
hyperplastic polyps were noted as normal findings.  In those patients in whom a 
pathological diagnosis of dysplastic polyps was reached, they were classified as being of a 
low risk, intermediate risk or high risk of subsequent development of colorectal cancer as 
per BSG guidelines (Cairns, Scholefield et al. 2010) (low risk; 1 to 2 polyps <1cm: 
intermediate risk; 3-4 polyps <1cm or > 1 polyp > 1cm: high risk; >5 polyps or > 3 polyps 
of which > 1 is > 1cm).  
Non-neoplastic colorectal pathology was defined as pathology which could have 
potentially accounted for a positive stool test not including adenomatous polyps or 
colorectal cancer.  This included but was not limited to colitis, diverticulitis and 
haemorrhoids.  
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In those in whom a diagnosis of colorectal cancer was reached, initial staging for 
comparison was following endoscopic and imaging modalities.  Subsequent, pathological 
classification in those who underwent operations was by the standard TNM (version 5) 
classification (Sobin and Fleming 1997). Individuals in whom a polyp cancer was 
considered to be completely excised and hence did not undergo further colonic resection, 
were presumed to be node negative and classified as TNM Stage I.  
The main outcome measure of the study was the presence of significant neoplasia, which 
was defined as the presence of either cancer or intermediate or high risk polyps as defined 
above.  
Deprivation category was calculated using the Scottish Index of Multiple Deprivation 
(SIMD) which is an index of relative deprivation combining 38 indicators across 7 
domains, namely: income, employment, health, education, skills and training, housing, 
geographic access and crime.  The overall index is a weighted rank for each domain 
allowing postcodes to be ranked in order of deprivation across Scotland.  Quintiles of 
deprivation were used to assign patients a relative deprivation category based on their 
postcode at time of colonoscopy with the first quintile representing the most deprived and 
the fifth quintile, the least deprived. (SIMD 2009) 
Approval for access to data was given by the Caldicott guardian for the data and approved 
by the local Bowel Screening Steering Group. 
 
Statistical analysis 
Associations between categorical variables were examined using χ
2
 tests for linear trend 
unless otherwise specified.  Multivariate analysis was performed using binary logistical 
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regression.  A value of p<0.05 was considered statistically significant. Statistical analysis 
was performed using SPSS software (SPSS Inc., Chicago, IL, USA). 
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6.3 Results 
From invitations sent between April 2009 and March 2011, representing the first complete 
round in NHS GG&C, 4631 individuals underwent colonoscopy following a positive stool 
test.  Complete results on both outcomes following colonoscopy and bowel symptoms 
noted at pre-assessment were available for 4182 (90%) patients which formed the basis of 
our analysis.  Of the 4182 patients, 390 (9%) had a diagnosis of cancer and 1964 (47%) 
had at least one dysplastic polyp identified.  Of those with dysplastic polyps 1309 (66%) 
patients were deemed to have significant polyps, therefore, significant neoplasia was 
detected in 1699 (41%) individuals.  
Overall, 1772 (42%) patients stated they had bowel symptoms of which 1661 (94%) had 1 
or more significant bowel symptoms present. Significant symptoms were altered bowel 
habit (1001 (24%) patients), rectal bleeding (896 (21%) patients), abdominal pain (62 (2%) 
patients), and tenesmus (8 (0.2%) patients). Symptomatic individuals were more likely to 
be female (46% vs 35%, p<0.001) and younger (46% vs 39% vs 37%, p<0.001) (Table 
6.1). The presence of symptoms was associated with the absence of significant neoplasia at 
colonoscopy (p<0.001). When individual symptoms were examined, only the presence of 
altered bowel habit remained significant in predicting those with an absence of significant 
neoplasia (p<0.001) (Table 5.2). On multivariate analysis, the presence of symptoms did 
not retain significance as being predictive of those without significant neoplasia (p=0.063) 
(Table 6.3). 
When those with non-neoplastic colorectal pathology (n=485) were removed from the 
analysis the presence of significant symptoms remained associated with the absence of 
significant neoplasia on univariate analysis (OR 0.80 (0.70 – 0.91), p<0.001). 
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In those that had significant neoplasia found at colonoscopy, lesions were confined to the 
right side of the colon in 207 (12%) patients (Table 6.4). Patients with right sided lesions 
were less likely to be symptomatic than those with left sided or mixed distribution of 
lesions (p=0.044). Right sided lesions were also associated with an absence of rectal 
bleeding (p<0.001). When adenomas were compared to T1/2 tumours and T3/4 tumours, 
patients with more advanced disease were more likely to be symptomatic (p= 0.027). 
When the stage distribution of those with colorectal cancer was examined, patients with 
more advanced tumours were more likely to be symptomatic (p=0.005).   
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6.4 Discussion 
The results of the present study showed that in the context of a positive occult blood stool 
screening test, the presence of significant bowel symptoms was not associated with an 
increased likelihood of detecting significant colorectal neoplasia. In addition, in those who 
did have significant neoplasia, lesions were more likely to be more advanced and more 
distal in those who were symptomatic than those who were asymptomatic. 
The results support the hypothesis that individuals who engage in the screening process 
have a high prevalence of symptoms and that their routine assessment within a screening 
programme has limited clinical value. This has been shown in three previous studies which 
have reported symptoms being present in 52% to 78% of those individuals attending for 
colonoscopy following a positive gFOBt screening test (Ahmed, Leslie et al. 2005; 
Harmston, Akwei et al. 2010; Saldanha et al. 2013). Our rate of 42% is slightly below 
these figures and this may be due to the differing demographic profile of the population 
sampled. Our geographical area encompasses some of the most deprived areas in Scotland 
and this may have impacted on symptom reporting. Alternately, it may reflect the process 
of assessing symptoms. Rather than use a proforma, data was collected in free-text form 
and coded retrospectively. However, as the sample size included in the present study was 
considerably larger than that of the previous largest study (n=563) this would act to reduce 
bias (Ahmed, Leslie et al. 2005).  
It has been previously postulated that the reason gFOBt positive screening patients have 
such a high rate of lower GI symptoms is that those who choose to respond to screening 
invites have a high rate of symptoms (Harmston, Akwei et al. 2010). As such, it has 
therefore been suggested that rather than identifying truly occult disease, screening 
represents an additional pathway for symptomatic individuals to present. Providing 
evidence for this however, would require assessment of symptoms in those who choose not 
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to respond to a screening invitation. Such a study population would be inherently difficult 
to assess and therefore such analysis was not carried out. 
It was of interest to note the inverse relationship between symptoms and likelihood of 
significant neoplasia at colonoscopy, a finding which differs from previous studies 
(Ahmed, Leslie et al. 2005; Harmston, Akwei et al. 2010; Saldanha et al. 2013). This 
remains when adjustment is made for those patients where significant neoplasia was absent 
but non-neoplastic colorectal pathology is identified. However, this fails to achieve 
significance on multivariate analysis when adjustment is made for age, sex and 
socioeconomic deprivation status. It would be of added interest to examine the hospital 
attendances and prior investigations of those who were symptomatic but failed to have 
significant neoplasia found at colonoscopy in the present study. Although individuals 
underwent a thorough pre-assessment process, it may be that a proportion of the 
symptomatic individuals were, in fact, inappropriately investigated following a positive 
screening test and further work is required to explore this concept. 
When those who had significant neoplasia were analysed separately there is evidence that 
symptoms were associated with more advanced and more distal disease. One previous 
study has examined tumour stage and the presence of symptoms in 200 patients with 
screen-detected colorectal cancer, however have no clear association with stage was 
reported (Harmston, Akwei et al. 2010). Comparison with studies examining the link 
between tumour stage and symptoms in studies performed out with screening is 
problematic due to the lack of an asymptomatic group for comparison. However, when the 
duration of symptoms has been studied there is conflicting evidence as to whether a 
prolonged duration of symptoms is associated with early stage (Jullumstro, Lydersen et al. 
2009) or late stage disease (Olsson, Bergkvist et al. 2004). The present study highlights the 
importance of screening as a tool in detecting early stage disease as only 37% of those with 
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early stage disease (TNM Stage I & II) had symptoms compared to 47% of those with late 
stage disease (TNM Stage III & IV).  
The present study has accepted limitations in that it is a retrospective analysis of a 
prospectively collected dataset. The use of a symptom proforma may have increased our 
symptom detection rate, however this is unlikely to have altered comparisons made within 
the study group itself. In addition, information regarding additional commonly regarded 
‘high-risk’ symptoms such as weight loss and anaemia were not assessed. These 
symptoms, however, are not true bowel symptoms and hence were not examined in the 
context of the present study.    
In conclusion, the present study reports a high rate of symptoms in patients undergoing 
colonoscopy following a positive stool test within the SBoSP, although such symptoms 
have limited clinical value in predicting the presence of disease. However, in those patients 
with significant neoplasia, being symptomatic was associated with more advanced tumour 
stage highlighting the importance of screening in detecting early stage disease.  
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Table 6.1: The relationship between the presence of significant lower gastrointestinal 
(GI) symptoms and the presence of significant neoplasia at colonoscopy following a 
positive screening test 
 
 
  
All patients 
 
 
 
 
 
n(%) 
Any significant lower GI 
symptom 
 
 
p-value 
Absent 
 
n(%) 
 
Present 
 
n(%) 
 4182 2521 1661  
Age     
         <55 877 (21) 472 (19) 405 (24)  
         56-64 1279 (31) 770 (30) 509 (31)  
         > 65 2026 (48) 1279 (51) 747 (45) <0.001 
Sex     
        Female 1695 (40) 900 (36) 795 (48)  
        Male 2487 (60) 1621 (64) 866 (52) <0.001 
Deprivation quintile     
         1 (most deprived) 1505 (36)  897 (35) 608 (37)  
         2 783 (19) 448 (19) 335 (20)  
         3 665 (16) 408 (16) 257 (16)  
         4 526 (12) 325 (13) 201 (12)  
         5 (least deprived) 698 (17) 440 (17) 258 (15) 0.054 
Significant neoplasia     
         Absent 2483 (59) 1368 (57) 1115 (63)  
         Present 1699 (41) 1042 (43) 657 (37) <0.001 
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Table 6.2: The relationship between the risk of significant neoplasia at colonoscopy 
and the presence of significant lower gastrointestinal (GI) symptoms following a 
positive screening test 
 
 
  
All patients 
 
n(%) 
Risk of significant 
neoplasia 
 
OR (95% CI) 
 
p-value 
Any significant lower GI 
symptom  
   
         Absent 2521 (60) 1  
         Present 1661 (40) 0.78 (0.69 – 0.89) <0.001 
    
Rectal bleeding     
         Absent 3286 (79) 1  
         Present 896 (21) 1.09 (0.93 – 1.26) 0.283 
Altered bowel habit     
         Absent 3181 (76) 1  
         Present 1001 (24) 0.58 (0.50 – 0.68) <0.001 
Abdominal pain     
         Absent 4120 (98) 1  
         Present 62 (2) 0.80 (0.47 – 1.35) 0.406 
Tenesmus     
         Absent 4174 (100) 1  
         Present 8 (0) 4.40 (0.89 – 21.81) 0.048 
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Table 6.3: Multivariate analysis of the risk of significant neoplasia at colonoscopy and 
the presence of significant lower gastrointestinal (GI) symptoms following a positive 
screening test 
 
  
All patients 
 
 
n(%) 
Risk of significant 
neoplasia 
(multivariate analysis) 
 
OR (95% CI) 
 
p-value 
    
Age    
         <55 877 (21) 1  
         56-64 1279 (31) 1.50 (1.25 – 1.81) <0.001 
         > 65 2026 (48) 1.93 (1.63 – 2.30) <0.001 
Sex    
        Female 1695 (40) 1  
        Male 2487 (60) 2.20 (1.93 – 2.51) <0.001 
Any significant lower GI 
symptom  
   
         Absent 2521 (60) 1  
         Present 1661 (40) 0.88 (0.77 – 1.01) 0.063 
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Table 6.4: The relationship between the presence of symptoms and the site and type of lesion in patients with significant neoplasia at 
colonoscopy following a positive screening test 
 
 
 All patients 
with 
significant 
neoplasia 
 Any significant lower GI 
symptom  
 
 
 
p-value 
Altered bowel habit 
 
 
 
p-value 
PR bleeding 
 
 
 
p-value
   Absent Present  Absent Present  Absent Present  
 n(%)  n(%) n(%)  n(%) n(%)  n(%) n(%)  
            
 1699  1083  616  1388 311  1321 378  
Site of lesion            
   Right sided 207 (12)  145 (13) 62 (10)  162 (12) 45 (14)  187 (14) 20 (5)  
   Left sided/mixed 1492 (88)  938 (87) 554 (90) 0.044 1226 (88) 266 (86) 0.173 1134 (86) 358 (95) <0.001
            
Type of lesion
a
            
   Adenoma 1309 (78)  849 (80) 460 (76)  1082 (79) 227 (74)  1025 (79) 284 (77)  
   T1/2 tumour 199 (12)  132 (12) 67 (11)  166 (12) 33 (11)  152 (12) 47 (13)  
   T3/4 tumour 163 (10)  88 (8) 75 (13) 0.027 119 (9) 44 (15) 0.012 125 (9) 38 (10) 0.516 
            
TNM Stage
b
            
    I 179 (48)  119 (53) 60 (40|)  149 (51) 30 (37)  136 (48) 43 (47)  
    II 76 (20)  42 (19) 34 (23)  56 (19) 20 (25)  59 (21) 17 (19)  
    III 95 (25)  55 (24) 40 (27)  74 (25) 21 (26)  75 (26) 20 (22)  
    IV 26 (26)  9 (4) 17 (11) 0.005 16 (5) 10 (12) 0.025 14 (13) 12 (13) 0.290 
  
a
 n = 1671 
b 
n = 376 
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7 A COMPARISON OF TUMOUR AND HOST 
PROGNOSTIC FACTORS IN SCREEN-DETECTED 
VERSUS NON SCREEN-DETECTED 
COLORECTAL CANCER: A 
CONTEMPORANEOUS STUDY 
7.1 Introduction 
Independent of stage at presentation, there are other additional adverse features of both the 
tumour itself and the individual who develops the disease, the so called ‘host’, that have 
been shown to be predictive of a worse outcome. For example, adverse tumour features, 
such as the presence of poor differentiation, venous invasion, resection margin status, 
tumour perforation and serosal involvement are all indicative of poorer cancer specific 
survival and should be included in pathological reporting of specimens (Compton, Fielding 
et al. 2000; Petersen, Baxter et al. 2002). These are now used in clinical practice to help 
identify patients with more aggressive TNM Stage II disease that are at a higher risk of 
recurrence and hence may benefit from adjuvant chemotherapy (Figueredo, Coombes et al. 
2008). Indeed, it has been argued recently that the combination of T-stage and venous 
invasion is superior to the tradition TNM stage in predicting outcome in node negative 
disease (Roxburgh, McMillan et al. 2014).  
With consideration to host factors, there is now a wealth of evidence that the presence of 
an elevated host systemic inflammatory response (SIR) is an independent negative 
prognostic factor in patients with cancer (McAllister and Weinberg 2014). In particular, in 
those undergoing resection for colorectal cancer those with an elevated pre-operative SIR 
have a worse outcome (Roxburgh and McMillan 2010). The SIR can be assessed routinely 
with standard bedside tests such as C-reactive protein (CRP) or the neutrophil to 
lymphocyte ratio (NLR)(Walsh, Cook et al. 2005; Ishizuka, Nagata et al. 2007; Proctor, 
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Morrison et al. 2011; Li, Liu et al. 2014). Such patients with an elevated SIR have poorer 
cancer-specific mortality independent of TNM stage (Crozier, McKee et al. 2006). 
Screening for colorectal cancer using the guaiac-based faecal occult blood test (gFOBt) 
increases the number of early stage cancers diagnosed and reduces cancer specific 
mortality (Hardcastle, Chamberlain et al. 1996; Kronborg, Fenger et al. 1996; Hewitson, 
Glasziou et al. 2007). In addition, there is increasing evidence that screening using the 
faecal immunochemical test (FIT), where the level of blood in the stool can be quantified, 
may have improved sensitivity over gFOBt, (Guittet, Bouvier et al. 2007; Hol, Wilschut et 
al. 2009; Parra-Blanco, Gimeno-Garcia et al. 2010). This has lead to the development of 
the Scottish Bowel Screening Programme (SBoSP), which is a gFOBt/FIT population 
based screening programme, where individuals with a weakly positive result on initial 
gFOBt testing are sent a confirmatory FIT (Fraser, Digby et al. 2012). This has been found 
to detect a large number of early stage tumours, however interval cancers do develop 
(Steele, McClements et al. 2012). In the context of a biennial screening programme, 
interval cancers are tumours that develop within 2 years of a negative screening test. This 
number appears to increase with successive screening rounds, suggesting that while 
screening is good at targeting so called screen-detected cancers, a proportion of tumours 
are resistant to the screening process in its current form (Steele, McClements et al. 2009; 
Steele, McClements et al. 2012). 
In the context of assessing colorectal cancer screening efficacy, previous work has 
examined differences between screen-detected and non screen-detected disease and have 
shown improved survival in screen-detected patients (Courtney, Chong et al. 2013; Gill, 
Bramble et al. 2012; Libby, Brewster et al. 2012; Mackay, Ramsay et al. 2012; Morris, 
Whitehouse et al. 2012; Pande, Froggatt et al. 2013; Roxburgh, McTaggart et al. 2013). 
However, such analysis has focused on stage and site of tumours and only one such paper 
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has included detailed analysis of adverse tumour factors beyond TNM stage that are of 
independent prognostic significance (Roxburgh, McTaggart et al. 2013). Furthermore, to 
date, no previous studies have included assessment of the pre-operative host systemic 
inflammatory response within the context of a colorectal cancer screening programme.  
The aim of the present study was to examine the efficacy of the first round of a population 
based gFOBt/FIT colorectal cancer screening programme in our geographical area with 
regards to cancer detection rates, and to compare and contrast adverse tumour and host 
prognostic factors in screen-detected and non screen-detected colorectal cancer.  
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7.2 Materials and methods 
Details for all individuals who were invited to the first round of the SBoSP during April 
2009 to the end of March 2011 in NHS Greater Glasgow & Clyde (NHS GG&C) were 
extracted from the prospectively maintained NHS GG&C Bowel Screening IT System 
(original date of extraction January 2012, updated April 2014). Methodology data on the 
screening algorithm and processing of samples of the SBoSP has been described in 
previous Chapters (Fraser, Digby et al. 2012). Data on individual outcomes from screening 
invite, combined gFOBt/FIT result, uptake of colonoscopy and outcome from colonoscopy 
were extracted. 
All individuals invited to screening in this first round were cross-referenced with the 
prospectively maintained West of Scotland Colorectal Cancer Managed Clinical Network 
(MCN) dataset and also linked to the Scottish Cancer Registry (SMR06).  This allowed 
comprehensive identification of any patient with a diagnosis of colorectal cancer. As 
screening invitations are biennial, patients with cancer detected more than 720 days after 
screening invite were excluded. Patients with colorectal cancer were then categorised as 
having screen-detected disease (SD), or non screen-detected disease (NSD). NSD patients 
were then further sub-characterised as being non-responders to the screening invitation 
(NR), having an interval cancer detected following a negative gFOBt/FIT (INT), having a 
cancer in patient who tested positive but did not attend for colonoscopy (NA) or a cancer in 
a patient who did not have cancer detected at screening colonoscopy (CN). Patients who 
had an initial suspicious adenomatous polyp detected through screening and as a result of 
subsequent investigations had colorectal cancer detected within 6 months of screening 
invite were termed SD.  
Individual patient records were then interrogated on a case-by-case basis to identify further 
clinicopathological variables for analysis. Tumours were staged according to the 
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conventional tumour node metastasis (TNM) classification (5
th
 Edition)(Sobin and Fleming 
1997). In those who did not undergo a resection, staging was determined from endoscopic 
and imaging modalities. Individuals in whom a polyp cancer was considered to be 
completely excised endoscopically and hence did not undergo further colonic resection, 
were presumed to be node negative and classified as TNM Stage I. Additional high-risk 
tumour features were identified from pathology reports.  
Both the absolute neutrophil count and the neutrophil to lymphocyte ratio (NLR) were 
used as a markers of the pre-operative SIR and were obtained from pre-operative blood 
results taken most immediately and not more than 6 weeks prior to surgery. With regards 
the NLR, a previously validated threshold of >5 was used as being evidence of a 
significantly elevated SIR (Walsh, Cook et al. 2005). An absolute neutrophil level greater 
than 7.5 x 10
9 
was defined as elevated as per local laboratory guidelines.  
Deprivation category was calculated using the Scottish Index of Multiple Deprivation 
(SIMD) which is an index of relative deprivation combining 38 indicators across 7 
domains, namely: income, employment, health, education, skills and training, housing, 
geographic access and crime. The overall index is a weighted rank for each domain 
allowing postcodes to be ranked in order of deprivation across Scotland. Quintiles of 
deprivation were used to assign patients a relative deprivation category based on their 
postcode at time of colonoscopy with the first quintile representing the most deprived and 
the fifth quintile, the least deprived (SIMD 2009). 
Permission for the study was granted by both the Caldicott Guardian of the Screening 
dataset and by the West of Scotland Colorectal Cancer MCN Management group. Data was 
stored and analysed in an anonymised manner. 
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Statistical analysis 
Associations between categorical variables were examined using the χ
2
 test.  For ordered 
variables with multiple categories the χ
2
 test for linear trend was used. Fishers exact test 
was used for assessing associations where individual cell counts were less than 5. A value 
of p<0.05 was considered statistically significant. Statistical analysis was performed using 
SPSS software (SPSS Inc., Chicago, IL, USA) 
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7.3 Results 
From April 2009 to March 2011, representing the first complete round of screening in 
NHS GG&C, 395 097 individuals were invited to participate, 204 535 (52%) responded 
and 6 159 (3.0%) tested positive. Of those who tested positive, 4 797 (78%) individuals 
proceeded to undergo colonoscopy and 421 patients had cancer detected (SD) (Figure 7.1). 
These figures differ slightly from previous chapters due to updating of the data within the 
Bowel Screening IT System and a later date of extraction for this chapter. After cross-
referencing with MCN and SMR06 datasets, 708 patients with NSD colorectal cancer were 
identified (468 (65%) patients NR; 182 (25%) patients INT, 43 (6%) patients NA; 15 (2%) 
patients CN). This generated an estimated sensitivity and specificity of the first round of 
the gFOBt/FIT screening test of 72.4% and 97.2% respectively (Table 7.1).   
 
Comparison of Screen-detected and Non Screen-detected Colorectal cancer 
Comparing SD and NSD patients, SD patients were more likely to be male (p=0.002), less 
deprived (p=0.001), have more distal disease (p=0.003), which was of an earlier stage 
(p<0.001) and were more likely to undergo a procedure with a curative intent (p<0.001) 
than NSD patients (Table 7.2). When high-risk tumour features were examined in those 
undergoing a curative procedure, SD patients had a less advanced T-stage, less evidence of 
venous invasion, peritoneal involvement and margin involvement (p<0.05). They also had 
less evidence of an elevated pre-operative SIR as evidence by both the NLR and the 
absolute neutrophil count (Table 7.3). Stage by stage analysis of factors was then carried 
out (Table 7.4). Patients with SD tumours had less evidence of an elevated SIR in stage II 
and III disease. There was no significant difference in venous invasion rates between SD 
and NSD tumours across all 4 stages (Table 7.4).  
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Figure 7.1: Outcome from the 1
st
 round of the Scottish Bowel Screening Programme 
in NHS GG&C 
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Comparison of Interval and Screen-detected Cancers 
Sub analysis of NSD patients was undertaken to examine INT patients in more detail. 
Comparing INT and SD patients, INT patients were more likely to be female (p<0.001), 
have more proximal disease (p<0.001), have more advanced disease (p<0.001) and less 
likely to be managed with a curative intent (p<0.001) (Table 6.5). In addition, they were 
more likely to have adverse prognostic factors such as venous invasion (p=0.026) and an 
elevated pre-operative SIR (p=0.025) (Table 6.6). However, on stage by stage analysis 
these differences failed to retain significance. In particular, venous invasion rates were 
similar across Stage 1 (17% INT vs 25% SD, p=0.344), Stage II (57% INT vs 47% SD, 
p=0.272) and Stage III (71% INT vs 70% SD, p=0.970) disease.   
 
Comparison of Interval and Non-Responder Cancers 
Comparing INT and NR patients, INT patients were more likely to be female (p=0.034) 
and less deprived (p<0.001) than NR patients (Table 6.7). There was trend towards INT 
patients having less advanced (p=0.052) and more proximal disease (p=0.090) however 
this did not reach significance. When those who were treated with a curative intent were 
examined, there was no difference in adverse pathological features between INT and NR 
patients. There was a trend for NR patients have an elevated pre-operative SIR (p=0.059) 
compared to INT patients (Table 6.8). 
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7.4 Discussion 
The results of the present study provide a comprehensive analysis of the outcomes from the 
first round of a stool-based colorectal cancer screening programme. It confirms previous 
studies that have found that screen-detected tumours are of an earlier stage than non 
screen-detected tumours, and reports, for the first time, that within Stage II and III disease, 
individuals with screen-detected tumours have more favourable host prognostic factors 
than those with non screen-detected tumours.    
Analysis of host factors, such as the presence of an elevated SIR has not previously been 
examined within the context of a colorectal cancer screening programme. The present 
study reports higher levels of systemic inflammation in patients with NSD tumours and 
this is not unsurprising as the SIR has been linked with tumour size (Crozier, McMillan et 
al. 2007). However, this difference remains when adjusted for stage in Stage II and Stage 
III disease. The presence of an elevated SIR has also been associated with increased 
deprivation (Roxburgh, Platt et al. 2011), increased pre-operative co-morbidity (Roxburgh, 
Platt et al. 2011) and higher rates of emergency presentation (Crozier, Leitch et al. 2009). 
It is unclear whether a higher rate of elevated host SIR in the NSD group may reflect 
patients who are more deprived and have more co-morbidities than those in the SD group. 
However, it has previously been shown that patients who are diagnosed with colorectal 
cancer through screening have a lower American Society of Anaesthesiologist (ASA) 
grade when compared to patients who do not respond to a screening invite (Gill, Bramble 
et al. 2012). Furthermore it has been reported that screening reduces the rate of emergency 
presentation and such a factor may be involved (Scholefield, Robinson et al. 1998; 
Goodyear, Leung et al. 2008). Further work exploring why SD patients have lower levels 
of inflammation than NSD patients is required and should involve full assessment of 
patient comorbidities. 
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It was interesting to note that within Stage I disease no differences between tumour and 
host factors between SD and NSD disease was identified, despite similar numbers to Stage 
II and III disease. This would be in keeping with the natural history of solid organ tumours 
whereby tumour heterogeneity develops as the lesion progresses. It is known that patients 
with Stage II and III disease represent a spectrum of disease with varied outcomes, 
whereas patients undergoing resection with Stage I disease have consistently better results.  
One of the criticisms of screening and analysis of data from screening programmes is that 
it can introduce two clear forms of bias (Kay and Witte 1991). The first is lead-time bias, 
where an earlier diagnosis of cancer in a pre-symptomatic phase artificially elongates an 
individual’s cancer-specific survival without altering that individual’s date of death. 
Secondly there is length time-bias, where the identification of indolent slow growing 
tumours artificially improves cancer-specific survival by detecting those who have a longer 
pre-clinical phase. The extreme form of length-time bias is overdiagnosis, whereby 
screening detects and eliminates tumours that may not have become apparent within a 
patients lifetime(Kay and Witte 1991). There is evidence from breast cancer screening that 
such overdiagnosis occurs, with a higher incidence of cancer being diagnosed in those who 
are invited to screening when followed up over 10 years (Allgood, Duffy et al. 2011).  
It could be argued that the present study, showing that some adverse tumour prognostic 
factors are less prevalent in SD tumours than in NSD tumours, is evidence for the effect of 
length-time bias. However, when adjustment is made for stage, the two key features in 
keeping with phenotypically more aggressive tumours, venous invasion and poor 
differentiation, do not achieve significance. Therefore, the conclusion that can be drawn 
from the present study is that the inherent biological characteristics of SD tumours do not 
differ from those of NSD disease. Furthermore, if length-time bias were to be the case in 
colorectal cancer screening, then a higher incidence of colorectal cancer in individuals 
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invited to screening would have been seen in long-term follow-up of gFOBt randomised 
control trials. This was not the case, for example, in the Nottingham gFOBt trial, similar 
incidence rates of cancer were seen between those in the screened and control groups 
(Scholefield, Moss et al. 2012). Both the Scottish and English bowel screening 
programmes are still relatively immature and as such, effects of the population 
programmes on incidence at a national level are yet to be examined.  
Within analysis of patients with NSD disease it is interesting to examine INT cancers in 
more detail as they are indicative of the sensitivity of a screening programme. The present 
study represents the first time the sensitivity and specificity of the current SBoSP 
algorithm has been examined in a population setting. In the present study, of the 661 
patients who developed cancer in those who responded to screening, 182 (28%) were 
gFOBt/FIT negative. A similar INT cancer rate of 30% was reported in the first round the 
Scottish gFOBt pilot study. This is perhaps surprising as this suggests that the present 
gFOB/FIT algorithm does not confer a significant advantage over the gFOBt programme 
with regards test characteristics. Further work analysing INT cancer rates over subsequent 
rounds will be required to assess the true influence of the change from the gFOBt to a 
gFOBt/FIT pathway.   
There is evidence that the level of haemoglobin present within an individuals stool is 
affected by individual demographics such as age, sex and deprivation (Digby, McDonald et 
al. 2014; Fraser, Rubeca et al. 2014). In particular older, males, who are more deprived 
have demonstrably higher levels of haemoglobin in their faeces. The results of the present 
study confirm that this can translate clinically into higher rates of INT tumours in females 
compared to males. There was, however, no difference in deprivation noted between 
individuals with SD and INT tumours in the present study. There are currently proposals to 
develop quantitative FIT as a first line test within the SBoSP and there will be the 
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opportunity to adjust positive thresholds for specific patient demographics (Steele, 
McDonald et al. 2013). Further work, in larger numbers, is required to establish whether 
the detected difference in faecal haemoglobin levels within deprivation quintiles, will 
translate in to practice with the development of less INT tumours in those who are 
deprived. 
It has previously been postulated that INT tumours do not only represent tumours missed 
by the screening test itself but that they may be more aggressive tumours that develop 
within the screening interval (Gill, Bramble et al. 2012; Steele, McClements et al. 2012). 
The present study is the first to examine in detail tumour and host prognostic factors and 
provides evidence to refute this hypothesis. There was no evidence of adverse tumour 
features in the INT group when compared to the NR group in the present study. Indeed, 
there was a trend for NR patients to have evidence of a higher host SIR.  
There were higher than expected number of cancers in both the NA and CN groups. 
However, on further investigation it became apparent that a substantial proportion of the 
NA patients (40%, data not presented), were already under investigation for colorectal 
symptoms and had sent back the screening test in the midst of undergoing non-screening 
investigations. Also, of the 15 patients who were CN, 12 (80%) patients (data not 
presented) had polyps detected at colonoscopy and hence were undergoing follow-up. For 
the purposes of the present study, a cancer diagnosis outwith 6 months of initial 
colonoscopy was defined as NSD, however it may be argued that these patients would not 
have been detected at that time had they not participated in screening. Accounting for that, 
there were however, 3 patients who had normal colonoscopies and hence could be defined 
as having true post-colonoscopy colorectal cancer. This figure compares favourably to 
other studies that have examined this outwith screening programmes and have provided 
rates of 2- 8% albeit with longer (3 to 5 year) follow-up (Bressler, Paszat et al. 2007; 
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Singh, Nugent et al. 2010; le Clercq, Bouwens et al. 2014). The majority of post-
colonoscopy colorectal cancers are thought to arise through procedural factors such as 
missed lesions and inadequate examination (le Clercq, Bouwens et al. 2014).  The SBoSP 
has tight quality control measures with all colonoscopists requiring to be Joint Advisory 
Group (JAG) accredited and have a greater than 90% completion rate (QIS 2007). It was 
outwith the scope of the present study to examine colonoscopy quality indexes in more 
detail, however, the low rate of true post-colonoscopy colorectal cancer was reassuring.   
The main strengths of the present study include the comprehensive and detailed dataset. 
Case notes were examined on a cases-by-case basis allowing for more detailed analysis of 
clinicopathological factors at a level of granularity that has not previously been 
undertaken. For example, in the present study after case note review, only 2% of tumours 
remained unstaged compared to 25% in a previous study utilising population databases 
(Morris, Whitehouse et al. 2012). In addition, we have included data from non-responders, 
which has been absent from other studies, and by utilising both regional and national 
cancer registry datasets have comprehensively captured those with NSD disease from 
corroborative sources. 
The main limitation of the study is the fact that this is a prevalence round of a screening 
programme and as such these results may not be applicable in subsequent rounds. This is 
important when analysing data presented regarding sensitivity and specificity. It is 
important to consider that population screening tests for colorectal cancer, using either 
gFOBt or FIT are designed to be repeated on a regular basis and therefore analysing a 
solitary round in isolation is not necessarily indicative of the efficacy of the programme as 
a whole. Finally, our measure of the SIR was using NLR and not mGPS, which has been 
shown to be a more sensitive measure of host inflammation with regards outcome (Proctor, 
Morrison et al. 2011). However, this is a retrospective study, and C-reactive protein, 
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required for calculating mGPS, was not routinely measured pre-operatively across all 
hospitals during this timeframe.  
In conclusion, the present study reports that within Stage II and III disease, individuals 
with SD tumours had more favourable host prognostic factors than patients with NSD 
tumours. However, there was no difference in adverse tumour features associated with an 
aggressive tumour phenotype. In addition, INT cancers do not appear to have more 
aggressive features than tumours that develop in the rest of the population and hence are 
more likely to arise as a result of the limitations of the testing algorithm itself rather than 
represent biologically more aggressive tumours. Further work, identifying a more sensitive 
test is required in order to increase the number of tumours that are detected through 
screening and hence improve outcomes in colorectal cancer. 
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Table 7.1: Estimation of sensitivity & specificity of the 1
st
 round of the Scottish Bowel 
Screening Programme in Greater Glasgow & Clyde 
 
 
 
Combined gFOBt/FIT 
screening test 
 
Positive Negative TOTAL 
Colorectal 
Cancer 
Present 
 
 
479 
 
 
182 
 
661 
Absent 
 
 
5680 
 
 
198 194 
 
203 874 
 
TOTAL 6159 198 376 204 535 
 
Sensitivity =   479 / 661   = 72.4 % 
Specificity =   198 194 / 203 874  = 97.2 % 
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Table 7.2: Baseline characteristics of Screen-detected and Non Screen-detected 
Colorectal Cancer (all patients) 
 
 
 All 
patients 
 
n(%) 
 
 Screen-
detected  
 
n(%) 
Non 
Screen-
detected 
n(%) 
 
 
p-value 
 1129  421 708  
Age      
         <64 437 (39)  164 (39) 273 (39)  
         64 – 70 300 (27)  114 (27) 186 (26)  
         >70 392 (35)  143 (34) 249 (35) 0.762 
Sex      
        Female 447 (40)  142 (34) 305 (43)  
        Male 682 (60)  279 (66) 403 (57) 0.002 
Deprivation quintile      
         1 (most deprived) 403 (36)  125 (30) 278 (39)  
         2 199 (18)  71 (17) 128 (18)  
         3 182 (16)  78 (19) 104 (15)  
         4 151 (13)  67 (16) 84 (12)  
         5 (least deprived) 189 (17)  78 (19) 111 (16) 0.001 
Site      
         Proximal to splenic flexure 325 (29)  100 (24) 225 (32)  
         Distal to splenic flexure  795 (71)  321 (76) 474 (67) 0.003 
         Synchronous 9 (1)  0 9 (1)  
TNM Stage      
         I 318 (28)  191 (45) 127 (18)  
         II 285 (25)  93 (22) 192 (27)  
         III 284 (25)  103 (25) 181 (26)  
         IV 220 (20)  28 (7) 192 (27) <0.001 
         Unstaged 22 (2)  6 (1) 16 (2)  
Management intent      
         Curative procedure 872 (77)  393 (93) 479 (68)  
         Palliative procedure 102 (9)  8 (2) 94 (13) <0.001 
         No procedure 155 (14)  20 (5) 135 (19)  
 
 186 
 
Table 7.3: Comparison of tumour and host prognostic factors between Screen-
detected and Non Screen-detected Colorectal Cancer (patients undergoing a 
procedure with a curative intent) 
 All 
patients 
 
n(%) 
 Screen-
detected  
 
n(%) 
Non Screen-
detected 
 
n(%) 
 
 
p-value 
 872  393 479  
Age      
         <64 350 (40)  148 (38) 202 (42)  
         64 – 70 221 (25)  107 (27) 114 (24)  
         >70 301 (35)  138 (35) 163 (34) 0.340 
Sex      
        Female 346 (60)  135 (34) 211 (44)  
        Male 526 (60)  258 (66) 268 (56) 0.004 
Deprivation quintile      
         1 (most deprived) 288 (33)  115 (29) 173 (36)  
         2 161 (19)  68 (17) 93 (20)  
         3 144 (17)  71 (18) 73 (15)  
         4 123 (14)  63 (16) 60 (13)  
         5 (least deprived) 154 (17)  75 (19) 79 (17) 0.016 
Site      
         Proximal to splenic flexure 240 (27)  94 (24) 146 (30)  
         Distal to splenic flexure  626 (72)  299 (76) 327 (69) 0.023 
         Synchronous 6 (1)  0 6 (1)  
T-stage      
         0/1 233 (27)  149 (38) 84 (18)  
         2 124 (14)  63 (16) 61 (13)  
         3 365 (42)  153 (39) 212 (44)  
         4 150 (17)  28 (7) 122 (26) <0.001 
N-stage
a
      
         0 522 (66)  228 (69) 294 (64)  
         1 182 (23)  73 (22) 109 (24)  
         2 89 (11)  32 (10) 57 (12) 0.138 
Differentiation
b
               
          Poor 69 (8)  24 (6) 45 (10)  
          Moderate/well 795 (92)  368 (94) 427 (90) 0.066 
Venous Invasion
c
      
          Present 405 (50)  163 (44) 242 (55)  
          Absent 413 (50)  213 (57) 200 (45) 0.001 
Peritoneal involvement
a
      
          Present 128 (16)  20 (6) 108 (24)  
          Absent 665 (84)  313 (94) 352 (77) <0.001 
Tumour Perforation
a
      
           Present 39 (5)  4 (1) 35 (8)  
           Absent 754 (95)  329 (98) 425 (92) <0.001 
Margin Involvement
a
      
            Present 27 (3)  5 (2) 22 (5)  
            Absent 766 (97)  328 (98) 438 (95) 0.012 
Absolute neutrophil count
d
      
            >7.5 70 (9)  13 (4) 57 (13)  
            <7.5 710 (91)  315 (96) 395 (87) <0.001 
Neutrophil/lymphocyte ratio
d
      
            > 5 123 (16)  28 (9) 95 (21)  
            < 5 657 (84)  300 (91) 357 (79) <0.001 
 
a.
n=793, 
b
n= 866, 
c
n= 818, 
d
n=780  
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Table 7.4a: Comparison of tumour and host prognostic factors, stratified by TNM 
stage (patients undergoing resection with a curative intent TNM stage I) 
 
 
 
Stage 
 All 
patients 
 
n(%) 
 Screen-
detected  
 
n(%) 
Non 
Screen-
detected 
n(%) 
 
 
p-value 
I  237  131 106  
Age      
         <64 102 (43)  55 (42) 47 (44)  
         64 – 70 64 (27)  41 (31) 23 (22)  
         >70 71 (30)  35 (27) 36 (34) 0.658 
Sex      
        Female 94 (40)  44 (34) 50 (47)  
        Male 143 (60)  87 (66) 56 (53) 0.034 
Deprivation quintile      
         1 (most deprived) 71 (30)  38 (29) 33 (31)  
         2 43 (18)  24 (18) 19 (18)  
         3 39 (17)  26 (20) 13 (12)  
         4 35 (15)  19 (15) 16 (15)  
         5 (least deprived) 49 (21)  24 (18) 25 (24) 0.715 
Site      
         Proximal to splenic flexure 41 (17)  23 (18) 18 (17)  
         Distal to splenic flexure  196 (82)  108 (82) 88 (83) 0.907 
         Synchronous 0  0 0  
Differentiation
a
               
          Poor 8 (5)  5 (4) 3 (3)  
          Moderate/well 225 (95)  125 (96) 100 (97) 0.250 
Venous Invasion
b
      
          Present 60 (29)  33 (27) 27 (32)  
          Absent 147 (71)  89 (73) 58 (68) 0.463 
Peritoneal involvement      
          Present 1 (0)  1 (1) 0  
          Absent 236 (100)  130 (99) 106 (100) 0.368 
Tumour Perforation      
           Present 2 (1)  2 (1) 0  
           Absent 235 (99)  129 (99) 106 (100) 0.202 
Margin Involvement      
            Present 0  0 0  
            Absent 237 (100)  131 (100) 106 (100)  
Absolute neutrophil count
c
      
            >7.5 4 (2)  2 (2) 2 (2)  
            <7.5 228 (98)  126 (98) 102 (98) 0.834 
Neutrophil/lymphocyte ratio
c
      
            > 5 16  (7)  8 (6) 8 (8)  
            < 5 216 (93)  120 (94) 96 (92) 0.667 
 
a
n=232,  
b
n=207, 
c
n=232 
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Table 7.4b: Comparison of tumour and host prognostic factors, stratified by TNM 
stage (patients undergoing resection with a curative intent TNM stage II) 
 
 
Stage 
 All 
patients 
 
n(%) 
Screen-
detected  
 
n(%) 
Non 
Screen-
detected 
n(%) 
 
 
p-value 
II  270 91 179  
Age     
         <64 91 (34) 28 (31) 63 (35)  
         64 – 70 71 (26) 25 (28) 46 (26)  
         >70 108 (40) 38 (42) 70 (39) 0.522 
Sex     
        Female 124 (46) 40 (44) 84 (47)  
        Male 146 (54) 51 (56) 95 (53) 0.644 
Deprivation quintile     
         1 (most deprived) 104 (39) 26 (29) 78 (44)  
         2 47 (17) 11 (12) 36 (20)  
         3 47 (17) 21 (23) 26 (15)  
         4 34 (13) 18 (20) 16 (9)  
         5 (least deprived) 38 (14) 15 (16) 23 (13) 0.003 
Site     
         Proximal to splenic flexure 107 (40) 38 (42) 69 (39)  
         Distal to splenic flexure  160 (59) 53 (58) 107 (60) 0.687 
         Synchronous 3(1) 0 3 (2)  
Differentiation              
          Poor 18 (7) 4 (4) 14 (8)  
          Moderate/well 252 (93) 87 (96) 165 (92) 0.287 
Venous Invasion
d
     
          Present 134 (50) 42 (47) 92 (52)  
          Absent 133 (50) 48 (53) 85 (48) 0.413 
Peritoneal involvement     
          Present 48 (18) 7 (8) 41 (23)  
          Absent 222 (82) 84 (92) 138 (77) 0.002 
Tumour Perforation     
           Present 20 (7) 1 (1) 19 (11)  
           Absent 250 (93) 90 (99) 160 (89) 0.005 
Margin Involvement     
            Present 11 (4) 1 (1) 10 (6)  
            Absent 259 (96) 90 (99) 169 (94) 0.078 
Absolute neutrophil count
e
     
            >7.5 35 (13) 5 (6) 30 (17)  
            <7.5 233 (87) 86 (94) 147 (83) 0.007 
Neutrophil/lymphocyte ratio
e
     
            > 5 48 (18) 8 (9) 40 (23)  
            < 5 220 (82) 83 (91) 137 (77) 0.005 
 
d
n=267, 
e
n=268 
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Table 7.4c: Comparison of tumour and host prognostic factors, stratified by TNM 
stage (patients undergoing resection with a curative intent TNM stage III) 
 
 
Stage 
 All 
patients 
 
n(%) 
Screen-
detected  
 
n(%) 
Non 
Screen-
detected 
n(%) 
 
 
p-value 
III  244 101 143  
Age     
         <64 112 (46) 42 (42) 70 (49)  
         64 – 70 58 (24) 25 (25) 33 (23)  
         >70 74 (30) 34 (34) 40 (28) 0.243 
Sex     
        Female 90 (37) 31 (31) 59 (41)  
        Male 154 (63) 70 (69) 84 (59) 0.093 
Deprivation quintile     
         1 (most deprived) 74 (31) 36 (36) 38 (27)  
         2 45 (19) 17 (17) 28 (20)  
         3 40 (16) 14 (14) 26 (18)  
         4 39 (16) 13 (13) 26 (18)  
         5 (least deprived) 44 (18) 20 (20) 25 (17) 0.446 
Site     
         Proximal to splenic flexure 76 (31) 31 (31) 45 (31)  
         Distal to splenic flexure  165 (68) 70 (69) 95 (66) 0.811 
         Synchronous 3 (1) 0 3 (2)  
Differentiation
f
              
          Poor 34 (14) 13 (13) 21 (14)  
          Moderate/well 209 (86) 88 (87) 121 (85) 0.348 
Venous Invasion
g
     
          Present 161 (69) 69 (70) 92 (68)  
          Absent 72 (31) 29 (30) 43 (32) 0.713 
Peritoneal involvement     
          Present 58 (24) 11 (11) 47 (33)  
          Absent 186 (76) 90 (89) 96 (67) <0.001 
Tumour Perforation     
           Present 10 (4) 1 (1) 9 (6)  
           Absent 234 (96) 100 (99) 134 (94) 0.040 
Margin Involvement     
            Present 11 (5) 4 (4) 7 (5)  
            Absent 233 (95) 97 (96) 136 (95) 0.729 
Absolute neutrophil count
h
     
            >7.5 24 (10) 6 (6) 18 (13)  
            <7.5 211 (90) 92 (94) 119 (87) 0.081 
Neutrophil/lymphocyte ratio
h
     
            > 5 48 (20) 11 (11) 37 (27)  
            < 5 187 (80) 87 (89) 100 (73) 0.003 
 
f
n=243, 
g
n=233, 
h
n=235 
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Table  7.5: Comparison of baseline characteristics Interval and Screen-detected 
cancers (all patients) 
 
 
 
 Interval  
 
n(%) 
Screen-
detected  
n(%) 
 
p-value 
 
 182 421  
Age    
         <64 64 (35) 164 (39)  
         64 – 70 59 (32) 114 (27)  
         >70 59 (32) 143 (34) 0.765 
Sex    
        Female 91 (50) 142 (34)  
        Male 91 (50) 279 (66) <0.001 
Deprivation quintile    
         1 (most deprived) 61 (34) 125 (30)  
         2 23 (13) 71 (17)  
         3 30 (17) 78 (19)  
         4 26 (14) 67 (16)  
         5 (least deprived) 42 (23) 78 (19) 0.758 
Site    
         Proximal to splenic flexure 69 (38) 100 (24)  
         Distal to splenic flexure  113 (62) 321 (76) <0.001 
         Synchronous 0 0  
TNM Stage    
         I 37 (20) 191 (45)  
         II 45 (25) 93 (22)  
         III 53 (29) 103 (25)  
         IV 46 (25) 28 (7) <0.001 
         Unstaged 1 (1) 6 (1)  
Management intent    
         Curative procedure 130 (71) 393 (93)  
         Palliative procedure 20 (11) 8 (2)  
         No procedure 32 (18) 20 (5) <0.001 
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Table 7.6: Comparison of tumour and host prognostic factors in Interval and Screen-
detected cancers (patients undergoing a procedure with a curative intent)  
 
 
 Interval  
 
n(%) 
Screen-
detected  
n(%) 
 
 
p-value 
 
 130 393  
Age    
         <64 44 (34) 148 (38)  
         64 – 70 40 (31) 107 (27)  
         >70 46 (35) 138 (35) 0.634 
Sex    
        Female 63 (49) 258 (66)  
        Male 67 (52) 135 (34) <0.001 
Deprivation quintile    
         1 (most deprived) 36 (28) 115 (29)  
         2 18 (14) 68 (17)  
         3 24 (19) 71 (18)  
         4 21 (16) 63 (16)  
         5 (least deprived) 31 (24) 75 (19) 0.285 
Site    
         Proximal to splenic flexure 45 (35) 94 (24)  
         Distal to splenic flexure  85 (65) 299 (76) 0.017 
         Synchronous 0 0  
T-stage    
         0/1/2 43 (33) 212 (54)  
         3/4 87 (67) 181 (46) <0.001 
N-stage
a
    
         0 77 (61) 228 (69)  
          1/2 49 (39) 105 (32) 0.137 
Differentiation
b
            
          Poor 13 (10) 24 (6)  
          Moderate/well 114 (90) 368 (94) 0.118 
Venous Invasion
c
    
          Present 68 (55) 163 (43)  
          Absent 56 (45) 213 (57) 0.026 
Absolute neutrophil count
d
    
            >7.5 12 (9) 13 (4)  
            <7.5 115 (91) 315 (96) 0.021 
Neutrophil/lymphocyte ratio
d
    
            > 5 20 (16) 28 (9)  
            < 5 107 (84) 300 (91) 0.025 
 
 
a
 n=459, 
b
n=519, 
c
n=500, 
d
n=455. 
 
 
 
 
 
 
 192 
 
Table 7.7: Comparison of baseline characteristics Interval and Non-responder 
cancers (all patients) 
 
 
 
 Interval  
 
n(%) 
Non-
responder 
n(%) 
 
p-value 
 
 182 468  
Age    
         <64 64 (35) 188 (40)  
         64 – 70 59 (32) 113 (24)  
         >70 59 (32) 167 (36) 0.816 
Sex    
        Female 91 (50) 191 (41)  
        Male 91 (50) 277 (59) 0.034 
Deprivation quintile    
         1 (most deprived) 61 (34) 196 (42)  
         2 23 (13) 90 (19)  
         3 30 (17) 71 (15)  
         4 26 (14) 54 (12)  
         5 (least deprived) 42 (23) 54 (12) <0.001 
Site    
         Proximal to splenic 
flexure 
69 (38) 142 (31)  
         Distal to splenic flexure  113 (62) 317 (69) 0.090 
         Synchronous    
TNM Stage    
         I 37 (20) 74 (16)  
         II 45 (25) 130 (28)  
         III 53 (29) 115 (25)  
         IV 46 (25) 135 (29) 0.052 
         Unstaged 1 (1) 14 (3)  
Management intent    
         Curative procedure 130 (71) 306 (65)  
         Palliative procedure 20 (11) 67 (14)  
         No procedure 32 (18) 95 (20) 0.210 
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Table 7.8: Comparison of tumour and host prognostic factors in Interval and Non-
responder cancers (patients undergoing a procedure with a curative intent)  
 
 
 Interval  
 
n(%) 
Non-
responder 
n(%) 
 
 
p-value 
 
 130 306  
Age    
         <64 44 (34) 140 (46)  
         64 – 70 40 (31) 63 (21)  
         >70 46 (35) 103 (34) 0.135 
Sex    
        Female 63 (49) 178 (58)  
        Male 67 (52) 128 (42) 0.062 
Deprivation quintile    
         1 (most deprived) 36 (28) 123 (40)  
         2 18 (14) 63 (21)  
         3 24 (19) 47 (15)  
         4 21 (16) 35 (12)  
         5 (least deprived) 31 (24) 37 (12) <0.001 
Site    
         Proximal to splenic flexure 45 (35) 91 (30)  
         Distal to splenic flexure  85 (65) 209 (70) 0.381 
         Synchronous    
T-stage    
         0/1/2 43 (33) 83 (27)  
         3/4 87 (67) 223 (73) 0.210 
N-stage
a
    
         0 77 (61) 187 (64)  
          1/2 49 (39) 105 (36) 0.569 
Differentiation
b
            
          Poor 13 (10) 29 (10)  
          Moderate/well 114 (90) 273 (90) 0.840 
Venous Invasion
c
    
          Present 68 (55) 157 (56)  
          Absent 56 (45) 121 (44) 0.761 
Absolute neutrophil count
d
    
            >7.5 12 (9) 41 (15)  
            <7.5 115 (91) 242 (85) 0.160 
Neutrophil/lymphocyte ratio
d
    
            > 5 20 (16) 68 (24)  
            < 5 107 (84) 215 (76) 0.059 
 
 
a
n=418, 
b
n=429, 
c
n=402, 
d
n=410 
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8 AN EXAMINATION OF PROGNOSTIC FACTORS 
IN NON SCREEN-DETECTED TNM STAGE I 
COLORECTAL CANCER 
8.1 Introduction 
Population screening for colorectal cancer using the faecal occult blood test (FOBt) has 
been shown to improve cancer specific mortality through the detection of early stage 
disease (Mandel, Bond et al. 1993; Hardcastle, Chamberlain et al. 1996; Kronborg, Fenger 
et al. 1996). Through this detection of early stage tumours, such screening programmes 
have the potential to change the entire landscape of the management and outcome of 
colorectal cancer. For example, studies in the pre-screening era noted that less than 20% of 
all patients presented with TNM Stage I disease (Nicholson, Finlay et al. 2011; Roxburgh, 
McTaggart et al. 2013). However, it has been shown that TNM Stage I tumours can 
account for approximately 50% of colorectal cancers detected through FOBt screening 
programmes (UK Colorectal Cancer Screening Pilot Group 2004; Logan, Patnick et al. 
2012). Hence, an overall stage-shift towards early stage disease is anticipated over the next 
decade (McClements, Madurasinghe et al. 2012). There is evidence from our geographical 
area, presented in Chapter 2, that such a stage shift has already occurred.  
Cancer outcome following a diagnosis of TNM Stage I colorectal cancer is very good, and 
an average 5-year cancer specific survival of over 90% is widely reported (Cancer 
Research UK). As such, adjuvant chemotherapy is not recommended in these patients 
(Nelson, Petrelli et al. 2001, SIGN 2011). Nevertheless, some will develop metastatic 
disease and ultimately succumb to their illness and others will die of alternate causes, such 
as cardiovascular disease. This would be increasingly relevant to those detected through 
screening, as while screening improves cancer specific mortality, no effect on overall 
survival has been shown on mature follow up (Hewitson, Glasziou et al. 2008).  
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Many risk factors associated with a diagnosis of colorectal cancer are similar to those for 
cardiovascular disease (Parkin, Olsen et al. 2009), which is the leading cause of death in 
individuals over the age of 50 (Office of National Statistics 2012). It is now increasingly 
recognised that independent of TNM Stage, there are host factors that may be of 
importance in predicting outcome. In particular, the presence of an elevated systemic 
inflammatory response (Ishizuka, Nagata et al. 2007; Park, Watt et al. 2015) as evidenced 
by an alteration in circulating acute phase proteins, such as C-reactive protein (CRP) and 
albumin (modified Glasgow Prognostic Score (mGPS)), is associated not only with poorer 
outcome in colorectal cancer, but more recently it has been linked to all-cause mortality in 
a large incidentally sampled cohort (Proctor, McMillan et al. 2015).  
There is a paucity of evidence examining tumour and, in particular, host factors in 
determining outcome specifically in patients with TNM Stage I colorectal cancer. Because 
of limited follow-up, an examination of these factors solely within screen-detected disease 
is not yet possible. However, as discussed in Chapter 7, there appears to be few differences 
between screen-detected and non screen-detected TNM Stage I disease. 
The aim of the present study was to examine tumour and host determinants of outcome in 
patients undergoing resection for TNM Stage I colorectal cancer with mature follow-up. 
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8.2 Materials and methods 
From January 2000 to December 2008 (inclusive), all patients undergoing a resection, with 
pathologically confirmed TNM Stage I disease, across four hospitals in the north of 
Glasgow were identified. Data was collected in both a prospective (Glasgow Royal 
Infirmary) and retrospective (Stobhill Hospital, Western Infirmary, Gartnavel General 
Hospital) manner. Any patient with a synchronous cancer, inflammatory bowel disease or 
who had received neo-adjuvant therapy was excluded. Those with their disease managed 
entirely endoscopically, without formal colonic or rectal resection, were also excluded 
from the study.  
Tumours were staged according to the conventional tumour node metastasis (TNM) 
classification (5
th
 Edition)
 
(Sobin and Fleming 1997). Further details on high-risk tumour 
features, such as the presence of venous invasion (Roxburgh, McMillan et al. 2014), poor 
differentiation (Compton, Fielding et al. 2000) or those in whom less than 12 lymph nodes 
were examined (Compton, Fielding et al. 2000) were extracted from pathology reports. 
Those with inadequate information on the number of nodes examined in pathology reports 
were excluded from the analysis. 
The mGPS was used as an estimate of the SIR as has been described previously, using pre-
operative blood results taken most immediately and not more than 1 month prior to surgery 
(McMillan 2012). Briefly, patients with a CRP < 10 mg/L were allocated a score of 0, a 
CRP >10 mg/L and albumin > 35g/L a score of 1 and a CRP >10mg/L and albumin 
<35g/L a score of 2. Due to limited events during follow-up, for survival analysis the 
mGPS was further dichotomised into being elevated (mGPS = 1 or 2) or not elevated 
(mGPS = 0).  
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Survival was determined from both individual electronic patient records and by matching 
patients to the Registrar General (Scotland). Date of censor was 12th December 2014.  
Overall survival (OS) was the primary outcome measure and was calculated from date of 
surgery until date of death. Cancer specific survival (CSS) was calculated from date of 
surgery until date of death from recurrent or metastatic colorectal cancer. A post-operative 
death was defined as a death within 30 days of operation.   
The study was discussed and approved by the West of Scotland Research and Ethics 
Committee (REC Ref: 11/AL/0382 – Molecular and cellular mechanisms underlying 
development and progression of colorectal cancer. September 2011) 
 
Statistical analyses 
The relationship between clinicopathological features and survival was examined using 
Kaplain-Meier log-rank survival analysis and univariate Cox proportional hazards 
regression to calculate hazard ratios (HR) and 95% confidence intervals (95% CI). 
Statistically significant variables on univariate analysis were then taken forward into a 
multivariate model using a backwards conditional method. Associations between variables 
were examined using the Chi-squared test. Fisher’s exact test was used for assessing 
associations where the expected individual cell counts were less than 5. A value of p<0.05 
was considered statistically significant. Statistical analysis was performed using SPSS 
software (SPSS Inc., Chicago, IL, USA) 
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8.3 Results 
A total of 191 patients were identified and included in the study. There were 105 (55%) 
males, 91 (48%) were over the age of 75 years and 7 (4%) patients underwent an operation 
as an emergency. In those with a pre-operative CRP result (n=150), 35 (24%) patients had 
evidence of an elevated mGPS (Table 8.1). 
The median follow-up of survivors was 116 months with a minimum follow-up of 72 
months. During follow-up 88 (46%) patients died of which 7 (8%) were postoperative 
deaths, 15 (17%) were cancer-related deaths and 66 (75%) were non cancer-related deaths. 
This resulted in a 5 year CSS of 95% and a 5 year OS of 76%. Excluding postoperative 
deaths, on univariate analysis, advancing age (p<0.001), emergency presentation (p=0.008) 
and an elevated mGPS (p=0.012) were associated with reduced OS. On multivariate 
analysis, only age (HR = 3.611, 95% CI:2.049 - 6.365, p<0.001) and the presence of an 
elevated mGPS (HR = 2.173, 95% CI:1.204 – 3.921, p=0.010) retained significance (Table 
8.2, Figure 8.1).  
There was an association between an elevated mGPS and emergency presentation 
(p=0.040). In view of this, survival in elective procedures was examined independently 
(Table 8.3). Excluding postoperative deaths, on univariate analysis, advancing age 
(p<0.001) and an elevated mGPS (p=0.034) were associated with reduced OS. On 
multivariate analysis, both age (HR = 3.503. 95% CI:1.980 – 6.196, p<0.001) and the 
presence of an elevated mGPS (HR = 2.104, 95% CI:1.155 – 3.835, p= 0.015) retained 
significance (Table 8.3). There were no further associations between the presence of an 
elevated mGPS and additional clinicopathological variables (Table 8.4). The unadjusted 
difference in mean OS between those with an elevated mGPS and those without was 31 
months (Table 8.4).  
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Data was further stratified to assess any temporal trends that may have developed over the 
timeframe. Comparing patients operated on between 2001 and 2004 to those operated on 
between 2005 and 2008, there were no differences in age (p=0.548), sex (p=0.292), mode 
of presentation (p=0.345), site of tumour (p=0.149), t-stage (p=0.969), tumour 
differentiation (p=0.656) or the presence of an elevated mGPS (p=0.520). Patients operated 
on between 2001 and 2004 were more likely to have less than 12 lymph nodes examined 
(61% vs 44%, p=0.020) and there was a trend towards a lower venous invasion rate (17% 
vs 28%, p=0.073). Date of operation was not associated with OS (Tables 8.2 & 8.3).  
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Figure 8.1: Relationship between an elevated modified Glasgow Prognostic Score 
(mGPS) and overall survival (OS) in patients following resection for TNM Stage I 
colorectal cancer (excluding postoperative deaths)  
 
 
  
 201 
 
8.4 Discussion 
The results of the present study show that with mature follow-up, although cancer specific 
survival was 95%, overall survival was 76% in patients undergoing resection for TNM 
Stage I colorectal cancer. Furthermore, in these patients, the presence of an elevated SIR, 
as measured by the mGPS, was associated with poorer outcome. Taken together, this 
supports the argument that the SIR can be used as a means of identifying patients with a 
poorer outcome even within very early stage colorectal cancer. 
The results of the present study confirm previous work that has shown that long-term 
oncological outcome in TNM Stage I disease is excellent (Cancer Research UK). However, 
a significant amount of patients will die of other causes and there is a paucity of evidence 
focussing on OS, which is ultimately of most relevance in patient outcome. In particular, to 
our knowledge, there have been no studies examining the relationship between the SIR and 
OS in TNM Stage I disease. Given that the SIR has been shown to be associated with 
adverse outcomes in both cardiovascular disease as well as cancer, it may represent a 
nexus from which overall survival may be predicted and improved in this patient cohort. 
For example, several large prospective cohort studies have identified inflammatory 
mediators including as CRP and albumin, as being predictive of both all cause, cancer-
specific mortality and cardiovascular mortality in the over 50s (Van Hemelrijck, 
Eichholzer et al. 2012; Van Hemelrijck, Harari et al. 2012)  
It is of interest to compare this to previous work in our geographical area that has identified 
that age and emergency presentation are associated with survival in TNM Stage II disease 
(Oliphant, Horgan et al. 2015). In the present study when adjusted for the SIR, as 
evidenced by mGPS, emergency presentation failed to retain prognostic significance. This 
is in contrast to a previous study, predominantly in TNM Stage II disease, that had shown 
that while emergency presentation and the SIR were linked, they both represented 
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independent predictors of CSS (Crozier, Leitch et al. 2009). This disparity is likely due to 
the focus on OS in the present study and the low number of cancer-related deaths. 
Furthermore, it may be speculated that within very early stage disease, emergency 
presentation, and its relationship with OS, represents a surrogate for a pro-inflammatory 
state that the mGPS more accurately recapitulates.   
In addition to the long-term sequelae, there are short-term consequences of an elevated 
preoperative SIR that are important to consider. Colorectal resections can be associated 
with significant morbidity including both infective and non-infective postoperative 
complications. The preoperative SIR has been previously shown to be predictive of the 
development of a postoperative infection (Moyes, Leitch et al. 2009) and is associated with 
an elevated postoperative SIR, as measured by CRP (Crozier, McKee et al. 2007). Such a 
rise in the postoperative CRP is associated with higher rates of both surgical-site and 
remote infective complications (Platt, Ramanathan et al. 2012). In particular, in a recent 
meta-analysis the use of Day 3 CRP as a predictor of an anastomotic leak in the 
postoperative course at a threshold of 172 mg/l was found to have a negative predictive 
value of 97% (Singh, Zeng et al. 2014).  
It is important to identify why individuals may have an elevated preoperative SIR in order 
to potentially identify a target for intervention. The SIR has been linked to a number of 
patient-related factors including smoking (Frohlich, Sund et al. 2003), diabetes 
 
(Dehghan, 
Kardys et al. 2007) and obesity (Ridker, Buring et al. 2003). In the context of colorectal 
cancer specifically, the SIR has been found to be associated with preoperative impaired 
patient physiology, however, it has been shown that it can determine outcome independent 
of comorbidity (Richards, Leitch et al. 2010). Therefore, to equate the SIR to a mere 
surrogate of comorbid disease would be to oversimplify a more complex interaction 
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between tumour and host. However, as a global assessment of the patient it may be that it 
represents a therapeutic target for potential intervention (Diakos, Charles et al. 2014). 
A diagnosis of cancer has been identified as a ‘teachable moment’ whereby individuals are 
more receptive to changes in risk-related lifestyle and behaviour (McBride, Emmons et al. 
2003). Indeed, the recently published BeWEL study has identified that a weight loss 
programme can be successfully instigated in patients who have adenomata identified at 
colonoscopy following a positive FOBt screening test (Anderson, Craigie et al. 2014). The 
authors reported that interventions including exercise not only reduced weight, but 
improved blood pressure and glucose metabolism markers after 1 year. The SIR was not 
reported on within the BeWEL study, however weight control and exercise programmes 
have previously been shown to reduce the SIR (Lira, Rosa Neto et al. 2014). The present 
study identifies a subgroup of patients that have a poorer outcome and hence may be 
suitable for targeting with such a programme.  
In addition to lifestyle measures such as diet and exercise, there is potential to manipulate 
the SIR through pharmacological methods. There is evidence that both statin (Ridker, Rifai 
et al. 1999; Ridker, Rifai et al. 2001) and aspirin (Ridker, Cushman et al. 1997) use can 
reduce circulating CRP levels and this can have a positive effect on outcomes from 
cardiovascular disease (Ridker, Buring et al. 2003). Furthermore, these medications have 
also been shown to have a potential role in the prevention of colorectal cancer development 
(Flossmann and Rothwell 2007; Bardou, Barkun et al. 2010) and progression (Rothwell, 
Fowkes et al. 2011). The argument for a ‘polypill’, combining blood pressure and 
cholesterol lowering medication as well as antiplatelet treatments, has previously been 
made to reduce deaths from cardiovascular disease (Wald and Law 2003) however its 
benefits remain uncertain when used in a relatively unselected patient population (de 
Cates, Farr et al. 2014). Prospective studies are required to assess whether these medication 
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should be routinely recommended in inflamed patients with early stage colorectal cancer 
due to these combined effects of cardiovascular protection and chemoprevention.  
The strengths of the present study include the relatively large numbers with long-term 
follow-up. In addition, the present study has included detailed high-risk tumour factors 
such as the presence of venous invasion. The main limitation of the study is that this is a 
historic cohort captured over a prolonged timeframe. As such, temporal changes in staging 
and management may have taken place. Indeed, the proportion of patients with less than 12 
nodes examined was lower in those operated on in earlier years. Such a problem is inherent 
when examining early stage disease that was uncommon prior to the introduction of 
screening. However, this has been adjusted for within survival analysis and it is reassuring 
that date of operation was not associated with OS in this cohort. 
Within the pathological reporting of specimens there were a large number of patients who 
had suboptimal lymph node examination and hence may be perceived as being 
understaged. The present study has shown this to be associated with historic changes in 
processing of specimens. In addition, it may also be due to the relatively high proportion of 
rectal tumours in this cohort. However, if this were to have introduced bias of understaging 
then it would be expected that outcomes would be poorer in this group, which was not the 
case. Finally, a perceived limitation may be the lack of cancer specific survival analysis 
within the present study. However, due to the small proportion of cancer deaths in this 
cohort, such analysis is problematic. Also, the relevance of CSS to the individual patient is 
limited and, particularly in the screened population, recommendations for reporting effects 
on OS have been made (Penston 2011).  
In summary, patients undergoing resection for TNM Stage I colorectal cancer have an 
excellent oncological outcome, however only around three quarters are alive at 5 years. 
The presence of an elevated preoperative SIR, as measured by the mGPS, is an 
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independent marker that identifies patients with poorer overall survival and potentially 
identifies a subgroup that may benefit from targeted intervention.  
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Table 8.1: Baseline characteristics of patients undergoing resection for TNM Stage I 
colorectal cancer 
 
 
 All patients 
n(%) 
 
 191 
Age  
    <75 100 (52) 
    >75 91 (48) 
Sex   
    Female 86 (45) 
    Male 105 (55) 
Mode of presentation  
    Emergency 7 (4) 
    Elective 184 (96) 
Tumour Site  
    Colon 122 (64) 
    Rectum  69 (36) 
T-stage  
    1 54 (28) 
    2 137 (72) 
Venous invasion
a
  
    Present 37 (22) 
    Absent 130 (78) 
Differentiation  
    Poor 3 (2) 
    Moderate/well 188 (98) 
Less than 12 lymph nodes   
    Yes 102 (53) 
    No 89 (47) 
mGPS
b
  
    0 115 (77) 
    1 22 (15) 
    2 13 (9) 
Date of operation  
    2001 - 2004 103 (54) 
    2005 - 2008  88 (46) 
Outcome at date of censor  
    Alive 103 (54) 
    Postoperative death 7 (4) 
    Cancer-related death 15 (8) 
    Non cancer-related death 66 (35) 
 
 
a
 data complete 167 (87%) patients 
b
 mGPS = modified Glasgow Prognostic Score. Data complete 150 (79%) patients
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Table 8.2: Factors associated with overall survival following resection for TNM Stage I colorectal cancer (excluding post operative deaths) 
 
 Univariate survival 
analysis 
 
HR (95% C.I.) 
 
p-value 
Multivariate 
survival analysis 
 
HR (95% C.I.) 
 
 
p-value 
     
Age (<75 / >75) 3.722 
(2.310 – 5.996) 
<0.001 3.611 
(2.049 – 6.365) 
<0.001 
Sex    (Female / Male) 0.895 
(0.579 – 1.385) 
0.620 -  
Mode of presentation (Elective / Emergency) 3.443 
(1.387 – 8.543) 
0.008 1.036 
(0.240 – 4.469) 
0.962 
Tumour Site (Colon / Rectum) 0.915 
(0.580 – 1.442) 
 -  
T-stage (1 / 2) 1.104 
(0.676 – 1.804) 
0.692 -  
Venous invasion (No / Yes) 1.304 
(0.762 – 2.229) 
0.333 -  
Differentiation    (moderate-well / poor) 1.661 
(0.407 – 6.778) 
0.479 -  
Less than 12 lymph nodes (No / Yes) 1.122 
(0.721 – 1.745) 
0.610 -  
mGPS  (0 / 1+2) 2.076 
(1.172 – 3.677) 
0.012 2.173 
(1.204 – 3.921) 
0.010 
Date of operation (2001-2004 / 2005 – 2008) 1.233 
(0.769 – 1.976) 
0.385 -  
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Table 8.3: Factors associated with overall survival following resection for TNM Stage I colorectal cancer (excluding emergency presentation 
and post operative deaths) 
 
 Univariate survival 
analysis 
 
HR (95% C.I.) 
 
p-value 
Multivariate 
survival analysis 
 
HR (95% C.I.) 
 
 
p-value 
     
Age (<75 / >75) 3.634 
(2.228 – 5.926) 
<0.001 3.503 
(1.980 – 6.196) 
<0.001 
Sex    (Female / Male) 0.832 
(0.530 – 1.305) 
0.423 -  
Tumour Site (Colon / Rectum) 0.939 
(0.589 – 1.498) 
0.791 -  
T-stage (1 / 2) 1.042 
(0.634 – 1.713) 
0.871 -  
Venous invasion (No / Yes) 1.343 
(0.772 – 2.336) 
0.297 -  
Differentiation    (moderate-well / poor) 1.745 
(0.427 – 7.130) 
0.438 -  
Less than 12 lymph nodes (No / Yes) 1.041 
(0.661 – 1.641) 
0.861 -  
mGPS  (0 / 1+2) 1.908 
(1.050 – 3.467) 
0.034 2.104 
(1.155 – 3.835) 
0.015 
Date of operation (2001-2004 / 2005 – 2008) 1.229 
(0.753 – 2.004) 
0.410 -  
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Table 8.4: Relationship between clinicopathological factors, overall survival 
(OS) and the modified Glasgow Prognostic Score (mGPS) in patients 
undergoing resection for TNM Stage I colorectal cancer 
 
 
                  mGPS  
 0 
n(%) 
1/2 
n(%) 
 
p-value 
 115 35  
Age    
    <75 65 (56) 17 (49)  
    >75 50 (44) 18 (51) 0.410 
Sex     
    Female 49 (43) 16 (46)  
    Male 66 (57) 19 (54) 0.746 
Mode of presentation    
    Emergency 1 (1) 3 (9)  
    Elective 114 (99) 32 (91) 0.040 
Tumour Site    
    Colon 69 (60) 25 (71)  
    Rectum  46 (40) 10 (29) 0.223 
T-stage    
    1 37 (32) 6 (17)  
    2 78 (68) 29 (83) 0.086 
Venous invasion
a
    
    Present 28 (27) 6 (19)  
    Absent 75 (73) 25 (81) 0.382 
Differentiation    
    Poor 3 (3) 0  
    Moderate/well 112 (97) 35 (100) 0.448 
Less than 12 lymph nodes     
    Yes 60 (52) 19 (54)  
    No 55 (48) 16 (46) 0.827 
Date of operation    
    2001 – 2004 52 (45) 18 (51)   
    2005 – 2008  63 (55) 17 (49) 0.520 
Mean OS     
    (months (95% CI)) 122 (112 – 131) 91 (71 – 110) 0.010 
 
 
a
 n= 134 (89%)  
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9 THE INTERRELATIONSHIPS BETWEEN 
TUMOUR AND HOST CLINICOPATHOLOGICAL 
CHARACTERISTICS IN SCREEN-DETECTED 
T1/2 COLORECTAL CANCER 
9.1 Introduction 
It is increasingly recognised that in addition to stage at diagnosis there are a variety of 
tumour and host factors that can affect an individuals’ outcome following a diagnosis of 
colorectal cancer. There are certain pathological characteristics of the tumour itself that are 
recognised to be indicative of phenotypically more aggressive disease. These include the 
presence of venous invasion, lymphatic invasion and perineural invasion (Pathologists 
2014). For example, in a previous landmark paper, the presence of any of these three 
features (collectively referred to as VELIPI) was suggested to be representative of early 
metastatic spread and was predictive of disease free survival in colorectal cancer (Pages, 
Berger et al. 2005). 
Also, the immune response at the tumour/host interface has been shown to be of prognostic 
significance, with over 40 published studies confirming that a pronounced local 
inflammatory cell infiltrate in or around the tumour is associated with an improved 
outcome (Roxburgh and McMillan 2012). Recently, an automated method of scoring the 
peri-tumoural inflammatory infiltrate has been proposed as a method of standardising 
reporting (Forrest, Guthrie et al. 2014). However, all previous work has focussed mainly 
on TNM Stage II and III disease, as this has been representative of the stage of disease 
most commonly encountered and our understanding of the role of the peri-tumoural local 
inflammatory response in early stage disease is poor.  
Recently, the development of colorectal cancer screening programmes has led to an 
increase in the proportion of early stage tumours being detected (Logan, Patnick et al. 
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2012). This has led to a stage shift amongst non-metastatic disease to higher numbers of 
early stage disease being commonly encountered in clinical practice (Chapter 2). Overall, 
patients with these early stage tumours have an excellent cancer specific outcome and the 
majority of patients who undergo a curative resection ultimately die of something else 
(Chapter 8). However, an examination of these tumours aids our understanding of the 
natural history of colorectal, in particular when and how certain high-risk characteristics 
develop. 
The aim of the present study was to examine the interrelationships between tumour and 
host clincopathological characteristics in screen-detected T1/2 colorectal cancer. 
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9.2 Materials and methods 
Derivation of cohort 
From the original extract of data from the first round of FOBt screening in NHS GG&C, as 
described in Chapter 3, details were available for a total of 398 patients with screen-
detected colorectal cancer. Of those, 370 patients underwent procedures with a curative 
intent. Excluding those who had undergone neoadjuvant therapy (n=31) or had T3/4 
disease (n= 157) identified a cohort of 181 patients in whom slides were retrieved from 
archive (1 patient; unable to retrieve). Following review by a consultant pathologist a 
further 13 were excluded (11 patients - debate as to whether true invasive cancer rather 
borderline high grade dysplasia present; 2 patients - fragmented endoscopic biopsies only). 
Of the 167 patients remaining, 119 patients underwent formal resection following which 
78 patients were included for final analysis with evidence of residual mural tumour on the 
resected specimen (Figure 9.1). Patients in whom no residual tumour on resection was seen 
or who were treated with endoscopic resection only were excluded due to the lack of an 
appropriate margin for scoring of the local inflammatory response.  
 
Data collection   
Tumours were staged according to the conventional tumour node metastasis (TNM) 
classification (5
th
 Edition)(Sobin and Fleming 1997). Additional high-risk tumour features 
such as the presence of venous invasion, perineural invasion and lymphatic invasion were 
identified from pathology reports. A patient was termed VELIPI positive if at least one of 
these features (including nodal involvement as evidence of lymphatic invasion) was 
present.  
Both the absolute neutrophil count and the neutrophil to lymphocyte ratio (NLR) were 
used as a markers of the pre-operative systemic inflammatory response  (SIR) and were 
obtained from pre-operative blood results taken most immediately and not more than 6 
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weeks prior to surgery. With regards the NLR, a previously validated threshold of >5 was 
used as being evidence of a significantly elevated SIR (Walsh, Cook et al. 2005). An 
absolute neutrophil level greater than 7.5 x 10
9 
was defined as elevated as per local 
laboratory guidelines.  
The local peri-tumoural inflammatory response was calculated from routine haematoxylin 
and eosin-stained (H&E) slides using both the visual Klintrup-Makinen (K-M) criteria 
(Klintrup, Makinen et al. 2005) and the automated inflammatory cell density (Forrest, 
Guthrie et al. 2014) as has previously been described. At least 1 H&E slide (range 1-3) was 
scanned using a high resolution digital scanner (Hamamatsu NanoZoomer, Hamamatsu, 
Welwyn Garden City) and images viewed and assessed using Slidepath Digital Image Hub 
and Image Analysis module  (Leica Microsystems, Wetzlar, Germany).  
The visual K-M score uses a 4-point scale to assess the degree of inflammation at the 
invasive margin of the tumour. Briefly explained, a score of 0 indicates no increase in 
inflammatory cells, a score of 1 represented mild or patchy increase, 2 a prominent 
reaction and 3 a florid ‘cup-like’ reaction. This was further dichotomised to a visual K-M 
grade of weak (score 0 to 1) or strong (score 2 to 3) inflammation in line with previous 
studies (Roxburgh and McMillan 2012). A mean score and grade was created for each 
patient dependent based on individual slide scores. To assess for concordance two 
investigators assessed 40 patients (r=0.490), after retraining (r=0.892). The local 
inflammatory reaction in the remaining patients was then assessed by a single observer. 
The automated inflammatory cell density utilises the ‘Measured stained cells algorithm’ in 
the Image Analysis module of Slidepath as has been described previously using the 
rectangular box method (Forrest, Guthrie et al. 2014). This algorithm has previously been 
optimised to count only inflammatory cells and exclude other cell types including tumour 
cells. In order to guide the software to the invasive margin this was manually selected. The 
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area of maximal tumour depth was identified visually and then, at a magnification of 20x, 
three rectangular boxes were drawn along the margin (Figure 9.2). The algorithm was then 
run and the density of inflammatory cells was calculated and output expressed as positive 
cells/mm
2
. The mean score of the three boxes and subsequently the mean score of all slides 
for each tumour specimen was then calculated. 
Ethical approval for the study was obtained from the West of Scotland Ethics Committee 
(REC ref 12/WS/0152 - An investigation into tumour and host prognostic factors in early 
stage colorectal cancer and their correlation with clinical outcome. June 2012). 
 
Statistical analysis 
Associations between categorical variables were examined using χ
2
 tests for linear trend 
unless otherwise specified. All variable were grouped according to standard or previous 
published thresholds. To compare inflammatory cell density, nonparametric analysis was 
performed. For data with two categories the Mann Whitney U test was used and in those 
with more than two categories an analysis of variance using the Kruskal-Wallis test was 
performed. A value of p<0.05 was considered statistically significant. Statistical analysis 
was performed using SPSS software (SPSS Inc., Chicago, IL, USA) 
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Figure 9.1: Derivation of cohort of patients with screen-detected T1/2 colorectal 
cancer for assessment of the local inflammatory response 
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Figure 9.2: Representative examples of rectangular boxes at the invasive margin used 
for the automated inflammatory cell density  
(note red ink dots in upper most picture used to identify tumour for alternative study) 
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9.3 Results 
A total of 78 patients with screen-detected T1/2 disease with evidence of residual mural 
tumour having undergone a formal resection were included. There were 56 (72%) males, 
the majority were deprived (52% most deprived two quintiles of deprivation) and 8 (10%) 
were taking aspirin. The majority of tumours were rectal (72%). Venous invasion and 
lymphatic involvement (including nodal disease) was present in 27% and 22% of patients 
respectively. There was no documented evidence of perineural invasion. Therefore, 30 
(39%) patients were VELIPI positive. Only 6% of patients had evidence of an elevated SIR 
as measured by either a raised neutrophil count or an elevated NLR. 
Using the visual K-M score, 33 (42%) patients had scores of 2 and 3 and were therefore 
graded as having evidence of a strong peri-tumoural inflammatory infiltrate. The 
association between the visual K-M score and grade, and the automated inflammatory cell 
density was then examined (Table 9.1, Figure 9.2). There were significant differences 
between the automated inflammatory cell density and both the visual K-M grade (p=0.001) 
and the visual K-M scores 2 and 3 (p=0.040). There was a trend for a difference between 
visual K-M scores 1 and 2 (p=0.059). 
The association between tumour and host features was then examined with regard to T-
stage (Table 9.2). There was an association between more advanced T-stage and increased 
lymphatic involvement (including nodal disease) (9% vs 31%, p=0.020). There was no 
difference in venous invasion rates (24% vs 29%, p=0.648) and the local inflammatory 
response as measured by either the visual K-M grade (p=0.630) or the automated 
inflammatory cell density (p=0.975).  
The interrelationships of tumour and host features were then examined both within the 
whole cohort and also in those with T1 disease only (Tables 9.3a & Table 9.3b). There was 
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no evidence of a link between the inflammatory cell infiltrate, measured with the either the 
visual K-M grade or automated inflammatory cell density, and tumour and host factors 
included for analysis. 
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Table 9.1: Association between automated inflammatory cell density, visual K-M 
score and visual K-M grade in patients with T1/2 colorectal cancer undergoing 
resection 
 
 Inflammatory cells per mm
2 
 
median (range) 
 
p-value 
   
visual K-M score   
         0 2.53 (0.02 – 4.07)  
         1 2.45 (0.21 – 5.05) 0.257 
a
 
         2 2.90 (0.74 – 6.01) 0.059
 b
 
         3 4.97 (3.82 – 5.55) 0.040
 c
 
   
visual K-M grade   
         Weak 2.34 (0.02 – 5.05)  
         Strong 3.53 (0.74 – 6.01) 0.001 
 
a
 visual K-M 0 versus 1, 
b
 visual K-M 1 versus 2, 
c
 visual K-M 2 versus 3 
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(a) 
 
(b) 
 
 
 
Figure 9.3: Comparison between automated inflammatory cell density, visual K-M 
score (a) and visual K-M grade (b) 
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9.4 Discussion 
The results of the present study have validated the use of an existing automated tool in 
assessing the local peri-tumoural inflammatory response within early stage T1/2 colorectal 
cancer. In addition, it has shown that the lymphatic involvement rate is lower in T1 
compared to T2 disease, however, venous invasion rates and the local inflammatory 
response are unchanged. This suggests that venous invasion and a pronounced local 
inflammatory response, are features that occur early in tumour development and may 
represent potential therapeutic targets for the future.  
The peri-tumoural inflammatory response has been assessed in a large number of studies 
over the past 40 years and has consistently been shown to be associated with better 
outcome (Roxburgh and McMillan 2012).  In addition, the lack of an inflammatory 
infiltrate and the presence of a high tumour associated stroma percentage have been shown 
to be associated with a poorer outcome (Park, Richards et al. 2014). The mechanism 
behind such a local reaction at the host-tumour interface is as yet not fully understood 
however may involve a process called epithelial-mesenchymal transition (EMT). EMT is a 
process whereby epithelial cells lose cell-to-cell contact and develop migratory and 
invasive properties, and is a normal physiological process involved in tissue growth and 
repair (Bates and Mercurio 2005).  It has been proposed that a loss of inflammatory 
infiltrate facilitates stroma formation that in turn leads to tumour growth and invasion 
(Park, McMillan et al. 2015).  
Within the present study, a pronounced local inflammatory reaction was not significantly 
associated with adverse tumour features such as venous invasion or lymphatic invasion. 
This was perhaps surprising as previous work in more advanced disease has suggested that 
this might be the case (Forrest, Guthrie et al. 2014). However, it is important to consider 
that early stage disease represents a relatively homogenous group with excellent cancer-
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specific outcome. It is likely therefore, that the local inflammatory response develops more 
significance as the disease progresses. Understanding this mechanism is crucial to both our 
understanding of why early stage disease progresses and also where potential 
immunomodulatory targets may be identified.  
It is necessary to put the present study into context with regards patient outcome. It has 
previously been proposed that the combination of T-stage and venous invasion is superior 
to nodal status in determining cancer specific outcome in T1/2 disease (Roxburgh, 
McMillan et al. 2014). Hence, all T1/2 tumours and not just those that were node-negative 
were included in the present study. Despite a minimal follow-up of 3 years, only 4 (5%) 
patients died, none of cancer (2 post operative deaths, 2 non-cancer related deaths – data 
not presented). Therefore, survival analysis was not undertaken. Larger cohorts with 
mature follow-up, such as used in Chapter 8 are required to assess whether the local 
inflammatory response remains a valid prognostic factor in early stage screen-detected 
disease.  
In order to ensure an assessment of the local inflammatory response is routinely adopted in 
clinical practice a practical, reliable and reproducible method of assessment is required. 
The present study utilises routine H&E slides and readily available digital imaging 
software to perform the analysis. It was reassuring to note that assessment of the local 
inflammatory infiltrate using the visual K-M was accurately measured using the automated 
inflammatory cell density within T1/2 disease. This has implications for further projects 
examining this in larger numbers and validates previous work (Forrest, Guthrie et al. 
2014).   
The strengths of the present study are the high quality dataset and use of two validated 
methods in examining the host inflammatory response. In particular, the automated 
inflammatory cell density provides a reproducible quantitative method of examining 
 223 
 
immune cell infiltrate. Also, the venous invasion rate in the present study was strong when 
compared to other studies in early stage cohorts due to the routine use of an elastin stain 
employed in this geographical area over this timeframe (Roxburgh, McMillan et al. 2010). 
This is a real strength of pathology reporting in our geographical area. For example, a 
recent study examining polyp cancers within Scotland, noted a venous invasion rate of 
28% in the West of Scotland, compared to 12% in the rest of the country (Scottish Screen-
detected Polyp Cancer Study, data unpublished).  
The reporting of other high-risk characteristics such as lymphatic invasion, outside of those 
with nodal involvement, and perineural invasion was poor. Particularly perineural 
invasion, where no evidence of its presence was recorded. This reflects current RCPath 
audit standards where venous invasion is a core-dataset item and the other two factors are 
not (RCPath 2014). The use of specific stains for lymphatic invasion to improve reporting 
have been proposed however are not yet in use in routine clinical practice (van Wyk, 
Roxburgh et al. 2014). In addition, there are further stains for optimising perineural 
detection available (Shimada, Kido et al. 2014) and it has been noted that repeated 
examination of slides will increase detection (van Wyk, Roxburgh et al. 2014). Use of such 
techniques would increase overall detection and impact the VELIPI rate. Therefore, it may 
impact on any potential relationships between VELIPI and the local peri-tumoural 
inflammatory response. It would be of benefit to repeat such a study using these additional 
stains to assess whether relationships differed. 
The main weakness of the present study was the difficulty in including patients for 
analysis. The visual K-M is not applicable to those who undergo polypectomy only or in 
those who have no residual tumour on their resection specimen, due to a lack of an 
invasive margin to assess. This accounted for over half of the patients initially selected for 
the study. However, to our knowledge, there is currently no validated method of assessing 
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intra-tumoural inflammatory cell infiltrate on routine H&E slides. Further studies should 
focus on either developing such a method or utilising immunohistochemistry to ensure all 
patients with T1/2 disease can be included. This is of increasing relevance with advances 
in endoscopic management that have led to a large number of patients with T1/2 disease 
avoiding resectional surgery (Williams, Pullan et al. 2013).  
In conclusion, the present study has validated the use of an automated tool in examining 
the peri-tumoural inflammatory cell infiltrate in patients undergoing a resection for T1/2 
screen-detected colorectal cancer. It has demonstrated that lymphatic involvement is higher 
in T1 compared to T2 disease, however, venous invasion rates and the local inflammatory 
response are unchanged. This suggests that venous invasion and a pronounced local 
inflammatory response, are features that occur early in tumour development. Such findings 
enhance our understanding of the relationship between tumour and host within early stage 
disease. 
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Table 9.2: The relationship between T-stage and tumour and host factors in screen-
detected T1/2 colorectal cancer  
 
a 
Mann Whitney test
 T-stage 
 
 
 T1 
n(%) 
T2 
n(%) 
p-value 
 33 45  
Age (years)    
    <61 / 61 – 70 / > 70 17(52) / 10(30) / 6(18) 13(29) / 15(33) / 17(38) 0.079 
Sex    
    Female / Male 9(27) / 24(73) 13(29) / 32(71) 0.875 
Deprivation (quintile)    
    1-2 (most) / 3-5 (least) 21(64) / 12(36) 16(36) / 29(64) 0.014 
Aspirin usage    
    No / Yes  31(94) / 2(6)  39(87) / 6(13) 0.296 
Site    
    Colon / Rectal 20(61) / 13(39)  36(80) / 9(20) 0.060 
N-stage    
    0 / 1 / 2 30(91) / 2(6) / 1(3) 32(71) 10(22) / 3(7) 0.097 
Tumour differentiation    
    Mod/well / Poor  32(97) / 1(3) 45(100) / 0(0)  
Venous invasion    
    Absent / Present  25(76) / 8(24) 32(71) / 13(29) 0.648 
Lymphatic involvement (inc 
nodal) 
   
    Absent / Present  30(91) / 3(9) 31(69) / 14(31) 0.020 
Perineural invasion    
    Absent / Present 33(100) / 0(0) 45(45) / 0(0)  
VELIPI    
    Absent / Present 24(73) / 9(27)  24(53) / 21(47) 0.082 
Absolute neutrophil count    
    < 7.5> / 7.5 33(100) / 0(0) 44(98) / 1(2)  
Neutrophil/lymphocyte ratio    
    < 5 / > 5 31(94) / 2(6) 42(93) / 3(7)  
Visual K-M grade    
    Weak / strong  15(45) / 18(55) 18(40) / 27(60)  0.630 
Automated inflammatory cell 
density (cells per mm
2
) 
   
     Median (range) 2.70(0.02 – 5.90) 2.95(0.21 – 6.01) 0.975
a 
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Table 9.3a: Interrelationships between tumour and host factors in screen-detected T1/2 colorectal cancer   
 
 
 Sex Deprivation  Aspirin 
usage 
Site T-Stage N-stage Venous 
invasion 
Lymphatic 
involvement 
(inc nodal) 
VELIPI Visual 
K-M 
grade 
Automated 
inflammatory 
cell density
a 
 
Age 0.746 0.174 0.007 0.876 0.079 0.497 0.592 0.459 0.689 0.782 0.632 
Sex  0.469 0.148 0.657 0.875 0.530 0.275 0.463 0.811 0.170 0.385 
Deprivation    0.552 0.073 0.014 0.568 0.984 0.559 0.566 0.764 0.819 
Aspirin usage    0.297 0.296 0.303 0.476 0.501 0.953 0.296 0.987 
Site     0.060 0.404 0.275 0.274 0.203 0.170 0.813 
T-Stage      0.097 0.648 0.020 0.082 0.630 0.975 
N-stage       0.223 <0.001 <0.001 0.675 0.363 
Venous invasion        0.034 <0.001 0.136 0.828 
Lymphatic 
involvement (inc 
nodal) 
        
<0.001 0.915 0.759 
VELIPI          0.744 0.707 
Visual K-M grade           <0.001 
 
a 
Mann Whitney /Kruskal Wallis test 
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Table 9.3b: Interrelationships between tumour and host factors in screen-detected T1 colorectal cancer   
 
 
 Sex Deprivation  Aspirin 
usage 
Site N-stage Venous 
invasion 
Lymphatic 
involvement 
(inc nodal) 
VELIPI Visual 
K-M 
grade 
Automated 
inflammatory 
cell density
a 
 
Age 0.812 0.554 0.279 0.481 0.540 0.058 0.119 0.012 0.143 0.165 
Sex  0.301 0.372 0.245 0.181 0.281 0.108 0.690 0.475 0.983 
Deprivation    0.270 0.590 0.390 0.939 0.170 0.825 0.741 0.408 
Aspirin usage    0.751 0.899 0.409 0.645 0.372 0.183 0.226 
Site     0.342 0.074 0.143 0.042 0.135 0.223 
N-stage      0.126 <0.001 0.012 0.193 0.245 
Venous invasion       0.072 <0.001 0.604 0.334 
Lymphatic 
involvement (inc 
nodal) 
       
0.003 0.439 0.317 
VELIPI         0.943 0.363 
Visual K-M grade          0.004 
 
a 
Mann Whitney /Kruskal Wallis test
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10 THE INFLAMMATORY MICROENVIRONMENT 
IN SCREEN-DETECTED PREMALIGANT 
ADENOMATOUS POLYPS 
10.1 Introduction 
Screening for colorectal cancer with the guaiac-based faecal occult blood test (gFOBt) has 
been shown to reduce cancer specific mortality through the detection of early stage disease 
(Mandel, Bond et al. 1993; Hardcastle, Chamberlain et al. 1996; Kronborg, Fenger et al. 
1996). However, as identified in Chapter 3, the majority of individuals who attend for 
colonoscopy following a positive screening test do not have cancer detected and a large 
proportion have adenomatous polyps. There is good evidence that colorectal cancer 
develops through the adenoma-carcinoma sequence and it has been estimated that 
approximately 25% of polyps greater than 1cm will develop into cancer over 20 years 
(Stryker, Wolff et al. 1987). There is some evidence from gFOBt screening that in the 
context of a high positivity rate the incidence of cancer in a given population can be 
reduced by removal of these polyps (Mandel, Church et al. 2000).  
However, identifying which patients with polyps have a higher propensity for malignant 
transformation is currently poorly understood. Current guidelines advise repeat 
colonoscopies at 1, 3 or 5 years depending on the number, size and grade of polyp detected 
at index procedure. With those with multiple polyps, greater than 1cm and high-grade 
changes being subjected to repeated examinations at sooner intervals (Cairns, Scholefield 
et al. 2010). Nevertheless, there is limited evidence that this impacts on patient outcome 
and a recent population study has suggested that colorectal cancer mortality may actually 
be higher in those patients who have a high risk polyp removed compared with the general 
population (Loberg, Kalager et al. 2014). It is therefore imperative that a further 
investigation of the natural history and progression of adenomatous polyps is undertaken. 
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There is now a wealth of evidence that progression and outcome of colorectal cancer is 
related to a complex interaction between tumour and host (Hanahan and Weinberg 2011). 
In particular, those with a more pronounced peri-tumoural inflammatory reaction have 
better cancer specific outcomes (Roxburgh and McMillan 2012). However, it is not clear 
whether such a relationship is relevant to malignant adenomatous polyps. Previous studies 
examining this phenomenon have been limited by both numbers and a focus on early 
invasive cancer and have failed to exam the host inflammatory response across the 
spectrum of dysplasia and therefore our understanding of the natural history of such polyps 
is limited (Cui, Yuan et al. 2009; McLean, Murray et al. 2011; Cui, Shi et al. 2012).     
The aim of the present chapter was to assess the role of the local inflammatory response in 
screen-detected dysplastic adenomas and to assess whether the type and intensity of 
inflammatory infiltrate differs between high-grade and low-grade dysplasia. 
 
 
  
 230 
 
10.2 Materials and methods 
A database of all patients with adenomas detected through the first round of the Scottish 
Bowel Screening Programme (SBoSP) in NHS GG&C (April 2009 to April 2011) had 
previously been created. The screening algorithm and derivation of this cohort has been 
discussed previously (Chapter 3). All colonoscopists have to comply with strict quality 
control measures as assessed by the Joint Advisory Group (JAG) accreditation, all polyps 
identified are removed at colonscopy.  
A representative sample of 207 polyps from 134 individuals was chosen for inclusion in 
the study. All samples were processed in a single pathology department (Glasgow Royal 
Infirmary). All polyps were greater than 10mm in size. Details on site and macroscopic 
morphological appearance of the polyp were obtained from endoscopic reports. Details on 
post-fixation size, grade of dysplasia and microscopic appearance were obtained from 
pathology reports. Patient details included age, sex, and socioeconomic deprivation status. 
The Scottish Index of Multiple Deprivation (2009) was used as a measure of deprivation as 
has been described previously (SIMD 2009). Details on patient usage of Aspirin was 
obtained from pre-assessment documentation. Follow-up details on any further 
colonoscopies and details of recurrent or metachronous neoplasia (colorectal cancer or 
dysplastic polyp), were obtained from patients medical records on a case-by-case basis.  
Ethical approval for use of this tissue was obtained from the West of Scotland Research 
Ethics Committee (12/WS/0152 – An investigation into tumour and host prognostic factors 
in early stage colorectal cancer and their correlation with clinical outcome. June 2012. 
Amendment approved December 2012). 
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Immunohistochemistry 
Assessment of inflammatory cell phenotype infiltrate was carried out by 
immunohistochemistry. Representative archival formalin fixed paraffin embedded tissue 
blocks were retrieved from archive and 2.5µm sections cut. Sections were then dewaxed 
rehydrated through graded alcohol. An autostainer (ThermoFisher, Autostainer 480s) was 
used to perform staining. Antigen retrieval was carried out in a PT module (ThermoFisher) 
using ThermoFisher dewax/retrieve solution pH9. Primary antibody was applied for 20 
minutes at RT following antigen retrieval. Signal was amplified and visualised using the 
ThermoFisher Quanto kit and the diaminobenzidine (DAB) colour developer. Cell surface 
antigens were evaluated for T-lymphocytes (CD3+) dilution 1:300 (ThermoFisher), 
cytotoxic T-lymphocytes (CD8+) dilution 1:100 (ThermoFisher), helper T-lymphocytes 
(CD45+) dilution 1:500 (ThermoFisher) and macrophages (CD68+) dilution 1:5000 
(ThermoFisher). 
Assessment of inflammatory infiltrate 
All stained slides were converted to electronic format using a high resolution digital 
scanner (Hamamatsu NanoZoomer, Hamamatsu, Welwyn Garden City) and images viewed 
and assessed using Slidepath Digital Image Hub and Image Analysis module  (Leica 
Microsystems, Wetzlar, Germany). The whole slide was then analysed in a semi-
quantitative manner to assess intra-epithelial cell infiltrate at a resolution of 20x. Immune-
cell infiltrate was graded on a four-point scale as absent, weak, moderate or strong (Figures 
10.1 to 10.4). Following initial scoring, this was further dichotomised into low and high for 
the purpose of analysis. A total of 30 slides for each stain were scored independently by 
two observers to confirm consistency of scoring. The remainder of the slides were then 
scored by a single observer. The inter-observer intraclass coefficents for each subtype 
 232 
 
were: CD3+ 0.66, CD8+ 0.66, CD45+ 0.29 (0.69 following retraining) and CD68+ 0.79. A 
kappa value above 0.6 indicates good concordance.  
The total inflammatory infiltrate was then derived for each polyp based on a combination 
of lymphocyte (CD3+) and macrophage (CD68+) scores. For example a polyp with CD3+ 
High and CD68+ High had a high total inflammatory infiltrate and a polyp with CD3+ 
Low and CD68+ Low had a low total inflammatory infiltrate. All others had a medium 
total inflammatory infiltrate.  
 
Statistical Methods 
Associations between categorical variables were examined using the χ
2
 test.  For ordered 
variables with multiple categories the χ
2
 test for linear trend was used. Wilcoxon signed-
rank test was used for analysis of paired variables. Binary logistic regression analysis was 
used to assess risk of neoplasia recurrence. A value of p<0.05 was considered statistically 
significant. Statistical analysis was performed using SPSS software (SPSS Inc., Chicago, 
IL, USA) 
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Figure 10.1a: Assessment of CD3+ T-lymphocyte inflammatory cell infiltrate 
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  Moderate     Strong 
 
Figure 10.1b: Assessment of CD8+ cytotoxic T-lymphocyte inflammatory cell 
infiltrate 
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Figure 10.1c: Assessment of CD45+ helper T-lymphocyte inflammatory cell infiltrate 
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Figure 10.1d: Assessment of CD68+ macrophage inflammatory cell infiltrate 
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10.4 Results 
Per polyp analysis 
A total of 207 polyps from 134 patients were included. 107 were high grade (HGD) and 
100 were low grade (LGD). The median age of patients was 65 years and 33 (25%) were 
female. The majority of polyps were left sided, pedunculated and were between 10mm and 
20mm in size. Only 23 (11%) of polyps had been exposed to aspirin use (Table 10.1). 
Comparing HGD and LGD polyps there were more older, female and less deprived 
patients in the HGD group (both p<0.05). HGD polyps were more likely to be larger and 
have a villous component (both p<0.05) (Table 10.1a). Examining the inflammatory 
infiltrate in polyps, high levels of CD3+, CD8+, CD45+ and CD68+ were observed in 
67%, 25%, 67% and 72% of cases respectively. CD3+ infiltrate was higher in HGD polyps 
compared to LGD polyps (74% vs 69%, p<0.05). CD8+ infiltrate was higher in HGD 
polyps compared to LGD polyps (36% vs 13%, p<0.001) where as CD45+ infiltrate was 
similar (69% vs 64%, p=0.401). There was no difference in CD68+ infiltrate (74% vs 70%, 
p=0.540) (Table 10.1b) or total inflammatory cell infiltrate (p=0.226).   
Both patient and polyp related factors were then examined to identify features associated 
with altered inflammatory infiltrates. There was no difference in the degree of CD3+, 
CD8+, CD45+ or CD68+ inflammatory infiltrate with regards to patient factors such as 
age, sex or deprivation. Aspirin exposure was associated with a higher level of CD45+ 
infiltrate (p=0.007). With regards to polyp factors, larger polyps were associated with a 
higher level of CD8+ infiltrate (p=0.004) and polyps with a villous component had higher 
levels of CD8+ infiltrate (p=0.021) Total inflammatory infiltrate was not related to patient 
or polyp factors (Table 10.2). 
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Per patient analysis 
In order to examine whether alterations in the microenvironment were related to altered 
host response, a per patient paired analysis was then carried out of those patients with 
multiple polyps (n=46 patients) (Figure 10.2).  This included those with multiple low-
grade dysplastic polyps (n=24 patients) and those with multiple mixed low and high-grade 
dysplastic polyps (n=20 patients). Due to low numbers, analysis of the 2 patients with 
multiple high-grade polyps was not carried out. On paired testing using Wilcoxon signed-
rank analysis there was an increase in CD3+ (p=0.059), CD68+ (p=0.046) and total 
inflammatory infiltrate (p=0.021) in high-grade polyps of those who had both low and 
high-grade dysplasia. There was no change in CD8+ (p=0.705) and CD45+ (p=0.605) 
infiltrate. No significant changes in inflammatory infiltrate were seen between polyps in 
those patients with low grade dysplasia only (CD3+, p=0.317; CD8+, p=0.083; CD45+, 
p=0.206; CD68+, p=0.705; total inflammatory infiltrate, p=0.617) (Figure 10.3). 
 
Risk of recurrent / metachronous neoplasia 
In those patients with a single polyp who had been included in the analysis (n=88 patients) 
outcome was assessed with regard to risk of recurrent or metachronous neoplasia. Of the 
88 patients, 39 (44%) patients were excluded as they had multiple polyps at index 
colonoscopy that had not been assessed in this analysis. On follow up, with a minimum of 
4 years, 34 patients had undergone at least 1 colonoscopy whereby 14 had evidence of 
further neoplasia (Figure 10.2). 
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Figure 10.2: Outline of patient cohort and explanation of per patient analysis in those with multiple polyps, and follow up in those with 
solitary polyps (shaded box) 
(HGD = High-grade dysplasia, LGD = Low-grade dysplasia)
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          CD3+ Mixed HGD/LGD              CD3+ All LGD 
    (n=20pts, p=0.059)             (n=24pts, p=0.317) 
 
   
          CD8+ Mixed HGD/LGD              CD8+ All LGD 
    (n=20pts, p=0.705)             (n=24pts, p=0.083) 
 
 
     
          CD45+ Mixed HGD/LGD              CD45+ All LGD 
    (n=20pts, p=0.605)             (n=24pts, p=0.206)   
 
 
Figure 10.3a: Per patient paired analysis of CD3+, CD8+, CD45+ T-lymphocyte 
cell infiltrate changes between polyps in patients with multiple polyps (mixed 
high/low grade dysplasia or low grade dysplasia only) 
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          CD68+ Mixed HGD/LGD              CD68+ All LGD 
    (n=20pts, p=0.046)             (n=24pts, p=0.705) 
 
 
    
       Total Inflammatory Infiltrate            Total Inflammatory Infiltrate 
              Mixed HGD/LGD                     All LGD 
 (n=20pts, p=0.021)             (n=24pts, p=0.617) 
 
 
 
 
 
 
 
 
Figure 10.3b: Per patient paired analysis of CD68+ macrophage and total 
inflammatory cell infiltrate changes between polyps in patients with multiple 
polyps (mixed high/low grade dysplasia or low grade dysplasia only)
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10.5 Discussion 
The present study shows that, within the context of a colorectal cancer screening 
programme, there was an increase in inflammatory cell infiltrate with progression from 
low-grade to high-grade dysplastic polyps. This was evident whether analysed within or 
between patients. Therefore, it is clear that there is a specific host response to dysplastic 
changes in colorectal adenomas. Given the prognostic value of the tumour inflammatory 
cell infiltrate in established cancer (Roxburgh and McMillan 2012) it may be that the 
inflammatory cell infiltrate will inform the likely outcome in patients with dysplastic 
polyps.  
The results of the present study are consistent with the observation that there is a specific 
interaction between adenomatous cells and the microenvironment (Cui, Yuan et al. 2009; 
McLean, Murray et al. 2011; Cui, Shi et al. 2012). A full understanding of the local 
inflammatory microenvironment of colorectal adenomas is essential if we are to learn 
about why some adenomas progress. The immunoediting hypothesis suggests that for 
neoplasia to develop there is an immune profile shift from immunosurveillance to 
immunosuppression (Koebel, Vermi et al. 2007). This concept suggests that the host 
immune response to neoplastic lesions has three phases. The first is elimination whereby 
the host immune system removes abnormal cells. The second phase is equilibrium where 
there is a development of neoplastic cells that are immune to host defences and a battle 
between host and tumour ensues. The final phase is escape whereby tumour cells 
overwhelm the host immunity and create a favourable microenvironment for tumour 
growth (Dunn, Old et al. 2004). Based on this theory, adenomatous polyps represent a 
neoplastic lesion in the equilibrium phase and hence identifying which polyps are appear 
more likely to escape would be of considerable benefit. Furthermore, modulation of this 
local host inflammatory microenvironment to prevent escape would be invaluable. 
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It is interesting to consider the finding of the present study with regards to patient outcome. 
Currently, follow-up of patients with adenomatous polyps is based on size, grade and 
number of polyps as previous studies have shown that patients with larger, high-grade and 
multiple polyps are at a higher risk of recurrence and of malignant transformation (Cairns, 
Scholefield et al. 2010). However, this current risk stratification technique is far from ideal 
and a recent population based study has suggested that there is little benefit in terms of 
cancer incidence reduction in following these guidelines (Loberg, Kalager et al. 2014). 
With just under half of all those attending for a colonoscopy following a positive bowel 
screening test having adenomatous polyps detected, accurate prognostic stratification is 
vital if we are to avoid unnecessary follow-up colonoscopy in a large proportion of the 
population (Logan, Patnick et al. 2012). If such a link were to be proven then it would 
represent a potential immunomodulatory target to help prevent the progression of 
adenomas in a pre-malignant phase. 
The present study was predominantly cross-sectional in nature and lacked numbers to 
study outcome with sufficient power. However, a pilot group of 34 patients who had 
solitary polyps excised were followed up and a high rate of recurrent or metachronous 
polyps were noted (over 40% within 4 years). This should inform planning for future 
studies in larger numbers to explore this further and could also include those with multiple 
polyps. However, care should be taken with such analysis as it would be prone to potential 
confounding factors such as the heterogeneity of inflammatory infiltrate between polyps 
within the same person as has been demonstrated within the present study.  
The strengths of the present study are that it is, to date, the largest study examining the 
local inflammatory response in colorectal adenomas. It has examined a variety of 
inflammatory cells using robust immunochemical techniques. In including a per patient 
analysis, changes in inflammatory infiltrate between different lesions within the same 
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colon is achieved and adds to the robustness of the findings. In addition, it has included 
details on aspirin usage, a potential confounder that has been missing from previous studies 
(Cui, Yuan et al. 2009; McLean, Murray et al. 2011).   A potential additional weakness is 
the use of CD68+ as a marker for macrophage infiltration. When considering the immune 
microenvironment, macrophage subtypes associated with either an increase in the adaptive 
or the innate response can be of interest and CD68+ staining does not account for that. 
Further studies examining macrophage subtypes to explore this concept are planned in this 
cohort. One further potential weakness may be our use of a derived total inflammatory 
infiltrate rather than a true observed one. For example, in colorectal cancer the Klintrup-
Makinen score, assessing inflammatory cell infiltrate at the invasive margin on routinely 
stained H&E slides, has been widely validated as means of observing a total inflammatory 
cell infiltrate and has been correlated with patient outcome (Klintrup, Makinen et al. 2005). 
However, as discussed in Chapter 9, the nature of endoscopic polyp resections, where there 
is no clear margin in the majority of cases, means that inflammatory cell infiltrate can only 
be examined within the adenoma itself and not at the margin. Therefore the Klintrup-
Makinen score cannot accurately be assessed.  
In conclusion, the present chapter has shown an increase in inflammatory infiltrate with 
progression from low-grade to high-grade dysplasia.  This would suggest a specific 
response to early disease progression confirming increased host immunosurveillance.  
Therefore, it may be possible that such a finding may have a use in the prognostic 
stratification and treatment of dysplastic polyps. 
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Table 10.1a: Baseline characteristics of adenomatous polyps by grade of dysplasia 
(per polyp analysis) 
 
 All 
polyps 
 
n(%) 
 Low-grade 
polyps 
 
n(%) 
 
High-grade 
polyps 
 
n(%) 
 
p-value 
 207  100 107  
Age      
    <65 111 (54)  61 (61) 50 (47)  
     >65 96 (46)  39 (39) 57 (53) 0.040 
Sex      
   Male 166 (80)  88 (88) 78 (73)  
   Female 41 (20)  12 (12) 29 (27) 0.006 
Deprivation Quintile      
    1 (most deprived) 81 (40)  49 (51) 32 (30)  
    2 25 (12)  8 (8) 17 (16)  
    3 36 (18)  21 (21) 15 (14)  
    4 23 (11)  6 (6) 17 (16)  
    5 (least deprived) 39 (19)  13 (13) 26 (24) 0.003 
Aspirin exposure      
    Yes 23 (11)  9 (9) 14 (13)  
     No 182 (89)  89 (91) 93 (87) 0.377 
Adenoma location      
     Proximal to splenic flexure 27 (13)  16 (16) 11 (10)  
     Distal to splenic flexure 180 (87)  84 (84) 96 (90) 0.223 
Macroscopic appearance      
      Sessile 53 (26)  28 (28) 25 (23)  
      Pedunculated 154 (74)  72 (72) 82 (77) 0.445 
Size (mm)      
       10-12 48 (23)  32 (32) 16 (15)  
       13-15 54 (54)  25 (25) 29 (27)  
       16-20 59 (59)  28 (28) 31 (29)  
        >20 46 (22)  15 (15) 31 (29) 0.002 
Microscopic appearance      
       Tubular 88 (43)  50 (50) 38 (36)  
       Tubulovillous/villous 119 (57)  50 (50) 69 (64) 0.036 
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Table 10.1b: Comparison of inflammatory infiltrate by grade of adenomatous polyp 
(per polyp analysis) 
 
 All 
polyps 
 
n(%) 
 Low-grade 
polyps 
 
n(%) 
 
High-grade 
polyps 
 
n(%) 
 
p-value 
 207  100 107  
CD3+      
      High 140 (67)  61 (61) 79 (74)  
      Low 67 (32)  39 (39) 28 (26) 0.049 
CD8+      
      High 52 (25)  13 (13) 39 (36)  
      Low 155 (75)  87 (87) 68 (64) <0.001 
CD45+      
      High 137 (67)  63 (64) 74 (69)  
      Low 69 (33)  36 (36) 33 (31) 0.401 
CD68+      
      High 149 (72)  70 (70) 79 (74)  
      Low 58 (28)  30 (30) 28 (26) 0.540 
      
Total inflammatory infiltrate      
      Low 30 (15)  17 (17) 13 (12)  
      Med 65 (31)  35 (35) 30 (28)  
      High 112 (54)  48 (48) 64 (60) 0.226 
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Table 10.2: Associations between adenomatous polyp and host variables and degree of inflammatory infiltrate (per polyp analysis) 
 
 T-lymphocytes 
 
CD3+ 
 
(p-value) 
Cytotoxic  
T-cells 
CD8+ 
 
(p-value) 
Helper  
T-cells 
CD45+ 
 
(p-value) 
Macrophages 
 
CD68+ 
 
(p-value) 
 Total 
inflammatory 
infiltrate 
 
(p-value) 
       
Age     
    (<65 / >65) 
0.566 0.970 0.152 0.732  0.665 
Sex     
    (Male / Female) 
0.397 0.059 0.168 0.850  0.800 
Deprivation Quintile    
    (1/2/3/4/5) 
0.252 0.416 0.866 0.128  0.470 
Aspirin exposure     
    (Yes / No) 
0.235 0.887 0.007 0.888  0.533 
Polyp location     
    (Proximal / Distal to splenic flexure) 
0.443 0.291 0.648 0.842  0.863 
Macroscopic appearance   
    (Sessile / Pedunculated) 
0.283 0.396 0.630 0.312  0.451 
Size     
    (<20mm / >20mm) 
0.081 0.004 0.058 0.410  0.529 
Microscopic appearance  
    (Tubular / Tubulovillous/villous) 
0.877 0.021 0.293 0.604  0.675 
Grade of polyp     
    (Low / High) 
0.049 <0.001 0.401 0.540  0.226 
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11 CONCLUSIONS 
11.1 Overview of thesis 
Screening for colorectal cancer has been introduced to reduce cancer specific mortality 
through the detection of early stage disease. However, at the beginning of this period of 
research it was apparent that population based screening programmes were still in their 
infancy and it remained unclear what the true impact would be. Moreover, geographical 
differences, particularly in terms of the demographic profile of the population invited to 
screening, were vitally important to its efficacy. Therefore, application of trial results to 
our socioeconomically deprived population may not be valid. Furthermore it was apparent 
that outside of TNM Stage, there had been little work exploring differences between 
screen-detected and non screen-detected disease. There is a wealth of evidence that 
additional tumour and host prognostic factors are of importance in determining outcome 
however, these have yet to be examined in the screen-detected population. In particular, the 
systemic inflammatory response has been consistently shown to be indicative of those 
patients who have a worse outcome, however has not been explored within screen-detected 
or early stage disease. 
Chapter 2 began by putting the current bowel screening programme into context by 
providing an overview into the site, stage and mode of presentation of colorectal cancer 
within our geographical area of study. By utilising population based data it could be shown 
that accompanying the introduction of screening, a rise in early stage disease has been 
seen. By examining pre, during and post screening introduction cohorts the timing of the 
change was explored and seen to mirror screening introduction. However, it became 
apparent that there were some limitations of using such large datasets. It was able to 
provide an overview of presentation within the region however lacked sufficient detail to 
explore detailed tumour and host variables.  
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Therefore, Chapter 3 sought to examine the first round of the screening programme in 
more detail to explore outcome through all stages of the screening programme. Data was 
initially extracted from the local Bowel Screening IT System and then on a case-by-case 
basis all those attending for colonoscopy were examined in more detail. Such labour 
intensive data collection was deemed necessary to ensure accuracy that was not possible 
with the population dataset used for Chapter 2. It highlighted the importance of deprivation 
in impacting outcome at all stages of the screening pathway. For example, it was 
discovered that deprivation was associated with not only uptake of the test, but the risk of a 
positive test, the likelihood of undergoing colonoscopy following a positive test and also 
the risk of having cancer detected at colonoscopy following a positive test.   
The rational behind Chapter 4 was that one of the criticisms of gFOBt based population 
screening is that a disproportionate number of left sided tumours are identified. This is 
thought to arise due to degradation of haemoglobin through gut transit rendering it less 
sensitive for right-sided lesions. This was indeed noted in our population and identified in 
Chapter 3. Therefore, it was theorised that use of a flexible sigmoidoscopy-first approach 
may be adequate to examine the large bowel in these patients. Such a change to the 
screening algorithm would have significant cost and resource implications. However, the 
results of this chapter show that a significant number of right sided lesions would be 
missed and it was concluded that such a change in the process would neither be feasible 
nor desirable. 
Through examination of the first round of screening in detail (Chapter 3) it became 
apparent that the colonoscopy dataset generated could be used to observe other factors 
associated with colorectal cancer risk. This led to an exploration of the potential 
chemopreventative effects of commonly used cardiovascular drugs such as aspirin, statins 
and ACE-inhibitors (Chapter 5) and also of the value of symptoms in predicting cancer risk 
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(Chapter 6). Chapter 5 reported that individuals on these commonly used medications 
either in isolation or combination, were less likely to have cancer, significant neoplasia or 
neoplasia than those who were not. This supports evidence from observational studies that 
have shown this outside of a screening cohort and supports the concept that these are 
potentially chemopreventative medications. Chapter 6 utilised data on symptoms collected 
at pre-assessment and correlated this with outcome at colonoscopy. One of the major 
driving factors behind the development of national screening programmes is previous 
research showing poor relationship between bowel symptoms and detection of colorectal 
cancer at colonoscopy. There was a high rate of common lower GI symptoms (around 40% 
of all patients undergoing colonoscopy following a positive screening test) and this 
actually negatively correlated with risk of cancer or neoplasia. This suggests that within the 
context of a national screening programme, recording of symptoms is of limited value.   
Through data linkage with the Managed Clinical Network dataset it was possible to 
identify those invited to screening whom subsequently had colorectal cancer detected 
outwith the screening programme (Chapter 7). This included those who had not responded 
to the invitation and those who had tested negative. This allowed an estimation of the 
sensitivity and specificity of the first round of screening in our geographical area. In 
addition it allowed for direct comparison of tumour and host prognostic factors between 
screen-detected and non screen-detected disease. This is the first time the host systemic 
response has been examined within the context of a national bowel screening programme. 
Screen-detected tumours were of an earlier stage than those detected outwith screening 
and, within TNM Stage II and TNM Stage III disease, had more favourable tumour and 
host prognostic factors. 
One of the limitations of examining the screen-detected cohort is that there is limited 
follow-up of this immature cohort. However, as identified in Chapter 7, there appears to be 
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little difference between screen-detected and non screen-detected colorectal cancer at an 
early stage and therefore findings on mature follow-up of non-screen detected TNM Stage 
I disease should be applicable to the screened cohort. Hence, Chapter 8 utilised a separate 
cohort from prior to the advent of screening in our geographical area to explore outcomes 
specifically in TNM Stage 1 disease. There is a lack of evidence regarding outcomes in 
early stage disease as it is something that has not been seen previously in large numbers. 
As has been shown in Chapter in 2 it is likely to be increasingly relevant in the post-
screening era where it may account for approximately a third of all non-metastatic 
colorectal cancer. It was found that cancer specific survival was excellent (95% at 5 years), 
however overall survival was less good (76% at 5 years) and that the presence of a elevated 
pre-operative systemic inflammatory response could predict those with a worse overall 
outcome.  
The final analysis of the thesis involved tissue work exploring the role of the local 
inflammatory response within screen-detected early stage colorectal cancer (Chapter 9) and 
premalignant adenomatous polyps (Chapter 10). When examining T1/2 disease there was 
evidence of higher levels of lymphatic involvement (including nodal disease) in T2 
tumours compared to T1 disease, however rates of venous invasion and the local peri-
tumoural inflammatory response were unchanged. This suggested that venous invasion and 
the local response occurred early in the disease process. There was difficulty in including 
patients for analysis due to high levels of patients with T1/2 disease undergoing 
endoscopic resection and hence not having an invasive margin on which the peri-tumoural 
inflammatory response could be assessed. Therefore, the decision was made to use 
immunohistochemistry to assess the intra-tumoural infiltrate in pre-malignant adenomatous 
polyps (Chapter 10). There was evidence of a more pronounced inflammatory infiltrate 
between low and high-grade dysplastic polyps which was noted both overall in the cohort, 
and also in a paired analysis of patients who had both low and high-grade dysplastic 
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polyps. This suggests a specific response to early disease progression confirming increased 
host immunosurveillance.  Therefore, it may be possible that such a finding may have a use 
in the prognostic stratification and treatment of dysplastic polyps.   
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11.2 Future work 
This thesis is the exploration of individuals invited to the prevalence round of screening in 
our geographical area. As such, it represents an immature cohort in whom outcome or 
survival analysis has not been possible. Clearly, future work exploring survival between 
individuals with screen-detected and non screen-detected colorectal cancer is required to 
assess what impact the differing tumour and host prognostic factors play in determining 
outcome. In particular, this thesis has demonstrated that patients with screen-detected 
TNM Stage II and III disease have a different host preoperative systemic inflammatory 
response. It has yet to be shown that this will retain its significance as a prognostic factor 
within screen-detected disease and future studies examining this are planned in this cohort.   
It is important to consider that population FOBt screening is a dynamic process, designed 
to be repeated in order to ensure efficacy, and so further work examining how these 
differences alter over subsequent rounds is also planned. In particular, as subsequent 
incidence rounds of screening continue, it is unclear what effect this will have on stage of 
presentation at a population level. Furthermore, the SBoSP is in the development phase of 
a change in the existing screening algorithm to utilise quantitative FIT rather than gFOBt 
as a first line test. This is due to commence in 2017, and is expected to affect not only 
positivity rates, but also participation, as it has been shown to be an easier test to perform. 
It will be of interest over the forthcoming years to examine screening uptake and efficacy 
as these changes are implemented in our deprived population.  
Overall, it is likely that the shift towards early stage disease identified in this thesis will 
continue and will be aided not only through improvements in the screening algorithm but 
also population campaigns such as Detect Cancer Early. It is likely therefore that there will 
be an increased focus on outcomes in TNM Stage I disease as larger numbers of these are 
detected. While overall cancer-specific outcome is excellent, identifying which individuals 
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require more intensive follow-up and who can be reassured is important not only from a 
patient perspective but also from a societal perspective in terms of resource utilisation. 
This is particularly pertinent with screen-detected early stage disease where one of the 
risks is of medicalisation of an otherwise healthy individual. Furthermore, examining T1/2 
disease allows us to enhance our understanding of early tumour growth and provides 
potential opportunities for early intervention. It has been demonstrated in this thesis that 
the preoperative systemic inflammatory response identifies a subset of patients who have a 
poorer overall survival following resection of TNM Stage I disease. A cancer diagnosis has 
been identified as a teachable moment where individuals are more susceptible to a positive 
health intervention. Therefore, it would seem practical to propose that patients with an 
elevated preoperative systemic inflammatory response are a subset that should be targeted. 
This could include both lifestyle and pharmacological interventions, aimed at reducing 
systemic inflammation, which may ultimately improve outcomes. Further studies, could 
include the instigation of such a rehabilitation programme in a manner not dissimilar to 
cardiac rehabilitation which is now a standard of care for patients who have undergone a 
cardiac event. 
Examining the tumour-host interface at a local level, this thesis has characterised the peri-
tumoural inflammatory infiltrate in screen-detected T1/2 disease. It has validated the 
previously created automated method of assessing this in early stage disease. One problem 
with this analysis was that a large proportion of patients with T1/2 disease were managed 
endoscopically and were hence excluded from this analysis. There are currently no 
validated means of assessing the local inflammatory infiltrate in polypectomy specimens. 
Further work identifying such a method should be developed to allow full characterisation 
of the local inflammatory response in early stage disease. Moreover, any studies on 
outcomes in early stage disease, including malignant polyps, require large numbers with 
long-term follow-up. Data on screen-detected malignant polyps identified during the 
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course of this thesis has been included in the Scottish Screen-detected Polyp Cancer Study 
(SSPoCS) which is due to publish outcomes within the next year. This is a national study 
of all screen-detected malignant polyps since the advent of screening in Scotland. Future 
studies examining what role the local inflammatory response has in malignant polyps 
should be undertaken and could utilise such a resource.         
Finally, screening has the potential to amass considerable population datasets that allow us 
to explore the natural history of colorectal cancer from its earliest stages of development. It 
would seem prudent to assume that if outcome following resection for colorectal cancer 
depends on the interaction between tumour and host, as witnessed by both the systemic 
inflammatory response and the local inflammatory response at the invasive margin, then 
the risk of transformation from premalignant adenomatous polyp to invasive carcinoma 
should do so too. Such a finding would have the potential to fundamentally alter our 
concept of risk-stratification in individuals with adenomatous polyps and may also identify 
a potential immunomodulatory therapeutic target. This should be the focus of further 
prospective observational studies and utilising screen-detected individuals would seem the 
most effective way of doing this.  
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